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Abstract 
Germinal centre autoantibody responses following heart transplantation 
Muhammad Saeed Qureshi 
The development of humoral autoimmunity following organ transplantation is increasingly 
recognised, but of uncertain significance. I address the key question whether autoimmunity 
contributes independently to chronic graft rejection. 
In a MHC class II-mismatched murine model, I show that antinuclear autoantibody responses 
were initiated upon graft-versus-host allorecognition of recipient B cells by donor CD4 T cells 
transferred within the heart allograft. Rejected allografts displayed features of chronic humoral 
vascular rejection, with rejection mediated by long-lasting germinal centre (GC) responses, 
whose maintenance was dependent upon additional, cognate help from recipient T follicular 
helper (TFH) cells, and which diversified to encompass responses against vimentin autoantigen. 
Heart grafts transplanted into stable donor/ recipient mixed haematopoietic chimeras also 
provoked GC autoimmunity and were rejected with similar tempo, indicating that autoantibody 
can mediate graft damage despite host tolerance to alloantigen. An autonomous effector role 
for autoantibody was further suggested by the demonstration that F1 (BALB/c x C57BL/6) 
recipients reject parental BALB/c heart allografts, with rejection again dependent upon GC 
autoimmunity and help from recipient TFH cells.  
Thus GC autoantibody responses contribute to graft rejection independent of host adaptive 
alloimmunity, through a mechanism by which donor CD4 T cells initiate an auto reactive GC 
reaction that is then maintained and propagated by host TFH cells. The demonstration that one 
set of CD4 T cells triggers autoimmunity, but that a second subset of TFH cell is responsible for 
maintaining the response as a germinal centre reaction, has wider implications for our 
understanding of the pathogenesis of autoimmune disease.  
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1. Introduction  
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1.1. Challenges in solid organ transplantation 
Solid organ transplantation is one of the most remarkable and dramatic therapeutic 
achievements in medicine in the last 6 decades. It offers patients with end stage organ 
failure a cost effective treatment that improves quality of life and life expectancy.  
It was not possible till 1954, when the first successful kidney transplant was performed by 
Dr. Joseph Murray (Harrison et al., 1956), between a patient and his identical twin brother. 
With the subsequent advances in organ procurement, surgical techniques, 
immunosuppression and organ preservation, transplant outcomes have continually 
improved, leading to an increasing demand for organs. Several approaches have been 
adopted to try and meet this demand, but strategies that successfully improve long-term 
transplant outcomes would undoubtedly make a huge difference. Chronic rejection remains 
the leading cause of transplant loss, and as many as a quarter of adult UK patients awaiting 
kidney transplantation have already received at least one kidney. However chronic rejection 
remains a poorly understood process and the underlying mechanisms that lead to graft loss 
have not yet been clarified. Immune recognition of mismatched donor antigens is thought 
to be a critical aspect of chronic rejection, but it is notable that it is now very unusual, with 
modern immunosuppression, for a transplant to fail from acute rejection, and yet the 
incidence of chronic rejection has not changed.  
Consequently, patients generally remain on immunosuppression for the life of the 
transplant. This approach is not ideal, because current nonspecific immunosuppression is 
associated with increasing opportunistic infections and neoplasm in the recipients. Hence, in 
the current scenario, when more marginal organs are being used to compensate for organ 
shortage, it has become all the more important to improve our understanding of the 
pathogenesis and molecular pathways that govern chronic rejection. This will allow us to 
develop more tailored and more effective therapeutic strategies, which will finally improve 
long term outcomes for transplant patients.  
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1.2. Immunology in transplantation  
Adaptive immunity against donor antigens is a major obstacle to organ transplantation. It 
became apparent from initial work of Medawar and his colleagues that lymphocytes are the 
principal mediators of rejection (Gowans et al., 1962; Medawar, 1944). Later, Snell and 
Gorer’s ground-breaking work in tissue transplantation led to the discovery of the major 
histocompatibility complex (MHC)(Snell, 1948). MHC molecules on the donor are the 
principal target of the alloimmune response in transplantation.  
1.2.1. Development of T and B lymphocytes 
T and B lymphocytes are involved in antigen specific immune responses. They are the only 
cells in the organisms which are capable to recognise and respond specifically to each 
antigenic epitope. B cells differentiate into plasma cells or plasmablasts and produce 
antibodies, thus are involved with humoral immunity and T cells are central to cellular 
immunity. Below I will discuss their central development and differentiation into functional 
cells.  
1.2.1.1. Development of T cell in thymus 
T cells are derived from haematopoietic stem cells that are initially found in the fetal liver 
and then in the bone marrow. Only a small subset of common lymphoid progenitors migrate 
to the thymus and differentiate into early thymic progenitors, also known as thymocytes. 
Thymocytes undergo a series of maturation steps within the thymus that can be identified 
based on the expression of different cell surface markers. The majority of the cells in the 
thymus give rise to αβ receptor T cells, however a small percentage does bear γδ T cells. 
During this process of development, thymocytes interact with the stromal cells and undergo 
process of maturation as described below in different anatomical locations of the thymus. 
Thymus is made of subcapsular region, cortex, cortico-medullary junction and medulla.  
The stem cell that has committed to become T cells, thymocytes lack expression of the co-
receptors CD4 and CD8 molecules and are termed a double negative (DN) cells (Yang et al., 
2010). These DN can be further subdivided by the expression of CD44 and CD25. Cells that 
lack expression of CD44 but possess CD25 undergo β-selection process (DN3). It is important 
to note here that multiple gene segments for individual chains (α, β, γ and δ) dispersed in 
the genomic DNA must bind and transcribe to produce a functional TCR. All the chains 
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undergo this process of recombination independent of each other and begins with 
recombination of genes for the β chain (Abbey and O'Neill, 2008). TCR genes are assembled 
through V(D)J recombination. This is a site specific recombination process directed by the 
lymphoid-specific recombinase (RAG1 and RAG2) and DNA repair proteins. RAG proteins 
create double-strand breaks at recombination signal sequences (RSSs) that flank TCR 
variable (V), diversity (D) and joining (J) gene segments, and these breaks are subsequently 
resolved by nonhomologous end joining. During this process, β chain loci recombination 
competes with γδ recombination. In this competition normally β chain succeeds and stops 
recombination of γδ chain. In cases where γδ chain recombination is productive, γδ T cells 
exit from thymus as γδ T cells at this point, constituting approximately 5% of the total T cells 
(Carding and Egan, 2002; Vantourout and Hayday, 2013). If Beta chain recombination is 
productive then it pairs with the surrogate alpha chain called pre-Tα to produce a pre-TCR 
which forms a complex with CD3 molecules. This complex leads to the survival, proliferation, 
arrest in further β chain loci rearrangement and upregulation and expression of CD4 and 
CD8 molecules thus making them double positive (DP) cells (Fehling et al., 1995; Rothenberg 
et al., 2008; Saint-Ruf et al., 1994). β-selection process is considered as a check point to 
identify whether this β chain is functional or not. If pre-TCR is functional then it forms 
dimers and initiates signaling which results in turning on α chain recombination and turning 
off βγδ recombination. Cells that do not undergo beta-selection die by apoptosis. Double 
positive cells (DP) re-express RAG genes which initiate TCRα recombination to produce αβ-
TCR (Klein et al., 2009). 
Double positive cells then undergo positive selection in thymic cortex in which thymic 
epithelial cells present self-restricted peptides in the context of class I and class II MHC 
molecules (Anderson and Takahama, 2012). Only a small fraction of these DP lymphocytes 
which bind to the self-peptides with intermediate affinity survive while the others which are 
incapable of binding to MHC molecules undergo apoptosis. As a result of this selection 
process, DP cells that recognise MHC class I differentiate into CD4- CD8+ and DP cells that 
recognise MHC class II differentiate into CD4+CD8- cells. Subsequently these single positive 
(SP) cells entre into thymic medulla where they undergo negative selection process in which 
these SP cells are exposed to a diverse set of self-antigens presented by medullary thymic 
epithelial cells and antigen presenting cells (APCs), such as dendritic cells and macrophages. 
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Single positive T cells that interact with high affinity or avidity to self-antigens are eliminated 
by apoptosis thus ensuring central tolerance. Following selection, down regulation of either 
co-receptor produces either naïve CD4 or CD8 single positive cells. Naïve T cells leave the 
thymus and migrate continuously to the secondary lymphoid organs to be primed by 
antigen and differentiate into effector T cells. 
T cell receptor complex is composed of αβ or γδ variable chains which are associated with 
invariant accessory proteins (CD3γε, CD3δε and CD247 ζζ chains) (Wucherpfennig et al., 
2010). TCR α and β chains are very polymorphic, which enable T cells to recognise a wider 
repertoire of antigenic peptides. Each chain is made of a variable (V) and a constant domain 
(C) with a joining segment (J) that lies between them. The β chain also has an additional 
diversity segment (D). Each V domain has three hypervariable regions known as CDR1, CDR2 
and CDR3 (complimentarity-determining regions). These hyervariable regions undergo 
recombinations and result in the generations of different TCRs specific for a particular 
antigen. CDR3α and beta regions bind to the central region of the antigenic peptide 
presented and is the most diverse part of the TCR and considered the main determinant of 
specificity in antigen recognition. CD3 chains and the CD247 ζζ chains that associate with 
TCR possess tyrosine based activation motif (ITAMS) in their intracytoplasmic tails which are 
phosphorylated to initiate T cell activation (Baniyash, 2004).  
1.2.1.2. Development of B cell  
Early B cell development and commitment to B cell lineage initiates in the foetal liver 
prenatally, thereafter it continues within the bone marrow throughout the life of animal. B 
cells play a pivotal role in adaptive immunity and are responsible for mediating the 
production of antigen specific immunoglobulins i.e. antibodies which help fight against 
invasive pathogens. The function of B cells was discovered in 1960s (Cooper et al., 1965) by 
Max Cooper et al after a series of experiments in birds, mammals and immunodeficient 
patients by showing that antibody production was completely abrogated in irradiated 
chickens after surgical removal of the Bursa of Fabricius. Bursa of fabricius is the primary 
site for B cell development in birds and from which the notation ‘B’ cell was derived.  
Haematopoietic stem cells (HSC) which are committed to become B cells differentiate into 
early lymphoid progenitor (ELP) which further differentiate into common lymphoid 
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progenitor (CLP). CLP on one end lead to development of DC and NK cells and on the other, 
differentiate into CLP-2 which is responsible for B cell lineage. This is considered the first 
stage of the immature B cells. A prerequisite for the development of B cells in the bone 
marrow is the suppression of protein Notch-1 (N1) signaling, which is necessary for T cell 
development (Cruickshank and Ulgiati, 2010). From here their development into B cells 
occur in several stages. Functional B cell receptor development is dependent on productive 
and sequential rearrangement of a heavy and light chain gene directed by RAG proteins. 
Immunoglobulins consist of two identical heavy and light chains, which are joined by di-
sulphide bonds. CLP and early B cells undergo Ig heavy chain recombination, first 
commencing with D-J recombination on both chromosomes (paternal and maternal). Non-
productive rearrangement will lead to apoptosis of early B cells at this stage while 
productive rearrangement on both chromosomes leads to V-DJ recombination. V-DJ 
recombination takes place on the first chromosome (maternal/paternal). If this 
recombination fails then V-DJ recombination takes place on the second chromosome. As a 
result of successful V-DJ recombination, 50% of the cells are signaled to survive and to 
become large pre-B cell. Due to non-productive V-DJ recombination, ½ of the cells undergo 
apoptosis. The recombined heavy chain then associates with the surrogate light chains to 
check that heavy chain can form the di-sulphide bond with this surrogate light chain which is 
structurally similar to light chain. At this stage, pre B cell receptor (pre-BCR) is expressed on 
the cell surface. Signalling through the pre-BCR drives intense proliferation and as a result, 
significantly increases their number and guarantees that they successfully carry out the 
heavy chain recombination. Furthermore, signalling through pre-BCR directs activation of 
the gene recombination for the light chain(von Boehmer and Melchers, 2010). These pro-B 
cells thus differentiate into the small pre-B cell stage  (Herzog et al., 2009). Small pre-B cell 
then undergo V-J rearrangement of the Ig light chain genes starting with kappa chain gene 
(κ chain) first and if the recombination is productive, the immature B cell expresses the µ 
chain and the κ chain which results in functional IgM. If the κ chain gene rearrangement was 
not productive then lambda chain genes (λ) undergo V-J rearrangement. As a result of 
successful rearrangement on λ chain gene, IgM+ immature B cell expresses µ chain and the 
λ chain. The odds of failing a light chain gene rearrangement is very low. The ones who have 
survived the heavy chain rearrangement, will survive the light chain rearrangement as well.  
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The fate of immature B cells is determined by the strength of B cell signalling (Yurasov et al., 
2005). In the absence of a signal that is stronger than that provided by tonic BCR signaling, 
the cells exit the BM as immature transitional B cell towards secondary lymphoid organs 
where they undergo final differentiation and maturation through distinct transitional B cell 
stages termed as T1 and T2 before differentiating into long lived mature follicular (FO) or 
marginal zone (MZ) B cells (discussed in detail below in section 1.2.3).  Thus, B cells undergo 
antigen dependent and independent phases of differentiation and maturation and each 
phase tightly regulated by signalling events. Apart from T1 and T2 B cells, there is another 
subset of B cells termed as T3 B cells which represent a subset of anergic B cells which have 
been selected away from the development pathway. With regards mature B cells, in 
addition to FO and MZ mature B cells, there is another population of mature B cells called as 
B1 cells which is found in the spleen, intestine, peritoneal cavity and pleural cavity but less 
commonly in the blood. B1 cells have a distinct haematopoietic origin in the fetal liver and 
appear to play a role during an infection or vaccination (Cunningham et al., 2014).  
Within the bone marrow, immature B cells undergo central tolerance to prevent 
autoimmunity by clonal deletion/receptor editing or clonal anergy. B cell receptor that bind 
with multivalent self-antigens with strong affinity result in clonal deletion or receptor 
editing while immature B cells that recognise monovalent self-antigen usually soluble 
proteins in the blood vessel become non-responsive or anergised and are characterized by 
IgD expression with little to no IgM.  
Receptor editing is a major mechanism of central tolerance in B cells in which a productively 
rearranged immunoglobulin light chain or heavy chain variable region gene undergo 
replacement with another one , either on the same chromosome, on the homologous 
chromosome or through an isotype switch (κ light chain to λ light chain) (Luning Prak et al., 
2011). During this process if a developing B cell expresses a heavy/light chain combination 
that recognise a self -antigen with sufficient affinity , it can be signaled to continue to 
express Ig gene recombination machinery including RAG1 and RAG2  genes. This then 
undergo further rearrangement that replace either the light chain or heavy chain variable 
regions so that a new BCR is produced that is no longer self-reactive. These immature B cells 
then migrate to the periphery as transitional B cell stages termed as T1 and T2 before 
differentiating into long lived mature follicular (FO) or marginal zone (MZ) B cells. The role of 
24 
receptor editing in the secondary lymphoid organ is controversial. The receptor editing in 
the periphery is also termed as receptor revision. The evidence for this is the expression of 
RAG gene in the spleen and lymph nodes especially after an antigenic challenge (Yu et al., 
1999). Furthermore, in vitro experiments in mice have suggested that RAG genes can be 
upregulated in B cells by stimulating them with LPS and IL-4 (Hikida et al., 1996). Similarly, in 
autoimmune mice RAG genes were reinduced in antigen activated early memory or 
preplasma B cells which helps to prevent autoimmunity in the periphery (Wang and 
Diamond, 2008). However, in another study peripheral receptor editing resulted in the 
development of an autoantibody (Brard et al., 1999). 
1.2.2. Allorecognition in transplantation 
Allorecognition refers to the recognition of donor antigens by the recipient T cells. The 
transplant antigens can be major histocompatibility (MHC) antigens or minor 
histocompatibility antigens (MiHA) which can be recognized by CD4 or CD8 T cells by 
different pathways of allorecognition.   
There are three classes of MHC genes (HLA in humans and H-2 in mice); but only class I and 
class II are involved in antigen presentation. MHC class I consists of two polypeptide chains, 
α and β2-microglobulin. Only the α chain is polymorphic and encoded by a HLA gene, while 
the β2-microglobulin subunit is not polymorphic and encoded by the Beta-2 microglobulin 
gene. The class I α chain is composed of three extracellular domains (α1, α2, and α3), a 
transmembrane segment, and a short cytoplasmic tail (Bjorkman et al., 1987). The α1 and 
α2 domains fold together to form a deep groove that constitutes the peptide binding site. 
The bound peptide and associated regions of the α1 and α2 domains interact physically with 
the T-cell receptor (Wu et al., 2002). The amino acid sequence of α3 domain interacts with 
β2-microglobulin and also serves as binding site for the CD8 co-receptor, which facilitates 
the interaction of T cells with MHC class I molecules. The peptides which associate with 
MHC class I molecules have preferential anchor residues, which are important for binding to 
specific MHC class I alleles (Gavioli et al., 1995; Haurum et al., 1995). This allows binding by 
a wide repertoire of peptides. The cytoplasmic tail of MHC class I molecule plays a critical 
role in intracellular trafficking and in dendritic cell-mediated antigen presentation and 
cytotoxic T lymphocyte (CTL) activation.   
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 MHC Class II molecules are composed of an ɑ chain and a β chain. The α-chain and β-chain 
of MHC-II is a membrane bound glycoprotein that contains external domains, a 
transmembrane segment and a cytoplasmic tail. The ɑ chain and β chain are made up of two 
domains (ɑ1 and ɑ2) and (β1 and β2) respectively. The α1 and β1 regions of the chains 
associate to form a membrane-distal peptide-binding domain, while the α2 and β2 regions, 
the remaining extracellular parts of the chains, form a membrane-proximal 
immunoglobulin-like domain. The antigen binding cleft, composed of two alph-helicles 
above a beta pleated sheet, specifically binds short peptides, about 15-24 residue long. The 
amino acid sequence around the binding site, which specifies the antigen binding 
properties, is the most variable site of the MHC molecule. All nucleated cells express MHC 
class I, whereas MHC class II proteins are expressed mostly on dendritic cells (DCs), B cells, 
and can be induced on endothelial cells. Classically, class I molecules present peptides of 
endogenous proteins to CD8 T cells and class II molecules to CD4 T cells. 
Minor histocompatibility antigens are normal proteins that are encoded by many 
chromosomes. Even when the transplant donor and recipient are identical at their MHC loci, 
differences in amino acid sequence on these minor histocompatibility antigens can lead to 
rejection.  As a consequence of mismatches at minor HC antigens, immunosuppression is 
still required in recipients of organs from HLA matched, non-identical twin siblings. The 
prototypic example of a minor antigen is the H-Y antigen, which is derived from group of 
proteins encoded by the Y chromosome. Allo-responses to this minor antigen may explain 
reduced long term survival of allografts in female recipients of male grafts (Gratwohl et al., 
2008). Other examples of minor histocompatibility antigens are MHC I-related chain 
antigens (MICA), ABO blood groups glycoproteins, and autoantigens. The MHC I-related 
chain antigens are surface glycoproteins and encoded by MICA gene. These are expressed 
on the surface of endothelial cells and are thought to be involved in innate immunity. These 
proteins are ligands for the activating receptor NKG2D on NK cells, CD8 T cells, and 
gamma/delta T cells. Exposure of allogenic MICA proteins in transplantation can elicit 
antibody formation in recipients (Zou et al., 2006). Pre-sensitization of kidney-transplant 
recipients against MICA antigens is associated with an increased frequency of graft loss and 
might contribute to allograft loss among recipients who are well matched for HLA  (Zou et 
al., 2007). The ABO blood group glycoproteins are other MiHA which are expressed on the 
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surface of endothelial and red blood cells. Finally immune responses to autoantigens have 
been reported to be associated with allograft damage (Dave and Bayless, 2014; Win and 
Pettigrew, 2010; Zhang and Reed, 2016). 
T cells recognise alloantigens by two pathways; the direct and indirect pathway of 
allorecognition (Rogers and Lechler, 2001). In the direct pathway, the intact donor MHC 
class I and class II are presented by donor antigen presenting cells (APCs), and are 
recognised by recipient CD8 or CD4 T cells respectively. In the indirect pathway, recipient 
CD4 T cells recognise endogenously processed allopeptide fragments presented in the 
context of host MHC class II by recipient APCs. In comparison, the precursor frequency of T 
cells that can respond via the indirect pathway of allorecognition is similar to self-restricted 
responses against conventional protein antigens (such as viral proteins), and 
approximately100 fold less than that observed in direct allorecognition (Liu et al., 1993).  
The direct pathway CD4 T cell responses are thought to be the principal contributor to early 
rejection episodes due to the high precursor frequency of alloreactive T cells in the 
periphery (Bach and Hirschhorn, 1964; Ichikawa et al., 1987; Rosenberg et al., 1987; 
Rosenberg et al., 1991). Consequently, the indirect pathway CD4 T cell responses are 
thought to be principally involved in chronic rejection (Conlon et al., 2012; Haynes et al., 
2012). 
1.2.3. Generation of humoral immune response and germinal centres 
Humoral immune response is mediated by antibodies produced by B cells against the 
invading extracellular microorganisms and prevent the spread of intracellular infections.  In 
transplantation, antibodies have been thought to be responsible for chronic rejection of 
organs (discussed below in section 1.3). Antibodies are generated as result of B cell 
activation following interaction with an antigen. The development of antibodies is 
remarkably complex, with a number of different B cell subpopulations at different 
anatomical locations (B1 (Herzenberg, 2000), marginal zone (Martin and Kearney, 2002), 
extrafollicular (MacLennan et al., 2003) and germinal centre (GC) (Allen et al., 2007a) 
contributing to varying degrees to the overall antibody response.  
Following maturation of the B cells in the bone marrow and spleen (discussed in section 
1.2.1.2), immunocompetent B cells remain in peripheral tissues until they are activated by 
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an antigen. B cell activation requires two distinct signals; the first activation signal occurs 
upon antigen binding to B cell receptors. Upon binding to the BCR, the antigen is 
internalized by receptor-mediated endocytosis, digested, and complexed with MHC II 
molecules on the B cell surface. The second activation signal occurs via either a thymus-
dependent (T-dependent) or a thymus-independent (T independent) mechanism. In a T-
independent immune response B cells can respond directly to the antigen like some 
bacterial cell wall components (e.g., lipopolysaccharide) or antigens containing highly 
repetitious molecules (e.g., bacterial flagellin). In a T-dependent immune response, the B 
cells need help from T cells in order to respond. 
Marginal zone (MZ) B cell response to antigen is thought to be T- independent and is a crucial 
component of the early response to blood borne antigens. This B-cell subset helps to bridge 
the temporal gap between the innate immune response and adaptive immune responses. They 
are charctersied by IgMhi, IgDlow, CD21hi and CD23low surface markers and mostly are non-
recirculating (Berland and Wortis, 2002; Martin and Kearney, 2000). Anatomically, marginal 
zone B cells are separated from mature follicular B cells by the marginal sinus. In addition to 
being anatomically distinct from other the other cell types, MZ B-cells exhibit a high antigen-
presenting capacity (Oliver et al., 1999; Tanguay et al., 1999), and preferentially secrete 
complement-fixing, multi-reactive immunoglobulin (Hardy and Hayakawa, 2001). Humoral 
response generated from marginal zone B cell arm is thought to play an important role in  
For T dependent humoral responses, there are two main mechanisms by which B cells form 
antibodies; extrafollicular pathway (EF) or germinal centres (GCs), depending on the type of 
help B cells receives from CD4 T cells (Garside et al., 1998).  Upon stimulation of BCR, B cells 
secrete macrophage inflammatory protein (MIP-1α) and dendritic cell chemokine-1(ABCD-1), 
which are T cell chemoattractants (Cyster, 1999). This promotes T-B cell interaction at T-B cell 
border of lymphoid organs. This involves a cognate, physical linkage between the MHC class II-
peptide complex of the B cell and T cell receptor of the alloantigen. At T-B border, B cells which 
have sustained interactions with CD4 T cells through signalling-lymphocyte-activation molecule 
(SLAM) receptors migrate to B cell follicles to develop into germinal centres (Qi et al., 2008) 
while others migrate to the medullary cords in the lymph nodes or the bridging channels in the 
spleen to form extrafollicular foci (EF pathway). Extrafollicular plasma cells secrete class-
switched antibody for around three days, after which the majority undergo apoptosis (Smith et 
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al., 1996). But a small fraction can live for longer periods in the secondary lymphoid tissues 
(Sze et al., 2000). This initial burst of antibodies with modest affinity for antigen plays an 
important role in the early control of infection (Luther et al., 1997).  
Long lasting antibodies are the result of germinal centres (GCs) which are characterised by a 
light zone and a dark zone. The germinal centre response begins in the dark zone where the B 
cells rapidly proliferate and are called centroblasts. These B cells undergo somatic 
hypermutation during which random mutations are generated in the variable domains of the 
BCR by the enzyme activation-induced cytidine deaminase (AID) (Berek et al., 1991; 
Muramatsu et al., 2000). B cells then enter the light zone and compete with each other for 
antigen. If the mutation resulted in a BCR with an improved affinity to the antigen, the B cell 
clone can out-compete other clones and survive. However, B cells which lack this high affinity 
recirculate between the dark and light zone to achieve high affinity BCR against the antigen by 
undergoing rounds of somatic hypermutations or die by apoptosis. Within the light zone, the B 
cells (centrocytes) which survive move about the FDCs network and pick up antigens, receiving 
pro-survival BCR signals (Allen et al., 2007a) thus internalising, processing and presenting the 
antigen as peptide complex in the context of MHC class II (MacLennan, 1994). In doing so, the 
high affinity B cells may be able to pick more antigen than low affinity B cells before 
internalisation. Then these GC B cells compete with other GC B cells and dead B cell blebs for 
follicular helper CD4 T cell (TFH cell) help in the light zone. It is now widely accepted that GC are 
dependent on special subset of CD4 T cells for their development called follicular helper CD4 T 
cells (TFH cell) (Yu and Vinuesa, 2010). The TFH cell in GC is positioned in such a way that only 
one TFH makes stable interaction with the B cell which bears the highest number of the antigen 
peptide complex on MHC class II molecule (Allen et al., 2007a; Allen et al., 2007b).  The 
centrocyte that receives help from TFH cell can either exit the GC as LLPC and memory B cells or 
return to the dark zone for further affinity maturation (Kelsoe, 1996; Victora et al., 2010). 
However, if centrocyte B cell does not receive help from TFH cell at this stage, the response 
collapses (de Vinuesa et al., 2000; Qi, 2012). 
The widely accepted view is that LLPCs are exclusively a consequence of a GCs response (Good-
Jacobson et al., 2010; Han et al., 1995; MacLennan, 1994; Takahashi et al., 1998; Vinuesa et al., 
2009). On immunostaining, these GCs have been characterised by PNA and GL 7 positivity, and 
it has been suggested that activated germinal centre B cells can be probed with peanut 
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(Arachis hypogaea) lectin (Rose et al., 1980), peanut agglutinin (PNA) (Coico et al., 1983; 
Muramatsu et al., 1999) or a rat monoclonal antibody (MAb), GL7 (Cervenak et al., 2001). PNA 
is a lectin with specificity for terminal galactosyl residues and it has been found that GC B cells 
have high levels of PNA compared to other lymphocytes. Similarly, GL7 was originally reported 
as a marker of activation for polyclonal T and B cells in mice (Laszlo et al., 1993). GL7 was also 
found to stain a subpopulation of T cells (Han et al., 1996) and a subpopulation of the large 
pre-B-cell stage during differentiation in the bone marrow (Murasawa et al., 2002). However, 
activated B cells express the GL7 epitope, but mature B cells do not; thus, GL7 serves as a 
marker for germinal centres in the immunized spleen (Han et al., 1996; Pasare and Medzhitov, 
2005; Shapiro-Shelef et al., 2003) or lymph nodes. Functional comparison between GL7hi and 
GL7lo splenic B cell population in immunised mice showed significantly more specific and 
higher total antibody production as well as antigen presenting capacity in the GL7hi population 
(Cervenak et al., 2001). In addition to the LLPC, GCs generate memory B cells, which are 
another aspect of long lived humoral immunity. Importantly, within the germinal centre, B cells 
undergo somatic hypermutation (SHM) of immunoglobulin (Ig) variable (V) region genes, and 
the subsequent selection of B cells based on the affinity of the encoded B-cell receptor (BCR) 
for the eliciting antigen (Ag) results in affinity maturation (Berek et al., 1991; MacLennan, 
1994).   
The TFH cell is critical for the initiation and maintenance of the GC response, but debate 
persists regarding their signature markers. Critical to their function is their ability to localise 
within the germinal centre follicle. This is achieved by upregulation of CXCR5; the receptor 
for B cell follicle-produced chemokine CXCL13 (Breitfeld et al., 2000; Schaerli et al., 2000; 
Vinuesa et al., 2005), and is probably expressed as a consequence of the T-B cell cognate 
interaction that occurs at the T-B cell border at the onset of the response (Garside et al., 
1998). Within the follicle, the TFH cell sustains the germinal centre response by providing 
essential survival signals to centrocytes (again through cognate interaction with the peptide-
MHC II complex of the B cell (Vinuesa et al., 2009)). The number of TFH cells is extremely 
limited and only high affinity helper T cells are selected to become TFH cells (Fazilleau et al., 
2009). Thus competition for the help they provide is postulated as one of the main 
mechanisms for driving affinity maturation, because only those B cells that bind target 
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antigen most strongly present enough peptide to receive effective help (Allen et al., 2007a; 
Allen et al., 2007b). 
Aside from CXCR5, TFH cells express a number of markers that distinguish them from other 
CD4 T cell subsets and which could in theory be targeted to achieve selective depletion. B 
cell lymphoma 6 (Bcl-6) has been described as the master transcription factor (Crotty et al., 
2010; Johnston et al., 2009; Nurieva et al., 2009; Yu et al., 2009), and is induced by 
interaction with the B cell. Germinal centres do not develop if the T cell population is 
deficient in Bcl-6 expression (Johnston et al., 2009; Yu et al., 2009). Equally critical is 
expression of signalling-lymphocyte-activation molecule associated protein (SAP, (Qi et al., 
2008)). T cells that lack SAP expression do not form the same stable, initial interactions with 
B cells at the T-B border as can be visualised with SAP+ve  T cells (Qi et al., 2008), and do not 
migrate into the follicle. Without SAP signalling, the GC response is curtailed. IL-21 secretion 
also appears to be fundamental for follicular helper T cell function (Linterman et al., 2010; 
Nurieva et al., 2008; Schmitt et al., 2009; Vogelzang et al., 2008; Zotos et al., 2010) and in its 
absence the GC response is terminated rapidly with production of low affinity antibody. 
Finally both ICOS and PD-1 expression also characterise the TFH cells subset (Good-Jacobson 
et al., 2010; King et al., 2008).  
1.2.4. Immunological tolerance and transplantation  
Immunological tolerance is basically a state of unresponsiveness in which the lymphocytes 
may remain alive but cannot mount an effective immune response against an invading 
antigen which is achieved by central and peripheral mechanisms. In central tolerance, 
lymphocytes with receptors specific for self-antigens are deleted/edited or become anergic 
during their development at an early stage (discussed in section 1.2.1). Furthermore some 
CD4+ve T cells receive signals in the thymus that select them to differentiate into natural T 
regulatory (nTRegs), which express the FoxP3 transcription factor and suppress the immune 
response by doth direct and indirect mechanisms (Ferrer et al., 2014; Louis et al., 2006; 
Nafady-Hego et al., 2010; van der Net et al., 2016). Escape of the self-reactive T cells and B 
cells into the periphery may result in autoimmunity. However, these are deleted by apoptosis 
or become anergic or are kept under control by natural regulatory T cells or induced T 
regulatory cells (iTRegs) (Curotto de Lafaille and Lafaille, 2009). Induced T regulatory cells 
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have similar effector function as nTRegs but they are produced in the periphery (Romano et 
al., 2019; Schmitt and Williams, 2013).  
In transplantation, a small group of recipients display stable graft function in the absence of 
immunosuppression, while maintaining an intact immune response to infections. This 
phenomenon is called operational tolerance. Operationally tolerant recipients have displayed 
differences in gene expressions, peripheral blood cell populations and transcripts compared 
to immunosuppressed patients in chronic rejection and healthy volunteers (Sarwal, 2016). 
Unique genetic expression has been identified from tolerant kidney and liver recipients 
compared to those with chronic rejection (Brouard et al., 2007; Martinez-Llordella et al., 
2007). This could potentially help identifying the potential candidates for reducing 
dependence on immunosuppression (Roedder et al., 2015).  
Furthermore the concept of divided tolerance or split tolerance was described in late 1950s 
in which there was selective acceptance of syngeneic C57BL male skin graft by C57BL female 
who were immunised at birth with allogenic cells derived from A strain males but rejection 
of donor skin grafts from A strain males (Lustgraaf et al., 1960). This concept has been 
further studied by others in which one organ may be accepted by a recipient while grafts of 
other tissues from the same donor were rejected (Chan et al., 2008; Chung et al., 2005; Luo 
et al., 2007; Mathes et al., 2003; Qian et al., 1997). Although mechanisms leading to split 
tolerance are not well understood, but is applicable to the immunological relationship 
between mother and foetus. De Mastre et al (de Mestre et al., 2010) studied this 
relationship in pregnant mares in which they found that antibody responses to paternal 
MHC class I antigens were robust while anti-paternal cytotoxic T cell responses were 
diminished compared to those mounted by non-pregnant mares. Furthermore they 
demonstrated that a state of split tolerance exist in trophoblast tissue in endometrial cups 
which is maintained by higher number of interferon gamma positive lymphocytes and 
FOXP3 positive cells in endometrial cups compared to the maternal peripheral blood 
lymphocytes. 
1.3. Chronic rejection 
Acute allograft rejection has been largely controlled, with advances in modern 
immunosuppression. Long term survival of grafts is hampered by a slow deterioration in 
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graft function, leading to eventual failure. This process, loosely termed chronic rejection, is 
characterised by the development of chronic allograft vasculopathy. The term chronic 
rejection was introduced by Hildemann in 1960 referring to rejection of skin grafts observed 
in animal models (Hildemann and Walford, 1960). They reported that some of the grafts in 
their study had delayed onsets of rejection, with prolonged periods of rejection 
accompanied by atrophy and fibrosis. During this process, the graft arteries developed 
intimal hyperplasic lesions that, by obstructing blood flow to the grafts, resulted in relative 
tissue ischaemia. This is known by various names in the literature, but will be referred to as 
allograft vasculopathy (AV) throughout this thesis. Allograft vasculopathy has an incidence 
of 8% within the first year of cardiac transplants, 32% within five years, and 43% within first 
eight years (Taylor et al., 2006). One study has even detected AV in almost 50% of cardiac 
allografts within the first year after transplantation (Tuzcu et al., 2005).  The development of 
AV is associated with high recipient morbidity and mortality (Taylor et al., 2006; Tuzcu et al., 
2005).  Similarly, chronic rejection accounts for 40% of renal graft losses beyond the first six 
months following transplantation (Li and Yang, 2009).   
AV is characterised by diffuse, progressive and concentric narrowing of the arteries as a 
result of formation of neointima (Billingham, 1992). The neointima consists predominantly 
of smooth muscle cells and associated extracellular matrix, fibroblast cells, macrophages 
and T cells. Initially, smooth muscle cells from media were thought to be the origin of these 
smooth muscle cells; but at least two other sources of these have been identified. This 
includes recipient smooth muscle cells as well as  donor or recipient endothelial cells 
(Hillebrands et al., 2001), which can differentiate into mesenchymal or smooth muscle cells 
under the influence of cytokines such as TGFβ (Zeisberg et al., 2007). The internal and 
external lamina remains intact. The media layer is mostly unaffected. However, AV results in 
the development of adventitial fibrosis (Libby and Pober, 2001) which may contribute to the 
vessel contraction independent of intimal proliferation. Adventitia provides the vasomotor 
tone to the arteries; adventitial fibrosis will thus limit the outward expansion of arteries to 
compensate for the thickened neointima (Mitchell and Libby, 2007). As a result, the lumen 
of the arteries is narrowed, leading to reduced blood flow to the grafts and ischemic 
parenchymal atrophy in the grafts.  
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Both AV and atherosclerotic diseases are atheromatous in origin, sharing many common 
characteristics like endothelial dysfunction, intimal thickening, aberrant buildup of 
extracellular matrix and leukocyte infiltration. But the pathological features of AV differ 
from that of atherosclerosis, in that AV is a diffuse and concentric plaque deposition in all 
vessel types within the allograft, mostly intra-myocardial vessels (Billingham, 1992; Lin et al., 
1994), whereas atherosclerosis is focal and eccentric and involves proximal coronary 
vessels. Signs of inflammation are seen in AV but rarely in atherosclerosis. Furthermore in 
atherosclerosis, there is deposition of calcium and disruption of internal elastic lamina, 
which is not observed in AV (Aranda and Hill, 2000). The development of AV can occur 
within a year (Weis and von Scheidt, 2000) compared to atherosclerosis which evolves over 
decades (Stary, 1989).  
1.3.1. Pathophysiology of allograft vasculopathy 
The pathophysiologic features of AV, although not completely understood, likely involve 
components of both immune-mediated and nonimmune-mediated endothelial damage 
(Gao et al., 1988).  There is substantial evidence that an interaction between alloantigen 
dependent alloimmune responses (adaptive and innate immune responses) and alloantigen 
independent factors (donor and recipient characteristics, ischaemic reperfusion injury (IRI)) 
contributes to the development of chronic rejection. The cumulative endothelial injury is 
thought to trigger a cascade of repair mechanisms that involve vascular cell proliferation, 
fibrosis and vascular remodelling, ultimately leading to intimal thickening and luminal 
narrowing (Hosenpud et al., 1992). The endothelial injury in AV can be denuding or non-
denuding. In non-denuding injury, a rapid replacement of injured endothelial cells leads to 
endothelial dysfunction (Russell, 2000). Both immune-related and nonimmune-related 
factors contribute to non-denuding injury. In contrast, denuding injury is caused by 
ischemia–reperfusion injury, which leads to exposure of underlying smooth muscle cells and 
extra cellular matrix to blood, thus raising the potential for thrombus formation. Although 
thrombus formation is not an obvious feature of AV, it can trigger the clotting cascade, 
which has been shown to contribute to the development of arterial disease (Yen et al., 
2002).  
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1.3.1.1. Alloantigen dependent alloimmune responses  
The trigger to cell-mediated rejection is allorecognition, in which non-self-antigens are 
detected by the host immune system (Rogers and Lechler, 2001). These non-self 
alloantigens are recognised by the host immune system by three distinct mechanisms called 
direct, indirect and semi-direct pathways. The direct pathway results from the recognition 
of foreign intact major histocompatibility (MHC) molecules on the surface of donor APCs by 
recipient T cells  (Rogers and Lechler, 2001). Direct alloimmunity is thought to be short lived, 
because donor APC are destroyed during the initial priming of T cells (Saiki et al., 2001). In 
support, direct alloreactivity was not detected in renal transplant recipients suffering 
chronic rejection (Baker et al., 2001a; Baker et al., 2001b). Indirect allorecognition occurs 
when donor antigens are internalized, processed, and presented as peptides by host APCs in 
the context of self-MHC II to recipient CD4 T cells. Because indirect pathway responses can 
theoretically occur for months or years after transplant, they are thought to be more 
relevant for the development of chronic rejection or AV (Conlon et al., 2012; Rogers and 
Lechler, 2001; Weis and von Scheidt, 2000). In the semi-direct pathway (Smyth et al., 2006), 
recipient DCs not only acquire donor MHC, but also re-present it as intact (non-processed) 
antigen on the cell surface to be recognized by recipient T cells (Marino et al., 2016). 
However its contribution to AV is unknown.  
CD4 T cell activation is central to the pathogenesis of AV. In animal models, blocking CD4 T 
cell co-stimulation achieves graft tolerance and significantly reduces vasculopathy (Fischbein 
et al., 2000; Glysing-Jensen et al., 1997). Clinical studies show a predominance of Th-1 type 
immune responses in AV (Methe et al., 2005a). Similarly increased Th-1 type immune 
responses both in blood and biopsy samples have been associated with chronic rejection 
(Methe et al., 2005b; van Besouw et al., 1997). The importance of T cells is highlighted by 
the fact that nude mice (that lack T cells, but contain a mature B cell compartment) do not 
develop AV, even when there is a major MHC mismatch between donor and recipient (Shi et 
al., 1996). Similarly, treating recipients with anti CD4 and anti CD8 monoclonal antibody 
ameliorates AV in donor hearts (Nagano et al., 1998). Activated T cells not only cause injury 
to the graft endothelium via cytokines such as IFN-γ (Koh et al., 2004), they also provide 
essential help to B cells for the generation of humoral immunity (Steele et al., 1996; Taylor 
et al., 2007). 
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Although research has tended to focus upon cellular immunity as central to the 
pathogenesis of AV; increasing evidence suggests that humoral alloimmunity plays an 
important role (Vongwiwatana et al., 2003). The development of anti-donor HLA 
alloantibody after kidney transplantation is now known to be a major determinant of graft 
survival (Gaston et al., 2010). The de novo development of donor HLA specific antibodies is 
linked to the development of post-transplant glomerulopathy, which is associated with a 
reduction of 10 years in median graft survival (Eng et al., 2011). Similarly, alloantibody 
development correlates with early heart (Ho et al., 2011), lung (Girnita et al., 2007) and liver 
(Stegall, 2010) transplant failure. Antibodies target endothelial cells and can mediate injury 
by complement-dependent and independent mechanisms. The role of antibody mediated 
rejection (AMR) in the pathogenesis of AV remained controversial until 1990, when Feucht 
et al reported C4d deposition, a durable marker of complement activation, in renal graft 
capillaries (Feucht et al., 1991). Later it was confirmed that C4d staining was associated with 
the presence of donor specific antibodies in acutely rejecting renal grafts (Collins et al., 
1999). Many reports have suggested an association between C4d deposition and 
histopathologic features of chronic rejection in renal grafts (Regele et al., 2002). As the 
presence of circulating anti-HLA alloantibodies often correlates with histological changes of 
chronic rejection within the allograft (Mauiyyedi and Colvin, 2002; Regele et al., 2002) and is 
associated with early graft failure (Lee et al., 2002), the combination of donor specific 
antibody (DSA) and C4d deposition has been accepted as a reliable criteria for diagnosis of 
AMR (Rodriguez et al., 2005; Smith et al., 2005). Complement activation leads to graft injury 
by producing leukocyte chemoattractant products C3a and C5a and by lysing endothelial 
cells through membrane attack complex C6, C7, C8 and C9 (Nakashima et al., 2002). 
1.3.1.2. Interaction between alloantigen independent factors and alloimmune responses 
Allograft Vasculopathy (AV) has long been regarded as synonymous with chronic rejection, 
but this is misleading, as it does not adequately take into account alloantigen independent 
factors. Alternatively, the ‘response to injury’ concept may provide a better model of the 
underlying factors and their interactions that lead to the development of AV. 
This concept states that graft vasculopathy is the result of a continuous inflammatory 
response to tissue injury initiated by both alloantigen-dependent and independent stress 
responses (Vassalli et al., 2003; Weis and von Scheidt, 2000).  
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A variety of nonalloimmune insults, including brain death, organ preservation, surgical 
trauma, ischemia-reperfusion injury, cytomegalovirus (CMV) infection, hypertension, 
hyperlipidaemia, have been associated with immune activation, endothelial dysfunction, 
and development of AV (Rahmani et al., 2006; Sharples et al., 2003; Valantine, 2003; Vassalli 
et al., 2003; Weis et al., 2004; Weis and von Scheidt, 2000). Upon endothelial activation, 
endothelial adhesion molecule and chemokine expression is upregulated, vascular growth 
factors and thrombogenic molecules are expressed, and immune cells invade the graft 
(Rahmani et al., 2006; Valantine, 2003; Weis and von Scheidt, 2000). One good example of 
how increased graft immunogenicity induces a host alloimmune response, even in the 
absence of non-self-antigens, is brain death–induced immune activation. In brain death 
donors, a series of neural, hormonal and molecular changes  (Pratschke et al., 2005) occur 
that result in upregulation of adhesion ligands and MHC molecules, as well as increased 
cytokine secretion. These changes can trigger T cell activation via the different 
allorecognition pathways. Nonspecific inflammation, derived from ischaemia-reperfusion 
injury or metabolic dysregulation, further promotes the shedding of intact, soluble MHC 
molecules, which again might prime the indirect allorecognition pathway (Pratschke et al., 
2005). 
1.4. Autoimmunity and Allograft vasculopathy 
Although several alloimmune dependent and alloimmune independent factors contribute to 
the development of AV against donor derived MHC antigens, the role of antibodies against 
non-HLA donor antigens has been increasingly associated with poor graft outcomes (Dave 
and Bayless, 2014; Dragun et al., 2013; Dragun et al., 2016; Dragun et al., 2005; Fedoseyeva 
et al., 2002; Fedoseyeva et al., 1996; Fedoseyeva et al., 1999; Mahesh et al., 2007; Zhang 
and Reed, 2016). These non-HLA antigens are expressed mostly on epithelial and 
endothelial cells. MHC class I chain-related gene A (MICA) and tissue specific autoantigens 
such as vimentin, cardiac myosin (CM) and collagen V are the most studied non-HLA 
transplant antigens. The impact of these non-HLA antibodies is most dramatically 
demonstrated by the acute AMR that occurs in about 3% of cases in the absence of 
demonstrable anti-HLA alloantibody (Amico et al., 2008). Nevertheless, their contribution to 
chronic rejection remains controversial, and it is possible that they either represent 
bystander responses that are triggered as a consequence of ongoing, aggressive alloimmune 
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responses (Fukami et al., 2009) or that they may affect rejection by precipitating or 
augmenting conventional T and B cell alloimmune responses towards the graft (Cardinal et 
al., 2013; Harper et al., 2016; Lovegrove et al., 2001; Yoshida et al., 2006). Fukami et al 
demonstrated that antibodies to donor-MHC class I can induce autoimmunity, mediated by 
IL-17, which plays a pivotal role in chronic rejection post-lung transplantation. His work 
involved intra bronchial administration of anti-MHC class I antibodies into native Balb/c 
mice lungs. Ligation of MHC class I molecules of the lung parenchyma by specific anti-MHC 
class I antibodies resulted in cellular infiltrates, endotheliitis, hyperplasia and fibrosis around 
vessels and bronchioles. This led to the occlusion of distal bronchial airways similar to 
chronic rejection following human lung transplantation. Lungs of recipient mice of anti-MHC 
class I antibody demonstrated induction of IL-17 which resulted in the de-novo development 
of antibodies to self-antigens, K-α1 tubulin and collagen V. Interestingly, IL-17 neutralization 
by anti-IL-17 resulted in reduction of autoantibody and lesions induced by anti-MHC class I 
antibodies.  Harper et al work (Harper et al., 2016) demonstrated that graft versus host 
recognition by donor CD4 T cells augmented the recipient cellular and humoral alloimmunity 
in BL6 recipients of bm12Kd.IE cardiac allografts. This augmentation of alloimmune 
response in the recipients resulted in more severe allograft vasculopathy and early graft 
failure. Recent evidence from heart and lung transplant recipients suggests, however, that 
the responses directed against several tissue specific self-proteins may contribute directly to 
chronic rejection (Burlingham et al., 2007; Goers et al., 2008; Jurcevic et al., 2001; Kalache et 
al., 2011). The strongest clinical evidence comes from lung transplant recipients (Burlingham 
et al., 2007), in which peripheral blood mononuclear cell (PBMC) responses to collagen II 
and collagen V were monitored prospectively in recipients using a trans-vivo delayed type 
hypersensitivity (TV-DTH) assay. They found that PBMCs from lung transplant recipients 
were frequently collagen V reactive, whereas collagen V reactivity was not detected in 
either normal healthy controls or kidney transplant recipients with goodpasture’s syndrome 
who were reactive to collagen IV. Furthermore, the highest relative risk of bronchiolitis 
obliterans (BOS) development was observed in patients with a positive response to collagen 
V. In a separate study, Kalache et al (Kalache et al., 2011) investigated the relationship 
between AV and anti-CM autoimmunity by performing a cross-sectional study of 72 heart 
transplant recipients (40 with AV and 32 without). In a multivariate analysis, they found that 
PBMC from patients with AV responded more frequently to, and to a broader array of, CM-
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derived peptides than those without AV. Furthermore, in their cohort, detection of either 
CM-peptide-reactive T cells or anti-CM antibodies was highly, and independently, indicative 
of development of AV. Fedoseyeva et al further demonstrated that in a murine model, 
modulating the T cell response to cardiac myosin self-protein resulted either in accelerated 
rejection, or indefinite heart graft survival (Fedoseyeva et al., 2002; Fedoseyeva et al., 
1999).  
These studies have, however focused on T lymphocyte autoimmune responses; how the 
development of autoantibody (as is typically described in human studies) contributes to 
graft rejection is still not clear.  
1.4.1. Autoantibody formation following transplantation 
Failure of the central mechanisms of clonal deletion and receptor editing to eradicate all 
self-reactive B cells results in the presence of autoreactive B cells in the periphery which are 
readily found in normal individuals (Wardemann et al., 2003). In the periphery, they are 
likely to encounter target autoantigen, and thus peripheral mechanisms must also exist to 
keep these autoreactive B cells in a quiescent stage (discussed in section 1.2.1). One of the 
main mechanism is through control of the availability of T cell help to these autoreactive B 
cells. In transplant recipients humoral responses are long lasting and result in the 
development of high affinity antibodies which are somatically mutated and class switched. 
These LL humoral responses are essentially the output of germinal centres which are 
ultimately dependent on the provision of help from CD4 T cell from follicular helper CD4 T 
cells (TFH) cells (discussed in 1.5). TFH cell recognise antigen peptide-MHC complex of the B 
cells with high affinity and result in the development of GC response. With recent work in 
autoimmunity, availability of help to autoreactive B cells from TFH cells has now been 
confirmed (King C, et al, 2008; Linterman MA, 2009) that supports the earlier findings that 
provision of T-cell help can itself trigger autoimmunity (Guay HM, 2007; Cook MC, 1998; 
Fulcher DA, 1996; Seo SJ, 2002; Keech CL, 2001).  
Several mechanisms have been proposed to explain how T-cell self- tolerance is broken to 
supply critical help for production of autoantibody. Tissue destruction from, for example, an 
infectious inflammatory process, may break anergy in the peripheral autoreactive T cells 
through presentation of target epitopes at much greater frequency than in the resting stage 
(Anderton and Wraith, 2002). In addition, inflammation may lead to the generation and 
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presentation of new cryptic T cell epitopes; either through release of self-proteins that are 
normally sequestered and unavailable for immune recognition, or alteration in protease 
activity within the APC (Manoury et al., 2002). Similarly, neoantigens may be formed 
through alterations in protein structure from posttranslational modification (Anderton, 
2004; Doyle and Mamula, 2012) or oxidative stress (Rasheed et al., 2006). It is also possible 
that a subset of T cells responding to the infectious agent may provide help through cross-
reactive recognition of autopeptide epitope presented by autoreactive B cells (Marrack et 
al., 2001). 
1.4.2. What is the target of this autoantibody within the allograft? 
Very little is known about the precise targets of the autoantibody responses that are 
thought to contribute to development of AV. This is a major obstacle in postulating for how 
circulating autoantibody contributes to vasculopathy through direct binding to allograft 
endothelial cells (ECs) as majority of target autoantigens are intracellular and are not 
exposed on the cell surface.  Nevertheless, intracellular proteins can be translocated as 
apoptotic blebs on the cell surface during apoptosis like caspase dependent cleavage of 
vimentin leads to its surface expression. Hence, autoantibody binding to the exposed 
autoantigens will not occur until they are exposed by endothelial damage triggered by 
innate and adaptive alloimmune responses (Fukami et al., 2009). This may also explain why 
transplant associated autoimmunity appear to damage predominately the allograft, rather 
than native organs (Benichou et al., 2007; Harper et al., 2016; Mahesh et al., 2007; Win et 
al., 2009). The expression of autoantigens on the apoptotic cells only raises further question 
that how autoantibody binding to these cells would mediate progression of allograft 
vasculopathy. However, certain autoantigens may also be expressed on the healthy EC like 
intercellular adhesion molecule-1 (ICAM-1). Antibodies to Anti-ICAM-1 may contribute to 
the endothelial cell activation by binding to the endothelium, causing activation of 
proinflammatory signalling pathways (Lawson et al., 2005).   
The other potential alternative may be that circulating autoantibody may be internalized 
through cell surface receptors (some of the identified receptors include myosin and 
calreticulin) and then bind to intracellular autoantigens within the cells (Yung and Chan, 
2008). A final possibility is that the impact of autoantibody on endothelial signalling is 
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mainly paracrine effect. The binding of autoantibody to other cells like leukocytes in the 
immediate vicinity leads to activation of endothelial activation (Leong et al., 2008).  
1.5.3. Mechanisms for the development of allograft vasculopathy following autoantibody binding 
There is paucity of information about the mechanisms how autoantibody contributes to AV. 
This is mainly due to the fact that vasculopathy has complex pathophysiology and the 
factors that initiate mononuclear cell infiltration leading to intimal smooth muscle 
proliferation and eventual fibrosis, remain largely unknown. However, there are two 
potential mechanisms by which autoantibody might be contributing to AV; firstly by directly 
binding to the healthy endothelial cells and secondly by binding to autoantigens exposed 
only as a result of EC death.  
1.5.3.1. Direct effects of bound autoantibody on healthy endothelial cells for the development of 
allograft vasculopathy 
The evidence for direct effects of bound autoantibody on healthy endothelial cell is 
provided by Bordon et al work in which incubation of endothelial cells with antiendothelial 
cell antibodies (AECA) can induce apoptosis of endothelial cells (Bordron et al., 1998). In this 
study, AECA positive sera from systemic sclerosis (SS) patients was compared with the 
controls with other diseases. AECA derived sera from six of the eight patients with SS led to 
the expression of phosphatidylserine (PS) on the surface of endothelial cells which was 
significantly more frequent in the SS group when compared to the control group. This 
surface expression of PS preceded other events associated with apoptosis including DNA 
fragmentation. This occurred independent of complement fixation as apoptosis-inducing 
anti-endothelial antibodies did not recognize the Fas receptor. Macrophage and natural 
killer cell can recognise the bound autoantibody to EC, this recognition can also trigger EC 
death by antibody dependent cell mediated cytotoxicity. Although there is limited evidence 
for the role of antibody dependent cell mediated cytotoxicity in autoimmunity, some 
murine transplant studies have suggested contribution of NK cells towards development of 
AV (Graham et al., 2009; Uehara et al., 2005). Apoptosis may seem an integral part to the 
development of AV, in that exaggerated healing process which it triggers may ultimately 
result in fibroproliferation.  
Autoantibody binding would also potentially result in activation of complement 
components, ultimately leading to formation of membrane attack complex (MAC).  This 
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MAC will kill target EC through necrosis, but apoptosis may also takes place. Early apoptotic 
cells are not only opsonized by complement components but may also be lysed raising the 
possibility that under certain conditions apoptosis may be associated with an inflammatory 
reaction (Fishelson et al., 2001). This inflammatory milieu may trigger the intracellular 
signalling cascade and leads to AV development. Although incubation of rat lung epithelium 
with collagen V positive immune sera results in complement-dependent cytotoxic killing, 
only a small number of murine studies suggest complement deposition in association with a 
vasculopathy that is presumably autoantibody mediated (Azimzadeh et al., 2005; Win et al., 
2009).  
Apart from cell lysis, intracellular signaling cascades can activate the EC. Membrane attack 
complex may play a crucial role in the formation of pores within EC membranes that then 
can trigger IL-1α signalling pathway. This down signalling cascade activation then leads to 
upregulation of inflammatory adhesion molecules and pro-coagulant mediators on the 
activated ECs. Similarly there is widespread expression of receptors for C3a and C5a on ECs 
(Gasque et al., 1997) and ligation of these receptors by C3a and C5a respectively after 
activation of complement system by bound autoantibody can trigger diverse responses 
including actin polymerization, expression of adhesion molecules and release of von 
Willebrand factor (Brunn et al., 2006; Saadi et al., 2000). Despite all this, there is no formal 
demonstration of progression of EC activation to development of vasculopathy and how 
such signalling cascades trigger the development of fibroproliferative responses is not clear. 
However, the informative evidence for the role of intracellular signalling in development of 
AV is provided by various studies in which anti-MHC class I alloantibody responses were 
examined on endothelium (Jin et al., 2005; Jin et al., 2007; Jindra et al., 2008; Zhang and 
Reed, 2009). Anti-MHC class I alloantibody triggers various signalling cascades including 
tyrosine phosphorylation of focal adhesion kinases, upregulation of Rho proteins and 
activation of Mammalian target of rapamycin (mTOR) pathways (Coupel et al., 2004). Focal 
adhesion kinases and Rho family proteins are critical for actin fibre formation and 
cytoskeleton reorganization and interestingly blockage of Rho kinase pathway in a murine 
model of heart transplant blocked the development of AV (Hattori et al., 2004). 
Conceptually it is quite possible for MHC class I alloantibody to activate signalling cascade as 
being a membrane protein whose main function is to conduct information across the 
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membrane, however whether similar transduction can take place with autoantigens that 
lack a well-defined signalling pathway is not known and the evidence for this is sparse in 
autoimmunity and transplantation (Dragun et al., 2005; Holmen et al., 2007; Lawson et al., 
2005).  
1.6.3.2. Indirect effects of autoantibody binding to autoantigens for development of allograft 
vasculopathy following  
Autoantibody binding to apoptotic ECs can lead to endothelial activation which is 
widespread. This in turn can trigger the complement components. Activated complement 
mediators then potentially can affect all the ECs in the vicinity, which is a nonspecific 
phenomenon, irrespective of their binding to apoptotic ECs. Similarly, the fibroproliferative 
process generated by apoptosis are paracrine effect which may get augmented by 
autoantibody binding to the autoantigens that have translocated to the surface of apoptotic 
endothelial cells. It is quite possible that the humoral autoimmunity may be contributing to 
AV by different mechanisms, different from alloimmune responses following 
transplantation. In support, the binding of antivimentin autoantibody to circulating 
leukocytes results in release of platelet activating factor and prothrombotic factors which 
exert a paracrine activating effect on platelets (Leong et al., 2008).  Although, thrombosis of 
vessels leading to their occlusion is not a characteristic of AV, clotting process has been 
implicated in its pathogenesis. In one of the study, tissue plasminogen activator (tPA) levels 
were measured in the arteriolar smooth muscle cells of allograft biopsies. This 
demonstrated that the allografts with low levels of t-PA had significantly higher AV and poor 
allograft survival compared to the group with normal levels of t-PA (Labarrere et al., 1995).   
Humoral autoimmunity may contribute to AV by augmenting recipient alloimmune 
responses (Harper et al., 2016).  Inflammatory milieu which is produced by autoantibodies 
can lead to nonspecific activation of donor and recipient DCs which may be responsible for 
priming of allospecific lymphocytes. Ligation of receptors for various activated complement 
meditators on the surface of T cells and APCs within the allograft have been described as 
one of the regulators of T cell proliferation and survival (Heeger et al., 2005; Peng et al., 
2008; Strainic et al., 2008; Zhou et al., 2007). Although activation of naïve alloreactive T cells 
take place in secondary lymphoid organs, local complement mediators may augment the 
ability of the primed CD8 T cells to respond to the allogenic endothelium (Raedler et al., 
43 
2009). Finally, spreading T and B lymphocyte responses from auto- to allo-antigens may 
contribute to progression of AV. There is a small fraction of autoreactive B cells which 
escape central deletion by receptor editing and still continue to express autoreactive 
receptors in the periphery, but at low levels (Gerdes and Wabl, 2004; Liu et al., 2005). Such 
dual positive autoreactive B cells may will possess principal Ig receptor specific for 
alloantigen. However, their ability to present allopeptide may greatly be augmented after 
ligation of their second autoreactive BCR (Ciubotariu et al., 1998; Suciu-Foca et al., 1998).   
1.5. Germinal centre responses and transplantation 
Most of our understanding of the germinal centre response is the result of the studies of 
murine responses to model protein antigen, and only a limited number of studies have 
examined germinal centre alloimmunity in transplantation (Chhabra et al., 2018; Conlon et al., 
2012; Kim et al., 2014). Given that the humoral responses generated following transplantation 
are typically long lived and therefore likely mediated by bone-marrow resident long-lived 
plasma cells further evaluation of the allospecific GC response is an important area for further 
study, particularly because the development of anti-donor HLA alloantibody after 
transplantation has been unequivocally correlated with poorer late graft outcomes (Gaston et 
al., 2010). A greater understanding of the mechanisms that lead to the production of long 
lasting plasma cells (LLPC) and memory B cells in clinical transplantation is likely to inform 
development of strategies that selectively target the humoral alloimmune response as a means 
of improving long-term allograft survival. 
The autoantibody responses that have been increasingly emphasised in chronic rejection of 
solid organ transplants also appear to be long-lasting, and presumably, are similarly the result 
of a germinal centre reaction. However, an independent role for the autoreactive germinal 
centre response in the progression of allograft vasculopathy (AV) has not yet been shown. 
Confirmation that autoreactive germinal centres responses can cause graft damage is 
therefore an important consideration that needs to be first addressed.  
 
  
44 
1.6. Experimental model and aims 
GC responses to model protein antigen have been examined in depth in the last decade, but 
not so far in relation to organ transplantation. Hence in this thesis, the development of 
germinal centres was mainly investigated in bm12 to BL6 model. The bm12 strain has a 
mutant form of I-A that differs by three amino acids from the I-Ab β-chain of BL6 strain. This 
has been (Ford et al., 2002; Hori et al., 1992; Kitagawa et al., 1990; Yuan et al., 2008), and 
continues to be (Lei et al., 2016; Win et al., 2009; Zhou et al., 2015), one of the most widely 
used models of chronic rejection, with several seminal manuscripts published in top line 
journals. In addition, it has long been used as a model of murine lupus (Eisenberg and Via, 
2012).  Nevertheless, this model remains relevant as a model for clinical transplantation for 
the following reasons:  
 The recipient and donor are minimally MHC mismatched. This resembles clinical 
kidney transplantation, where organs are typically allocated to recipients on the 
basis of close HLA matching.  
 We have shown that manipulation of the donor CD4 T cell population prior to 
transplantation impacts upon graft outcomes (Win et al., 2009). This has immediate 
relevance to the recent introduction into clinical practice of ex vivo perfusion of 
organs after retrieval, but prior to transplantation. Such strategies are likely to alter 
the resident CD4 T cell population within the allograft.   
In this model, we have shown that development of IgG antinuclear autoantibody following 
transplantation is dependent on the presence of passenger CD4 T cells in the donor hearts 
(Win et al., 2009). Histopathological examination of the transplanted donor hearts revealed 
endothelial complement deposition, which was highly suggestive of humoral vascular 
damage to the allografts. These features were absent, and vasculopathy was minimal, in 
heart grafts from B cell deficient recipients; conversely hearts grafts in recipients primed for 
autoantibody generation prior to transplant developed severe AV and were rejected rapidly. 
From the above work (Win et al., 2009), we concluded that the development of 
autoantibody in the recipient was dependent on the presence of passenger donor CD4 T 
cells in allograft, however, role of recipient CD4 T cells was not investigated. Although cGVH 
model does not propose any essential role for the recipient’s endogenous T cells, some 
murine transgenic GVH models have suggested that recipient T cells may be involved in the 
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development of SLE like autoimmune syndrome (Chen et al., 1998; Choudhury et al., 2005; 
Gonzalez et al., 1995; Rolink et al., 1983). Nevertheless, no definite role has been identified 
in bm12 to B6 model. Hence, further exploration was needed to ascertain the role of 
recipient CD4 T cells in this model.  
The aims of this thesis are as follows:  
1. To study the interaction between donor and recipient CD4 T cells with recipient B 
cells in the initiation and maintenance of autoantibody responses following bm12 
heart transplantation. 
2. To investigate the role of germinal centre autoantibody responses following solid 
organ transplantation in progression of allograft vasculopathy. 
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2. Methods 
  
47 
2.1. Animal related work 
2.1.1. Animal husbandry 
C57BL/6 (BL6, H-2b) [wild-type (WT)] and BALB/c (H-2d) mice were purchased from Charles 
River Laboratories (Harlow, UK); all other animals were bred and maintained in specific-
pathogen free facilities at Central Biomedical Services, University of Cambridge. Animals 
were cared for and used in accordance with the Animals (Scientific Procedures) Act 1986.  
Details of the different strains of mice, together with their H2 haplotype, are provided in 
Table 2.1. Donor and recipients were sex matched. 
Sh2d1a−/− BL6 mice (SAP-ve.BL6) were gifted from Michelle Linterman (University of 
Cambridge, UK) (Linterman et al., 2009). SAP-ve.BL6 mice have defective TFH CD4 T cell 
population and hence unable to form germinal centres The SAP gene (Sh2d1a−/−) is X-linked 
and male SAP-ve animals were not able to breed with SAP-/- females; hence SAP+/- 
heterozygous female was crossed with a WT BL6 male. The offspring were genotyped 
according to the protocol discussed in section (2.2.10) and only SAP-ve.BL6 males were used 
in experiments. In addition heterozygous female SAP+/- were crossed with male bm12 mice 
to produce SAP-ve on the bm12 background. For bm12, homozygosity was achieved by 
backcrossing bm12.SAP+/- heterozygous females with a homozygous male bm12. Bm12 
status was confirmed by genotyping by identifying the presence of the bm12 band and 
absence of the BL6 WT band on gel electrophoresis of the PCR product (discussed in section 
2.2.10).  
Similarly, for SAP-ve TCR75 animals, male TCR75 mice were crossed with heterozygous SAP+/- 
BL6 females and from the offspring, SAP+/- TCR75+/- RAG+/- females were back-crossed with 
male TCR75+/-RAG-/-SAP+/+ in order to generate TCR75-/-SAP-ve RAG-/- mice on a RAG 
background. TCR75 status was assessed by phenotyping for Vß8.3 chain and CD4 and RAG 
status was assessed by absence of B cells. As mentioned above, only male SAP-ve bm12 and 
male SAP-ve TCR75 mice were used in experiments.   
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Table 2.1. Mouse strains with their MHC and genetic modifications 
Mouse strains Description  MHC T cells B cells Genetic  
Modification 
BL6 Wild type H-2b Kb Db  
I-Ab I-E-ve 
WT WT N/A 
BALB/c H-2d Kd Dd Ld 
I-Ad I-Ed 
WT WT N/A 
bm12 BL6 natural 
mutant 
Kb Db  
I-Abm12 I-
E-ve 
WT WT N/A 
TCRbd-/- BL6 TCR deficient 
on BL6 
background 
Kb Db  
I-Ab I-E-ve 
Absent WT Knock out for β and 
δ chains for T cell 
receptors 
bm12TCRbd-/- TCR deficient 
on bm12 
background 
Kb Db  
I-Abm12 I-
E-ve 
Absent  WT Knock out for β and 
δ chains for T cell 
receptors on bm12 
background 
bm12.Kd  Cross of bm12 
with BL6.Kd 
Kd Kb Dd  
I-Abm12  
Wild type WT  
CD45.1 BL6 Wild type H-2b Kb Db  
I-Ab I-E-ve 
WT WT Transgenic for 
congenic marker 
which is CD45.1 in 
this animal 
RAG2-/- BL6 Recombinase 
activating gene 
2KO 
Kb Db  
I-Ab I-E-ve 
Absent Absent  Deletion of Rag2 
gene 
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TCR75 TCR75 BL6 on 
Rag 
background 
Kb Db 
I-Ab 
Monoclonal; 
specific for I-Ab 
restricted H2-Kd 
54-68 
Absent Insertion of 
transgene for TCR 
Vα1.1/Vβ8.3 under 
CD1 promoter 
Deletion of Rag1 
gene 
KdTCRbd-/- BL6.Kd was 
crossed with 
TCRbd-/-  
Kd Kb Db 
I-Ab 
Absent WT Addition of 
additional Kd 
transgene to TCRbd-/- 
DM-/-BL6 DM knockout  Kb Db  
I-Ab I-E-ve 
WT Lack DMA 
molecule, 
confirmed 
on 
genotyping 
Deletion of DMA 
molecule on all 
antigen presenting 
cells 
SAP-/- BL6 SAP knockout  Kb Db  
I-Ab I-E-ve 
Have CD4 T cells 
but cannot 
differentiate into 
TFH cells 
WT Targeted mutation 
on SH2D1A/SAP 
gene  
SAP-/-bm12 SAP knockout 
on bm12 
background 
Kb Db  
I-Abm12 I-
E-ve 
Have CD4 T cells 
but cannot 
differentiate into 
TFH cells 
WT Targeted mutation 
on SH2D1A/SAP 
gene 
SAP-/-TCR75 TCR75 BL6 
with additional 
SAP molecule 
deletion 
Kb Db 
I-Ab 
Monoclonal; 
specific for I-Ab 
restricted H2-Kd 
54-68 but TFH cells 
defective function 
WT Targeted mutation 
on SH2D1A/SAP 
gene 
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2.1.2. Surgical procedures 
All surgical procedures were carried out under 10-40x magnifications using a light 
microscope (Carl Zeiss OPM11-FC Thornwood, NY, USA). Anaesthesia was induced and 
maintained by inhalation of 1-2% isofluorane (Abott Laboratories Ltd, UK). Sterile conditions 
were observed throughout the procedures.  
2.1.2.1. Heterotopic heart transplantation 
Background 
Vascularised cardiac grafts were transplanted intra-abdominally by the technique of Corry et 
al(Corry et al., 1973). Briefly, the donor aorta was anastomosed to recipient abdominal 
aorta and donor pulmonary artery was anastomosed to recipient IVC. Blood enters the 
recipient aorta and after perfusing the coronary circulation at the coronary ostia returns to 
the right atrium. Then blood is pumped out to the recipient IVC (Figure 2.1)(Hasegawa et al., 
2007) 
Donor operation 
The abdomen was opened with a midline incision. The skin and abdominal wall were 
retracted with a self-retaining retractor. The small bowel was dissected and retracted to 
expose the abdominal aorta and IVC; then 100µl Heparin Sodium at 250units/ml (i.e. 
approximately 0.5mg/ml) (Wockhardt, Wrexham, UK) was injected into the vena cava. The 
abdominal aorta and vena cava were then divided and the donor animal exsanguinated. 
Thoracotomy was performed and the thymus removed. The heart was cooled in situ by 
irrigation with 4°C saline.  The inferior vena cava, hemiazygos vein and superior vena cava 
were ligated and divided using 7/0 silk suture (Pearsalls Ltd, Somerset, UK). The ascending 
aorta was transacted proximal to the origin of the right brachiocephalic artery and the main 
pulmonary artery was transacted proximal to the division into right and left pulmonary 
arteries. A single 7/0 suture was tied around the base of the heart, ligating the branches of 
the pulmonary veins. The heart was removed, gently compressed to expel blood and placed 
in 4°C sterile saline until re-anastomosis.  
Recipient operation 
Recipients were given 100µl Temgesic (Reckitt Benckiser Healthcare, Hull, UK) at 100µl/ml in 
phosphate buffered solution (PBS; OXOID, Hampshire, UK) by subcutaneous injection. The 
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abdomen was opened with a midline incision and skin and abdominal wall retracted. To 
expose the retroperitoneum, the small bowel was gently dissected and retracted superiorly 
and left on the chest of the recipient covered in wet and warm saline gauze. Blunt dissection 
of the retroperitoneum revealed the infra-renal abdominal aorta and IVC. Any lumbar 
vessels were ligated with a single 7/0 suture. Two microsurgical clips were applied across 
both the aorta and IVC, firstly inferior to the renal arteries and secondly superior to the 
division of the IVC. The donor heart was removed from cold saline and placed in the 
recipient abdomen. An aortotomy was performed and the donor aorta sutured to recipient 
aorta end-to-side using continuous 10/0 proline sutures (Bear Medic, Tokyo, Japan). A 
venotomy was performed and anastomosis of the donor pulmonary artery and recipient IVC 
performed using interrupted 10/0 proline sutures. Surgicell (absorbable cellulose, Johnson 
and Johnson Medical Ltd, UK) was lightly applied around the anastomosis to reduce 
bleeding and the clamps released. After the establishment of donor heart sinus rhythm, the 
abdominal wall and then skin were closed using 5/0 suture (Industrial & Scientific supplies 
Ltd, Linton, UK). The animal was placed in a 32°C incubator until recovery was complete.  
It is important to note here that the donor lymphatic vessels are not anastomosed to the 
recipients and they may take upto 4 weeks to re-connect with the recipient lymphatic 
system after transplantation(Ruggiero et al., 1993). However during this period when the 
donor lymphatic vessels are disconnected, the priming of the alloimmune response takes 
place. For vascularized organs, with the disruption of lymphatics after transplantation, an 
alternative route of donor passenger leukocytes migration called reverse transmigration 
across capillaries has been described and donor passenger lymphocytes can be found in the 
spleens of recipient within 24hours of transplantation, hence spleen was used as a 
secondary lymphoid organ to study the humoral responses.  
Monitoring graft function 
Heart grafts behaved functionally as aorto-caval fistulae which were assessed by weekly 
abdominal palpation. Cessation of myocardial contractions was termed as rejection of the 
grafts and confirmed at the time of explantation of grafts. Grafts were explanted at 
predetermined time points after transplantation; half of the heart was embedded in OCT 
compound (VWR International, Lutterworth, UK) flash-frozen in liquid nitrogen and stored 
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at -800 C, and the other half was fixed in 10% formal saline and sent for EVG staining to 
determine the degree of luminal stenosis.  
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Figure 2.1. Mouse heterotopic heart transplant model.  
The aorta and pulmonary artery of the donor heart are anastomosed to the recipient’s 
abdominal aorta and inferior vena cava respectively; image from Hasegawa et al, permission 
granted from publisher Rights Link /Springer Nature (Hasegawa et al., 2007). 
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2.1.2.2. Skin grafts 
Full thickness tail skin was obtained from sacrificed donor animals, cut into 1cm2 and placed 
in cold (4°C) saline. Recipient animal anaesthesia was induced and maintained with 
inhalational 1-2% isoflurane, subcutaneous analgesia was given and the animals placed 
prone on a heated (37°C) operating board. 1cm2 area of skin was removed from the upper 
dorsum of recipient and the donor skin was laid over the prepared area. The donor skin was 
sutured to the recipient’s by 5/0 sutures, firstly in the four corners and then four stitches in 
between them. Rejection was defined as loss of skin graft at least two days post 
transplantation; loss of skin graft within 48 hours of grafting was defined as a technical 
failure.  
2.1.3. Delivery of drugs, cells and antibodies 
2.1.3.1. Intravenous (iv) injection 
Where required, populations of purified lymphocytes or monoclonal antibodies were 
suspended in 100-200µl Hartmann’s solution (Animal care Ltd, York, UK) and injected 
intravenously (iv) via the tail vein. Prior to injection, animals were placed in an incubator 
(39°C) for 10 minutes until veins were prominent.  
2.1.3.2. Intraperitoneal (ip) injections 
For some experiments, monoclonal antibodies were suspended in 300-500µl Hartmann’s 
solution and injected intraperitoneally (ip) into anaesthetised recipients (anaesthesia 
induced and maintained by inhalational isoflurane).  
2.1.3.3. Subcutaneous (sc) injections  
When required, sc injection was given by anaesthetising the recipient by 2% isofluorane and 
skin was retracted on the dorsum of the recipient and immunogenic substances were 
injected along with complete Freund's adjuvant (CFA) or incomplete Freund's adjuvant (IFA).  
2.1.4. Collection of blood and harvesting tissues 
2.1.4.1. Collection of blood samples for serum 
 Approximately 20µl of peripheral blood was obtained through a superficial tail vein using a 
25 gauge needle into a microvette (Sarstedt) from all the postoperative recipients or 
recipients of the purified lymphocytes after heating the animals in an incubator at 38°C for 
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10 minutes. The veins were compressed after collecting the blood until bleeding stopped. 
Where required, up to 1ml of blood was obtained at the time of sacrifice by direct cardiac 
puncture under terminal anaesthetic. 
2.1.4.2. Collection of peripheral blood lymphocytes 
Blood was collected in tubes pre-coated with heparin and processed as described in section 
below. 
2.1.4.3. Harvesting organs and tissues and their storage 
 Organs or tissues were harvested from the experimental animals killed by cervical 
dislocation or under terminal anaesthesia. Spleens were collected in Roswell Park Memorial 
Institute 1640 tissue culture medium (GibcoTM, Invitrogen, Paisley, UK)  (RPMI) or embedded 
in OCT compound (VWR International, Lutterworth, UK), flash-frozen in liquid nitrogen and 
stored at -80°C and hearts were harvested and fixed in  10% formal saline.  
2.1.5. In vivo depletion of CD4 T cells 
CD4 T cells were depleted from the donors by three ip injections of 1.0mg of anti-CD4 mAb 
(YTS 191.1, hybridoma from the European Collection of Animal Cell Cultures) at six, five and 
1 day prior to heart graft procurement. Depletion of CD4 T cells (typically >99%) 
(Motallebzadeh et al., 2012) was measured by flow cytometry of peripheral blood 
lymphocytes on the day before heart procurement and confirmed by flow cytometric 
analysis of donor splenocytes on the day of retrieval. 
2.1.6. In vivo depletion of NK cells 
PK 136 mouse hybridoma (anti-NK1.1 antibody) was purchased from ATCC (HB-191) and was 
grown and purified in house. Recipient mice were depleted of NK cell population by 
treatment with anti-NK1.1 antibody; animals received 500μg of antibody ip or iv on days -2, 
0 and 2(Ali et al., 2016; Yu et al., 2006)  
2.1.7. In vivo depletion of CD20 positive B cells 
Murine anti-CD20 antibody was (250μg) injected to mice as per protocol of the experiment 
to deplete CD20+ B cells (Hamaguchi et al., 2006). 
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2.1.8. Generation of bone-marrow chimeras 
2.1.8.1. Generation of mixed chimerism 
Mixed haematopoietic chimeras were set up using previously well described protocols, 
using a combination of depleting antibodies and total body irradiation (TBI)(Nikolic et al., 
2010). Briefly, CD45.1 BL6 recipients were treated with anti-CD4 (YTS) on day -6 and -1 and 
anti-CD8 on day -1, 0, 1, and day 7. On day 0 recipients received 4Gy TBI and a single dose of 
2mg of anti-CD154 mAb (MR1). Following conditioning on day 0 recipients also received an 
iv injection of 3x107 purified bm12 bone marrow cells. Chimerism was confirmed by flow 
cytometric analysis of peripheral blood lymphocytes at least 4 weeks after reconstitution.   
2.1.8.2. RAG2-/-DM-/- bone-marrow chimeric mice 
To generate RAG2-/- . DM-/- bone-marrow chimeric mice, RAG2-/- mice were sublethally 
irradiated (2Gy) using a Caesium-137 source and reconstituted with 2 x 107 DM-/- bone 
marrow cells iv. Chimerism was confirmed by flow cytometric analysis of peripheral blood 
lymphocytes at least 4 weeks after reconstitution. 
2.1.9. Preparation of hyperimmune sera for ELISA  
To obtain antibody-containing serum for positive control for ELISA, animals were given a 
relevant immune challenge (table 2.2) followed by cardiac puncture under terminal 
anaesthesia 5 weeks post challenge.  
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Table 2.2. Generation of hyperimmune serum 
Serum Immune challenge 
Recipient Challenge 
Anti-nuclear antibody  TCRbd-/- 5x106 highly purified bm12 CD4 T cells  
Anti-H2-Kd antibody BL/6 BALB/c heart graft 
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2.2. Laboratory based procedures 
All laboratory procedures were performed at the departments of Surgery, Medicine and 
Virology. 
2.2.1. Cell preparation 
All cell preparation was performed in a Microflow SE laminar flow hood (BIOQUELL, 
Andover, Hampshire, UK) with (RPMI) 1640 tissue culture medium (GibcoTM, Invitrogen, 
Paisley, UK) referred to as ‘medium’, unless otherwise stated. Centrifugation was performed 
in a Howe 6K10 Centrifuge (Sigma Laboratory Centrifuges GmbH, Osterode am Harz, 
Germany) at 1200 revolutions per minute (rpm) for 7 minutes at 4°C, unless otherwise 
stated. Cells were counted with an Improved Neubauer counting chamber (Hawksley, 
Lancing, UK) under 20 x magnifications with a conventional table-top light microscope. 
2.2.1.1. Splenocytes 
Spleens were harvested, disaggregated and teased through a 40μm nylon cell strainer 
(Becton Dickinson, Franklin Lakes, NL, USA) using the rubber end of a 2 ml syringe plunger. 
The cells were washed with medium, centrifuged and resuspended and used as required by 
the protocol of the experiments. 
2.2.1.2. Bone marrow cells 
Media + 5% foetal calf serum (FCS) was used to flush bone marrow (BM) from the tibias and 
femurs of sacrificed animals. Single cell suspensions were obtained by teasing the BM 
through a 40 µm nylon cell strainer (as above). BMCs were washed with medium, 
centrifuged and resuspended.  
2.2.1.3. Peripheral blood lymphocytes (PBLs) 
Approximately 20µl of blood was collected as in Section 3.2.5 into a microvette containing 
approximately 5µl of unfractionated heparin. This heparinised blood was mixed with 200µl 
of 0.17M ammonium chloride for 5 minutes at room temperature to lyses erythrocytes and 
then centrifuged at 3000rpm for 3 minutes. The supernatant was subsequently aspirated by 
pipette and discarded. The PBLs were resuspended in red cell lysis buffer, centrifuged and 
the supernatant discarded and then stained as described in section 2.2.3.2. 
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2.2.1.4. Cell isolation from heart tissues 
Briefly, hearts were excised and rinsed with HEPES buffered DMEM (GIBCO 42430-082) to 
remove any blood clots and remaining blood. Tissue was cut into 2 mm pieces using a sterile 
scalpel, then transferred into 5ml bijoux and incubated with collagenase digestion mix 
(section 2.2.8) and incubated for 30 min in a 370C water bath. The suspension was then 
passed through a 70μm sieve (BD Falcon) to remove undigested tissue and returned to the 
water bath for a further 15 min. Collagenase action was stopped by adding ice cold working 
medium (RPMI, 10%FCS, 2ME, L-Glut, Streptomycin and Penicillin) and suspension was then 
washed x2 with DMEM. To ensure a final single cell suspension, the cells were incubated 
with Trypsin-EDTA (Sigma G1393) for 10 min at 370C and used as per experiment 
requirement. 
2.2.1.5. CD4+ T cell purification 
Splenocytes were resuspended in 500μl of MACS buffer and passed through the autoMACS 
machine using program Possel and the negative fraction was collected; this procedure was 
effective at removing dead cells. The negative fraction was centrifuged and resuspended 
with 750µl of MACS buffer and 100µl of MHC class II beads (to remove the MHC class II 
positive cells). Cells were then incubated for 20 minutes on ice. After washing and 
resuspension in 500µl of MACS buffer the cells were passed through the autoMACS machine 
using the Possel program and the negative fraction was collected; this was centrifuged, 
resuspended with 750µl of MACS buffer and 100µl of CD4 beads, and incubated for 
20minutes on ice. After washing and resuspension of cells in 500µl of MACS buffer, the cells 
were passed through the auto MACS machine using the possel-d program and the positive 
fraction was collected. Purified CD4+ T cells were washed, counted, made up to the required 
volume in normal saline or Hartman’s solution and injected into the animals according to 
the protocol of the experiment. This resulted in >97% purification of CD4 T cells.  
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2.2.2. Serum preparation 
Approximately 20μL of blood was collected from the superficial tail vein of animals as 
described above and stored overnight at 40C. Samples were centrifuged twice at 13000rpm 
for 7 minutes, the serum was collected and subsequently heat inactivated at 560C for 30 
minutes. Samples were stored at -200C until analysis. 
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2.2.3. Flow cytometry 
2.2.3.1. Introduction and basic principle 
Flow cytometry detects fluorescent-labelled antibodies or ligands that can be made to bind 
specific cell-associated molecules.  
In my work, flow cytometry was used primarily for characterising cell surface expression 
molecules using fluorochrome-conjugated antibodies (immunophenotyping). This included  
A) Characterisation of individual lymphocyte populations (like CD4 T cells, CD8 T cells 
and B cells) with special interest in characterisation of CD4 T cell subset like TFH cells. 
B) Phenotyping of animals 
C) Characterisation of cell populations following in vitro cultures 
D) To trucount the lymphocytes 
This is based on the basic principle of single cell preparations successive binding steps of 
incubation with labelled antibodies or ligands. Each step was followed by wash with excess 
buffer to remove unbound reagents. 
In multiple colour flow cytometry, I made various adjustments and controls in order to 
create optimal settings that offer adequate sensitivity but also minimise the background 
fluorescence and spectral overlap between different fluorochromes. Some protocols and 
control that were consistently used in my experiments are described below. 
Fc Receptor (FcR) blocking 
Several cell types express FcƔII (CD32) and FcƔIII (CD16) receptors for complexed IgG (Fc 
receptors or FcR), including NK cells, monocytes ad macrophages. Antibody preparations 
can bind to FcR-bearing cells through their Fc portions, regardless of their antigen 
specificity. To minimise background staining from FcR ligation, FcƔR sites were blocked by 
incubation with anti-CD16/CD32 antibodies prior to staining. 
Dead cell exclusion 
Cell membrane of nonviable cells can trap fluorescent reagents and therefore, dead cells 
were excluded from the analysis using the dead cell marker 7-AAD. 
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Autofluorescence control 
I used unstained cells to establish levels of background autofluorescence, and to adjust 
voltage settings such that the unstained population of interest appeared in the first quartile 
of a 4-decade logrithmatic scale for each fluorochrome to be measured.  
Single stain controls 
The emission spectra of some fluorochrome can overlap causing fluorescence from one 
fluorochrome to spill into the other. To overcome this problem, control cells were stained 
with single fluorochromes separately and were thus used a compensation controls to 
calculate any spectral overlap which was accounted in data analysis. 
 2.2.3.2 General protocol 
Flow cytometry was carried out using single cell suspension of lymphocytes in 96-well U-
bottomed plates (BD, Franklin Lakes, NJ, USA). Cells were washed (with 150 µl/well of FACS 
buffer here and hence forth), blocked with 50µg/ml anti-mouse CD16/CD32 (clone 2.4G2, 
BD Pharmingen, San Diego, CA, USA) at 5µl/ml in FACS buffer for 30 minutes at 4°C. Cells 
were then incubated with dead cell exclusion dye 7-AAD (BD Pharmingen, San Diego, CA) 
and/or the indicated primary and subsequently secondary monoclonal antibodies in 
different dilutions (mAb) (table 2.3.) in the dark for 30 min at 4°. Biotinylated antibodies 
were detected with allophycocyanin-conjugated streptavidin (BD Pharmingen, San Diego, 
CA) or APC-Cy 7 conjugated to streptavidin (BD Pharmingen). Prior to analysis cells were 
transferred to flow cytometry tubes (BD Falcon, Franklin Lakes, NJ, USA) and cells analysed 
on a FACSCanto II flow cytometer with FACSDiva (BD Biosciences, San Jose, CA) and or on 
FlowJo (Tree Star, Inc, Ashland, OR) software.  
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2.2.3.3. TrucountTM analysis for cell quantification 
When required, a 20µl aliquot of the single cell suspension was stained to label the 
populations of interest and then added to a BDTrucountTM tube (BD Biosciences) containing 
a known number of fluorescent beads. It was mixed thoroughly and run through the flow 
cytometer. The number of events in the selected gate was compared to the number of 
beads in the same run to calculate the density of the cell population of interest in the 
sample.  
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Table 2.3. Antibodies used for flow cytometry 
Antigen specificity/ (Clone) Conjugate or 
fluorochrome 
Dilution Isotype/ (Source) 
Mouse CD4  
GK1.5 
Biotin  
 
1:500 Rat IgG2b, k 
BD PharmingenTM 
Mouse CD4 
L3T4 
PeCy7  
 
1:1000 Rat IgG2b, k 
BD PharmingenTM 
Mouse CD4 
RM4-5 
APC 1:500 Rat IgG2b, k 
BD PharmingenTM 
Mouse CD11c 
HL3 
PE 1:50 Rat IgG2b, k 
BD PharmingenTM 
Mouse CD19 
ID3 
PE 1:200 Rat IgG2a 
BD PharmingenTM 
Mouse CD19 
MB19-1 
FITC 1:200 Rat IgG2a, k 
BD PharmingenTM 
Mouse CD44 
IM7 
FITC 1:100 Rat IgG2b, k 
BD PharmingenTM 
Mouse CD62L 
MEL-14 
PeCy7 1:1000 Rat IgG2a, k 
BD PharmingenTM 
Mouse CXCR5 
2G8 
Biotin 1:100 Rat IgG2a, k 
BD PharmingenTM 
Mouse CXCR5 
2G8 
APC 1:100 Rat IgG2a, k 
BD PharmingenTM 
Mouse CXCR5 
2GB 
Purified 1:100 Rat IgG2a, k 
BD PharmingenTM 
Mouse PD-1 (CD297)  
J43 
PE 1:500 Armenian Hamster IgG2, k 
E Biosciences 
Mouse ICOS 
7E.17G9 
PE 1:500 Rat IgG2b, k 
BD PharmingenTM 
Rat Thy1.1 APC-Cy7 1:1000 Mouse IgG 
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OX-7 BD PharmingenTM 
7-AAD Percp-cy5.5 1/200 BD PharmingenTM 
GL7 (GL-7) Biotin/FITC 1:100 Rat IgM, Affymetrix UK 
 
Mouse CD45.1 
A20 
APC/Cy7 1/100 Rat IgG2a, k 
BD PharmingenTM 
Mouse CD45.1 
A20 
Biotin 1/500 Rat IgG2a, k 
BD PharmingenTM 
Mouse CD45.2 
104 
APC/Cy7 1/100 Rat IgG2a, k 
BD PharmingenTM 
Mouse CD45.2 
104 
Biotin 1/500 Rat IgG2a, k 
BD PharmingenTM 
Mouse CD105 APC 1/100 Rat IgG2a, k 
Mouse Isoselectinβ4 APC 1/100 Rat IgG2a, k 
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2.2.4. Indirect immunofluorescence Hep-2 analysis  
2.2.4.1. Background and basic principle 
Indirect immunofluorescence hep-2 analysis was used for measurement of autoantibody. It 
is an excellent screening test for detection of autoimmune disorders but not specific. Our 
laboratory adapted this screening test to study the development of autoantibodies 
following solid organ transplantation. 
In the indirect immunofluorescence technique, samples are incubated with antigen 
substrate and unreacted antibodies are washed off. Then the substrate is incubated with 
specific fluorescein labelled conjugate and unbound reagent is washed off. On microscopy, 
autoantibody positive samples exhibit an apple green fluorescence corresponding to areas 
of the cells or nuclei where autoantibody has bound. 
2.2.4.2. Protocol 
The presence of antinuclear autoantibodies (ANAs) was determined by HEp-2 indirect 
immunofluorescence. Test sera were diluted 1:10 in PBS and incubated for 30 minutes on 
slides coated with HEp-2 cells (from Hep-2 ANA – IFA Kit; Binding Site, Birmingham, UK). 
ANAs were then detected with FITC-conjugated anti-mouse IgG mAb (STAR 70; Serotec, 
Oxford, UK). Serial two-fold dilutions (1 in 10 to 1 in 2560) of hyperimmune sera from TCRbd–
/– animals injected iv with 5x106 purified bm12 CD4 T cells, was used to generate a standard 
curve (figure 2.1). Monospecific positive and negative prediluted controls (Hep-2 ANA – IFA 
Kit as above) were used according to the manufacturer’s instruction. Pooled sera from naïve 
BL6 animals were used as an additional negative control. 
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2.2.4.3. Analysis of slides 
For each test serum, 5 photomicrographs were taken and the intensity of staining 
determined by integrated morphometric analysis using MetaMorph software or image J 
software. The relative fluorescence score (fluorescein binding units) was then derived by 
comparison to a standard curve of hyperimmune serum that was assigned an arbitrary value 
of 1000 fluorescence binding units. 
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2.2.5. ELISA 
2.2.5.1. Background and basic principle 
ELISA is an immunoassay for the detection of an antibody or an antigen in a test solution. 
The assay was developed as an alternative to the radio immunoassay which posed a 
potential health threat.  
I used this assay to detect and quantify the development of alloantibody and autoantibody 
in serum samples following a challenge. 
2.2.5.2. Protocol for detection of alloantibody 
96-well ELISA plates were (Immulon 4HBX, Thermo, Milford, MA) with antigen diluted in 
Na2CO3-NaHCO3 buffer [pH 9.6]) and incubated overnight at 4°C. Non-specific binding sites 
were blocked with Marvel dried skimmed milk powder (Premier International Foods, UK) in 
PBS (block) at 200 µl/well for 2 hours at 37°C. After washing (x6 with PBS/0.05% tween 20 
[Sigma, Poole, UK] in PBS throughout), samples were diluted 1:9 in block and 50 µl/well 
added. Serial tripling dilutions were carried out down the 8 rows of the plate, and the plate 
incubated at 37°C for one hour. Bound IgG antibodies were detected by incubating for 1 
hour at 37°C with biotinylated rabbit F(ab′)2 anti-mouse IgG  (1/1000 in block; STAR11B; AbD 
Serotec, Oxford, U.K.) and Extravidin Peroxidase conjugate (1/1000 in block; Sigma, Poole, 
U.K.).  Before addition of secondary antibody and between all subsequent steps, plates were 
flicked and washed 6 times with PBS/0.05% tween. In order to generate a colorimetric 
signal, Sure Blue substrate (KPL, Gaithersburg, MD) was added to each well and reaction 
was stopped by the addition of 0.2 M H2SO4. Plates were read in the FLUOstar OPTIMA plate 
reader (BMG Labtech, Aylesbury, U.K.) at 450nm.  
Analysis of results 
For each sample, an absorbance versus dilution curve was plotted and the area under the 
curve calculated (Callaghan et al., 2007). The AUC was then calculated as a percentage of 
the AUC of a standard of serial diluted pooled hyperimmune sera (sera pooled from BL6 
animals transplanted with BALB/c skin or cardiac grafts collected at week 5 post-transplant 
– that was assigned an arbitrary value of 100%. Pooled sera from naïve BL6 or TCRbd-/- 
animals were used as a negative control. The capturing antibodies and incubations specific 
to the different ELISAs based on this method are summarized in table 2.4.  
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Table 2.4. Protocol for alloantibody ELISAs 
Analyte Coating agent Positive control Development 
time (seconds) 
Anti-H2-Kd 
antibody  
Recombinant 
conformational H2-Kd 
at 5µg/ml 
H2-Kd immune serum  90 
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2.2.5.3. Protocol for detection of anti-vimentin autoantibody 
Anti-vimentin antibody was detected by performing anti-vimentin antibody ELISA which is 
adopted by modifying the protocol as described by Mahesh et al (Mahesh et al., 2007). 
Mouse vimentin was plated at 1 μg/well onto 96-well ELISA plates and incubated overnight 
at 4°C. Nonspecific binding sites on the plates were blocked with phosphate-buffered saline 
(PBS) with 0.1% Tween 20 and 5% milk (block) for 2 hours. For each ELISA, standard curve 
was plotted using doubling dilutions of murine monoclonal IgG anti-vimentin antibody 
which cross-reacts with murine vimentin (clone RV202, 500 μg/ml; BD Biosciences, Oxford, 
UK) beginning at 1:4000 dilution in block. Experimental samples (50 μl, diluted 1/100 in 
block) were incubated for 1 hour at 37°C followed by wash by PBS/0.05% tween six times. 
Bound IgG anti-vimentin Abs were detected by incubating for 1 hour at 37°C with 
biotinylated rabbit F(ab′)2 anti-mouse IgG  (1/1000 in block; STAR11B; AbD Serotec, Oxford, 
U.K.) and ExtrAvidin Peroxidase conjugate (1/1000 in block; Sigma, Poole, U.K.).  Before 
addition of secondary Ab and between all subsequent steps, plates were flicked and washed 
6 times with PBS/0.05% TWEEN. Sure Blue substrate (KPL, Gaithersburg, MD) was then 
added, the reaction was stopped at 10 minutes by the addition of 0.2 M H2SO4, and the 
absorption at 450 nm was measured in a FLUOstar OPTIMA plate reader (BMG Labtech, 
Aylesbury, U.K.). Standards were used to determine the titre of the samples. For each ELISA 
a standard curve was plotted, and the OD readings were read off the standard curves to 
obtain relevant IgG anti-vimentin titres.  
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2.2.6. ELISPOT 
2.2.6.1. Background and basic principle 
ELISPOT is highly sensitive assay that detects ASCs or cytokine secreting cells at a cell level 
ex vivo. This was developed as a stable alternative to the conventional plaque forming cell 
assays that relied on haemolytic lysis of Protein A coated sheep red blood for the detection 
of ASCs.  
In my work, I used this assay to quantify the antigen-specific IgG and dsDNA antibody 
secreting cells (ASCs) in the spleen and bone marrow.  
Like ELISA, following steps were taken to avoid any non-specific binding of the antigen and 
antibody. 
 High affinity antibodies that displayed negligible cross-reactivity were used for 
capture and detection. 
 Non-specific binding was minimized by incubating coated plates with serum 
containing blocking solution to saturate available sites prior to addition of cells. 
 Relevant positive and negative biological controls were also included in each test 
run.  
 Unbound reagents were removed after each step and the plates were washed with 
mild detergent solution to minimize non-specific binding. 
2.2.6.2. General Protocol 
96-well MultiScreen Filter Plates were coated (Millipore, Billerica, MA, USA) with 100µl/well 
of antigen diluted sterile buffer. The plates were incubated for 2 hours at 37°C, 5% CO2  
followed by 5 times wash with sterile PBS + 0.5% BSA (hereafter referred to as ‘PBS buffer). 
Then 100µl/well full media (RPMI culture medium + 10% FCS, 1% penicillin-streptomycin 
[Sigma, Poole, UK] + 1% L-Glutamine 200mM [Sigma] and + 0.1% 50mM 2mercaptoethanol 
[2ME; Sigma]) was added. Single cell suspensions from spleen and BM were prepared by 
pushing through a 40µm falcon cell strainer and resuspended at 1 x 106/ml in full media and 
added to the plate in triplicates of 1x105, 1x104 and 1x103 cells per well. The plates were 
incubated for 18 hours at 37°C, 5% CO2, ensuring the plate was not moved within this time.  
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After washing (x10) with 0.05% tween in PBS (hereafter referred to as ‘wash buffer’) and 
patting dry, 100µl/well biotinylated Rabbit(ab’)2 anti-mouse IgG (STAR11B, AbD Serotec, 
Oxford, UK) at 1µl/ml in in PBS buffer for 2 hours at 37°C. After washing (x6) with wash 
buffer, the plate was incubated with 100µl/well ExtrAvidin Peroxidase conjugate (Sigma, 
Poole, UK) 1µl/ml in PBS buffer for 2 hours at RT.  
To make the developing solution, one tablet of 3-amino-9-ethyl-carbazole (AEC; Sigma, 
Poole, UK) was added to 2.5ml dimethyl formamide (DMF; Sigma, Poole, UK), 1 ml of the 
resulting solution was added to 19 ml acetate buffer, filtered through a 0.2µm filter 
(Sartorius Stedim, Surry, UK) and 10µl of 30% Hydrogen peroxide solution (Sigma, Poole, UK)  
added. After washing (x6), spots were developed by incubation with 100µl/well of the above 
developing solution in the dark at RT till spots appeared. The plate was washed (x3) with 
distilled water and left overnight in the dark to dry before being read on an AIDTM Elispot 
Reader version 3.5 (Autoimmun Dignostika, Strasberg, Germany). Data was expressed as 
mean number of responders per 106 cells (± SD). 
The coating agents, dilutions and development times for specific to the different ELISPOT 
assays based on this method have been summarized in table 2.5.  
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Table 2.5. Summary of various ELISPOT assays 
Specificity Capturing 
coating agent 
Concentrations 
and diluting 
buffer 
Development 
time (min.) 
Pre-
treatment 
of plates 
Pan IgG Rabbit anti-
mouse IgG 
(STAR 8B; 
Serotec, 
Oxford UK) 
 
2µg/ml diluted 
in 0.1M 
bicarbonate 
buffer  
(Na2CO3-
NaHCO3, pH 
9.6).   
15 NIL 
Anti-dsDNA 
antibody 
dsDNA 
(produced in 
house) 
20µg/ml in 
sterile distilled 
water 
30 Pre-coat 
plates with 
20µg/ml 
poly-L-
Lysine 
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2.2.7. Histology 
2.2.7.1. Background and basic principles 
Histology reveals the relationship between the different types of cells and tissue types 
found within tissues and organs in health and disease. Although it is less quantitative than 
other cellular and biochemical assays, it allows visual analysis of localized tissue differences, 
thus giving greater insight into the cellular and molecular interactions that may be 
significant for disease progression. 
I used tissue histology to assess 
A) Donor heart grafts for the development of allograft vasculopathy and C4d deposition 
by immunohistochemistry. 
B) Recipient spleens for the development of germinal centres and T-B cell interactions 
by immunofluorescence. 
2.2.7.2. Protocol for tissue preparation 
General histology 
Tissues were placed in 10% formalin saline solution and paraffin-mounted by the 
Department of Pathology, Papworth Hospital, Cambridge, UK. 
Immunohistochemistry and immunofluorescence 
Tissues were embedded in OCT compound (VWR International, USA), flash frozen in liquid 
nitrogen, and stored at -80 °C. Frozen tissues were cut into 7µm serial sectioned and placed 
onto Poly-L-Lysine coated slides (Sigma Aldrich Inc.) After drying for 30minutes, the tissue 
sections were fixed in chilled acetone for 10minutes. Sections were then air dried for 30 
minutes and stored at -80°C.  
2.2.7.3. Protocol for tissue staining 
General histology 
Paraffin fixed sections were stained by the Department of Pathology, Papworth Hospital, 
Cambridge, UK with either Haematoxylin and Eosin (H&E) or elastin van Gieson (EVG) for the 
assessment of arterial vasculopathy and parenchymal rejection of transplanted hearts. 
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Immunohistochemistry staining 
C4d staining was performed under supervision of Sylvia Rehakova. 7µm sections of tissues 
were stained by using the Avidin- Biotin- Peroxidase complex (ABC) technique (Vector 
Laboratories Inc.) for detection of the complement by-product C4d. Sections were thawed 
and rehydrated with 1%PBS, and tissue peroxidase activity was quenched by incubation with 
0.3% H2O2 in PBS for 10 minutes. The sections were washed in PBS and then endogenous 
biotin sites on the tissues was blocked by using Avidin and Biotin blocking solution, each for 
15min.  Non-specific binding sites were blocked by incubating sections with 5% Rabbit 
serum (Sigma) in PBS for 20min. Sections were incubated with primary antibody (table 2.6) 
diluted in PBS for 30min at RT. The bound primary antibody was detected by incubation 
with biotinylated secondary antibody followed by incubation with ABC solution [avidin and 
biotinylated horseradish peroxidase (HRP) complex] solution (Vector Laboratories Inc.) each 
for 30min. All incubations were carried out in humidified chamber followed by two 5min 
washes in PBS. For development, sections were incubated with 0.3mg/ml DAB with 0.03% 
hydrogen peroxide for 30 seconds. The sections were subsequently counterstained with 
Harris’ haematoxylin (Sigma Aldrich Inc.) for one second. Sections were dehydrated with 
increasing concentration of ethanol, cleared in xylene and mounted in DPX (Sigma Aldrich 
Inc.). 
Immunofluorescence staining 
Non-specific binding sites were blocked by incubating sections with 5% BSA (Sigma Aldrich 
Inc.) and 4% goat anti mouse serum (Sigma Aldrich Inc.) for one hour at RT. Endogenous 
biotin was blocked by incubating tissue section with avidin and biotin blocking kit solutions 
(Vector Laboratories Inc.), each for 15 min and washed three times each for 10 minutes with 
1%PBS after every step. Sections were then incubated with primary antibodies conjugated 
to a fluorochrome; or antibodies conjugated to biotin, followed by incubation with 
fluorochrome conjugated secondary antibody (Table 2.6). Antibodies were diluted in 
blocking BSA-goat anti-mouse serum and incubated for one hour in dark humidified 
chamber followed by three washes in excess PBS for 10min.  However, in case of confocal 
microscopy, primary antibodies were incubated overnight at 4°C in dark humidified 
chamber.  
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Sections were counterstained with 20% Harris’ haematoxylin (Sigma Aldrich Inc.) for 20 
seconds, washed in excess water and mounted in Fluor SaveTM reagent (CalbiochemR, 
Merck-Millipore). Where required, sections were counterstained and mounted with 
vectashield’s hard set mounting medium with 4’ , 6- diamidino-2-phenylindole (DAPI)) 
(Vector Laboratories Inc).  
Anti-mouse antibodies which were used for immunofluorescence staining of splenic sections 
are shown in table 2.6. 
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Table 2.6. Antibodies used for immunohistochemical staining 
Primary antibodies Secondary antibodies 
Antigen 
specificity/ 
(Clone) 
(dilution) 
Conjugate or 
fluorochrome 
Isotype/ (Source) Clone 
(dilutions) 
Source 
Mouse B220 
(RA3-6B2) 
(1/200) 
Purified Rat IgG2b kappa 
(BD Pharmingen 
TM) 
Cy3 polyclonal goat 
anti rat IgG 
(1/500 dilution) 
Jackson Labs 
Mouse B220 
(RA3-6B2) 
(1:200) 
APC Rat IgG2b kappa 
(BD Pharmingen 
TM) 
NIL  
Mouse GL7  
(GL-7) 
(1/100) 
FITC Rat IgM 
(Affymetrix UK 
Ltd.) 
NIL  
Mouse GL7  
(GL-7) 
(1/100) 
Biotin Rat IgM 
(Affymetrix UK 
Ltd.) 
Cy2 streptavidin 
Polyclonal goat 
anti rat IgG 
(1/500 dilution) 
Jackson Labs 
PNA  
(1/200) 
Fluorescein Vector 
laboratories Inc. 
NIL  
Mouse C4d 
(16D2)  
(1/100) 
Purified Abcam® , UK Biotinylated 
polyclonal rabbit 
anti rat IgG 
(1/500) 
Abcam® , UK 
Mouse CD4 
GK1.5 
(1/200) 
Biotin Rat IgG2b kappa 
BD PharmingenTM 
Streptavidin Alexa 
Fluor 555 
(1/500) 
Invitrogen 
FDC  
FDC-M1 
(1/250) 
Purified Rat IgG 2c Cy3 polyclonal goat 
anti rat IgG 
(1/500) 
Jackson Labs 
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2.2.7.4. Imaging 
I used conventional and confocal microscopy to analyze tissue sections. Conventional 
microscopy was used for quantification of GCs in recipient spleens and calculation of AV in 
donor heart grafts. However, confocal microscopy was used to study T and B cell 
interactions in recipient splenic sections following transplant or cell challenge. 
In confocal microscope, presence of confocal pinholes removes out of focus light from the 
image thus generating images of improved resolution.  It has a higher level of sensitivity 
compared to conventional microscope due to highly sensitive light detectors and its ability 
to accumulate the captured image over time. 
Conventional Microscope 
Sections were viewed using an IX81 microscope at 20x magnification, 70 UplanApo Lense 
(Olympus, Japan). Images were photographed using an ORCA-ER digital camera (Hamamatsu 
Photonics, Japan) and acquired with CellR 2.6 software (Olymous Imaging Solutions, 
Germany).  
Confocal Microscope 
For confocal microscopy, sections were viewed using a Zeiss Laser Scanning Microscope 700 
(LSM 700) (Carl Zeiss AG). Images were photographed using ZEN 2011 (Carl Zeiss AG) 
imaging software.   
2.2.7.5. Analysis of results 
Histological evaluation of allograft vasculopathy and parenchymal rejection 
Allograft vasculopathy was assessed on elastin van Gieson-stained paraffin sections by 
morphometric analysis, using digital imaging software (Cell^R, Olympus, Japan) to calculate 
luminal stenosis as follows. 
Percentage cross-sectional area luminal stenosis= 
Area within internal elastic lamina (IEL) – Area of lumen         x   100 
                                   Area within IEL 
All elastin-positive vessels in each section were evaluated, with an average of 10 vessels per 
heart examined.  
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Quantification of germinal centres 
The development of germinal centres within the secondary lymphoid organs in the 
recipients of allograft was quantified by staining with B220 and PNA or B220 and GL7. The 
percentage of follicles with GCs was derived by dividing the PNA or GL 7 positive follicles to 
total number of B220 positive follicles within a good recipient splenic section. 
Percentage of GCs= 
Number of PNA+ or GL7+ GCs       x 100 
Total number of B220+ follicles 
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2.2.8. Endothelial migration assay 
2.2.8.1. Background 
Cell migration of quiescent cells in response to biological insults can indicate cell activation. 
Thus migration may be the result of a physiological response to insult such as wound 
healing, but may sometimes contribute to disease pathogenesis. Activation of ECs by 
antibody and complement is thought a contributing factor to the development of AV. Cell 
invasion assays allow in vitro quantification of cell activation in response to specific insults.  
In my work, I used migration of ECs as an in vitro test for EC activation following exposure to 
antinuclear autoantibodies.  
2.2.8.2. Procurement of tissues and Preparation 
Hearts were harvested from two weeks old new born babies to get highest yield of 
endothelial cells (ECs). In our experience, we get good yield of ECs if procured from new 
born babies and are more than 8 in numbers. Mouse endothelial cells were cultured using a 
previously described protocol. Briefly, single cell suspension from hearts was achieved by 
following the protocol as mentioned in 2.2.1.4. 
2.2.8.3. MACS purification endothelial cell 
The resultant cell suspension was washed once with working medium, cell button was 
resuspended in 500μL of MACS buffer (Mitenyi Biotec 130-091-221) and incubated with Fc 
gamma receptor blocking antibody (BD rat anti-mouse CD16/CD32) 1/200 dilution for 30 
min on ice. Biotinylated antibodies were added to the suspension: CD31, 1/100 (BD 
553371); CD105, 1/200 (eBioscience 13-1051) and isolectin B4 (Vector B-1205), 1/25 dilution 
in MACS buffer and incubated for 30 min on ice.  CD31 (PECAM-1), CD105 (endoglin) and 
isolectin B4 are all expressed on EC surface. Suspension was washed in MACS buffer, 50μL of 
anti-biotin beads were added (Miltenyi Biotec 130-090-485) and incubated for 15min at 40C. 
Cells were washed in MACS buffer as before. Cell separation was done using autoMACS 
Column machine (Miltenyi Biotec) using Possel program and collecting the positive fraction. 
2.2.8.4. Endothelial Cell Culture 
Purified endothelial cells seeded in 1% gelatine (Sigma) coated flasks with 5 ml of Growth 
Medium and incubated at 370C with 5% CO2.  24 hours later all non-adherent cells were 
removed using a sterile pipette and 10-15 ml of fresh growth medium added. Medium was 
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changed every 72 hours and cells left to grow until reaching ~80-90% confluence at which 
point cells were passaged, using Cell Dissociation Solution (Sigma C-5789). Endothelial cells 
for experiments were used at passage 3-6; preferably just after 3. 
Collagenase Digestion Mix 
1 ml Collagenase (1mg/ml) (Roche 10103586001) 
20μL DNAse stock (1mg/ml) (Roche 1284932) 
200μl FCS (sigma 4135) 
8.8ml HEPES buffered DMEM (GIBCO 42430-082) 
Growth Medium (50ml) 
37.5 mls HEPES buffered DMEM (GIBCO 42430-082) 
10 mls FCS (Sigma 4135) 
50μL (50 mM) of 2ME (Sigma 516732) 
500μL P/S (Sigma 4333) 
500 μL L/Glut (Sigma 6392) 
500 μL MEM non-essential amino-acids (Sigma M7145) 
500 μL Sodium Pyruvate (Sigma S8636) 
500 μL Endothelial Cell Growth Factor (Sigma E9640) 
2.2.8.5. Endothelial migration assay 
In vitro wound induced endothelial cell migration was assessed using a previously described 
protocol (Herve et al., 2005). ECs were seeded in 8cm Petri dishes, pre-coated with 1% 
gelatine, and were incubated in full endothelial growth medium(see above) until 
confluence. Cells were then “starved” for 24hrs, growth medium was then aspirated and 
instead cells were incubated with Minimal medium (1% FCS, 1% penicillin-streptomycin, 
2mM L-Glutamine, 0.05 mM 2ME, 1mM Sodium Pyruvate, MEM Non-essential amino acids) 
that lacked any endothelial cell growth factor for 24h to minimize baseline proliferation. A 
rectangular lesion was made in the monolayer using a sterile (1000µl) pipette tip across the 
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diameter of the dish. Cells were rinsed with PBS and then incubated with serum of interest, 
1:500 dilution, for a further 24 hrs. Cells were washed with PBS to remove serum and fixed 
with paraformaldehyde (BD Cytofix kit 554714) for 30 min. Cells were then stained with 
Crystal Violet 0.05%. Dishes were then washed x2 and allowed to dry. The number of cells 
which had moved across the starting line was measured. Five fields were analysed for each 
well at 4x magnification and expressed as mean ± SD. 
Furthermore, in order to remove any confounding factors to this assay because of the 
presence of complement factors and other proteins in serum; autoantibody was column-
purified using a column purification kit as per manufacturer instructions (NAb™ Protein G 
Spin Purification Kit, Pierce, Rockford, IL, USA). Cells were incubated with immunoglobulin 
from serum of transplanted mice, or with antibodies of interest for a further 24-36h, fixed 
with paraformaldehyde (BD Cytofix kit, BD Biosciences), and then stained with 0.05% Crystal 
Violet solution. The negative fraction from column purification was used as negative control. 
For positive control, commercial anti-H-2Db mAb (BD Pharmingen, San Diego, CA, USA) was 
added to endothelial cells (diluted in medium in 1/200). For each plate, five fields along the 
lesion were analysed and numbers of cells encroaching the lesion were counted using light 
microscopy.  
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2.2.9. Polymerase chain reaction  
2.2.9.1. Background and basic principle 
The polymerase chain reaction (PCR) allows the in vitro amplification of selected regions of 
DNA. This assay is relatively rapid and highly sensitive, often requiring only small amounts of 
template DNA for amplification.  
In my work, I used this assay 
 To genotype genetically modified (GM) mice 
 And to selectively amplify cDNA coding for transcriptional factor B cells lymphoma factor 
6 (Bcl-6) for TFH cells 
The PCR entails repeated cycles of heating and cooling of the reaction mixture for the 
enzymatic replication of DNA. The reaction mixture contains template DNA, single standard 
DNA oligonucleotides called primers that contain amino acid sequences complementary to 
the start and end of the target region to be amplified, free nucleotides, and the enzyme 
DNA polymerase suspended in an appropriate buffer.  
Firstly, high temperatures are used to denature the DNA helix into two linear strands. Then 
mixture is cooled to facilitate association of primers to the single stranded DNA. The 
temperature is then adjusted to help enzymatic extension of the bound primer by DNA 
polymerase, for generation of a strand complementary to the template DNA, using free 
nucleotides in the reaction mixture. The series of steps is repeated and replicated, 
fragments from each cycle act as template in subsequent cycles, allowing exponential 
accumulation of target DNA. Heat-stable DNA polymerases that can tolerate successive 
cycles of high temperatures during denaturation allow the reaction to proceed 
uninterrupted in a thermal cycler.  
The 5’ ends of the primers can be modified to incorporate new nucleotide sequences at 
either end of the selected DNA region; this was used in my work to introduce terminal 
restriction endonuclease sites, in order to facilitate subsequent cloning of the amplified 
fragments into mammalian expression vectors.  
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2.2.9.2. Protocol 
Primer design 
Primers were designed using commercial software provided by Sigma Aldrich Inc. (Table 
2.7). When required, restriction endonuclease recognition sites were added at the 5’ ends of 
primers for downstream cloning of amplified DNA into expression vectors. A detailed 
sequence of primers used is shown in table 2.8 and 2.9. All primers were ordered from 
Sigma Aldrich Inc. 
PCR conditions 
In case of genotyping the following mixture was used. 
 10mM dNTP (Sigma Aldrich Inc)-1.25µl 
 10µM forward primer- 2µl 
 10µM reverse primer-2µl 
 2.5mM MgCl2 (Applied Biosystems, Life Technologies Inc.)- 2.5µl 
 1µg of plasmid DNA 
 1 unit Amplitaq Gold DNA Polymerase- 1.25µl 
 Betaine- 5µl  
 PCR 10x buffer in a 40µl volume-2.5µl 
The details of various primers and protocol are given in table 2.9. 
In case of amplification of DNA for Bcl-6 viral transduction, I used phusion high-fidelity DNA 
polymerase (New England BioLabs). 
 10mM dNTP (Sigma Aldrich Inc)-0.5µl 
 10µM forward primer-1.25µl 
 10µM reverse primer-1.25µl 
 5x phusion buffer-5µl 
 1µg of plasmid DNA-5µl 
 0.25µl phusion DNA Polymerase-0.25µl 
 Water to ,make it to 25µl 
PCR amplifications were performed in Biometra T3 Thermocycler (Biometra, Goettingen, 
Germany). 
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Analysis of PCR products 
PCR products were run in 1% Agarose gel as described below in section 2.2.10 for analysis 
and further purification.  
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Table 2.7 Parameters for primers 
Parameters 
Primer length 15-25 bases 
Melting temperature (Tm) 55-65 0C 
Tm difference between forward and 
reverse primers  
<50C 
Annealing temperature (Ta) 100C lower than the lowest Tm of the 
primers  
Percentage GC content  40-60% 
Secondary structure and self-
complimentary  
Selected the ones which did not possess 
secondary structures 
 
Table 2.8. Primers used in cloning 
Primer Sequence 
For lentiviral cloning of Bcl-6  
BCL6for ATGGCCTCCCCG GCTG 
BCL6rev TCAGCAGGCTTTGGGGAG 
BAMHIBCL6for CGTACAGGATCC ACG ATG GCCTCCCCGGCTG 
BAMHIBCL6rev CGTACAGGATCCACTTCAGCAGGCTTTGGGGAG 
BCL6 middlefor CATCGTTCTCAACAGCCTCA 
BCL6 middlerev TGAGGCTGTTGAGAACGATG 
BCL6rev156position AAGACAGTGCTCATGGCC 
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Table 2.9. Genotyping of animals 
Animal Primers Thermocycler protocol 
SAP-/-.BL6 
On gel 
electrophoresis, 
band should be 
present at 350bp 
with absent WT 
band at 1000bp 
(Fwd) 
GACATCTTATCCTCCAGTTTTATT  
(rev) 
AAAGTTTGTAAAGACACTATAAGTTA 
Denaturation 
 940C-2min 
 940C-30sec x 35 cycles 
Annealing temperature 
 600C-40sec x 35 cycles 
 720C-2min x 35 cycles 
Final extension 
 720C-2min 
 
TCRbd-/- 
On gel 
electrophoresis, 
Beta and delta 
knockout bands 
should be 
present at 280bp 
with absent WT 
bands. 
(β WT fwd)  
TGT CTG AAG GGC AAT GAC TG 
(βWT rev) 
 GCT GAT CCG TGG CAT CTA TT  
(δ WT fwd)  
CAA ATG TTG CTT GTC TGG TG 
(δ wt rev) 
GTC AGT CGA GTG CAC AGT TT 
(KO fwd)  
CTT GGG TGG AGA GGC TAT TC 
(KO rev)  
AGG TGA GAT GAC AGG AGA TC  
 
Reaction 1. For TCR beta gene  
Denaturation 
 950C-10min 
 950C-30sec x 35 cycles 
Annealing temperature 
 540C-40sec x 35 cycles 
 720C-1min x 35 cycles 
Final extension 
  720C-10min 
Reaction 1. For TCR delta gene 
Denaturation 
 950C-10min 
 950C-30sec x 35 cycles 
Annealing temperature 
 540C-40sec x 35 cycles 
 720C-1min x 35 cycles 
Final extension 
  720C-10min 
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Bm12 
On gel 
electrophoresis, 
in bm12 
reaction, for 
bm12 positivity, 
band should be 
present at 268bp 
with negative 
WT band. 
In BL6 reaction, 
band should be 
negative for 
homozygous 
bm12 status.  
(Bm12 fwd) 
GAG TTC CTG GAG CAA AAG 
(bm12/BL6 rev shared)  
CTG CTG GGC CTC ATG AG 
(BL6 Fwd) 
GAG ATC CTG GAG CGA AC 
For bm12 band 
Denaturation 
 950C-10min 
 950C-30sec x 35 cycles 
Annealing temperature 
 550C-30sec x 35 cycles 
 720C-1min x 35 cycles 
Final extension 
  720C-3min 
For BL6 
Denaturation 
 950C-10min 
 950C-30sec x 35 cycles 
Annealing temperature 
 550C-30sec x 35 cycles 
 720C-1min x 35 cycles 
Final extension 
  720C-3min 
 
DMa 
On gel 
electrophoresis, 
DMa KO band 
should be 
present at 520bp 
with a lack of 
BL6 band at 
270bp. 
(DMa WT)  
CAC ATT CCG GCA CAC TCT ATT CTG 
(DMa shared) 
TCT GGA CAC TGG GAT TTG ACC TTC 
(DMa KO) 
CCT TCT ATC GCC TTC TTG ACG 
Denaturation 
 950C-10min 
 950C-30sec x 35 cycles 
Annealing temperature 
 600C-1min x 35 cycles 
 720C-1min x 35 cycles 
Final extension 
  720C-5min 
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2.2.10. Analysis of DNA 
2.2.10.1. Analysis of DNA by Agarose gel electrophoresis  
Background and principle 
Gel electrophoresis is a laboratory method used to separate mixtures of DNA, RNA and 
proteins according to their molecular sizes. In gel electrophoresis, the molecules are pushed 
by electrical field through a gel that has small pores. The molecules travel through the gel 
pores at a speed that’s inversely proportional to their sizes. It means that smaller molecules 
travel long distances than the larger molecules.  It is fast and simple technique and with a 
sensitivity to detect as little as 1-10ng of nucleic acids. Bands can be readily recovered from 
the Agarose gel for downstream applications.  
I used this technique to  
 Measure the size and purity of DNA fragments following PCR and restriction 
endonuclease digestion 
 To identify and isolate DNA fragments of interest  
Protocol 
Gels were cast in UV transparent plastic trays placed in a gel caster (Bio Rad Laboratories 
Inc.) powered Agarose was dissolved in Tris-acetate (TAE) buffer  (pH8) by heating at low 
power in a microwave oven for 2-3minutes till a clear transparent solution was achieved. 
The solution was cooled to 60°C and supplemented with SYBR Safe DNA Gel Stain 
(Invitrogen, Life, technologies Inc.). The agarose solution was poured evenly onto the tray to 
a 1.0 cm depth approximately and gel was allowed to settle for 30-45 minutes at room 
temperature on a level bench. The tray was placed in the Sub-cell GT Cell (Bio Rad 
Laboratories Inc.) electrophoresis chamber filled with sufficient TAE buffer to submerge the 
gel. 
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Preparation of DNA samples 
DNA samples were prepared by diluting them with a glycerol loading buffer (5% Glycerol, 
Bromophenol blue and xylene cyanol in 1M Tris). The bromophenol blue dye also moves to 
the anode at the rate of 300bp fragment, helping track loading and migration of sample. 
Gel Run  
DNA samples were applied to the gel and a voltage of 100 V was applied across the 
electrophoresis tank for approximately 30 minutes or till the loading blue dye reached the 
bottom edge of the gel. Gels were visualised and photographed using the Gene Gnome 
Chemiluminescence Imaging System (Syngene UK, Cambridge, UK).  
For genotyping, different bands of DNA for different animals and different reactions are 
shown below in figure  
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Figure 2.2. DNA gel electrophoresis images of various animals using the conditions and 
primers as described in table 2.9, confirming the presence of respective bands for the 
animal of interest. 
a. Presence of a DNA band at 268bp with absent WT (BL6) band confirms the presence 
of homozygous status of bm12.  
b. Presence of a DNA band at 520bp with a lack of WT (BL6) band confirms the 
homozygous status of DM-/- animals 
c. Presence of a DNA band at 350bp with a lack of WT (BL6) band at 1000bp confirms 
the homozygous status of SAP-/- animals. 
  
WT band 
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Recovery of fractionated DNA 
Gels were visualised using a Trans illuminator (Syngene UK, Cambridge, UK) and the DNA 
band of interest was excised using a sharp clean scalpel and cleaned using QIA quick Gel 
Purification Kit (Qiagen Inc.). 
2.2.10.2. Analysis of DNA by DNA sequencing 
DNA sequencing of PCR products and plasmid DNA was carried out by the Source Bioscience 
Sanger sequencing facility, DNA sequences were analysed using the online ClustalW2 
sequence alignment software provided by the European Molecular Biology Laboratory-
European Bioinformatics Institute (EMBL-EBI).  
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2.2.11. Recombinant DNA technology 
2.2.11.1. Background and basic principle 
It is a technique used in genetic engineering to combine DNA from different genomes. It 
involves the identification, isolation and insertion of gene of interest into a vector such as a 
plasmid or bacteriophage to form a recombinant DNA molecule that is capable of 
autonomous replication in a suitable host. The vector backbone can contain additional 
genes and sequences that may for example, facilitate expression of the insert DNA or help 
track uptake of the construct by a host cell.  
I used this technique to deliver cDNA of Bcl-6 which is a master regulator of TFH cells to a 
lenti-vector. So, I have had to construct the cDNA of Bcl-6 in the lenti-vector and then co-
transfect it with its packaging plasmids to facilitate expression of cDNA gene.  
I carried out this part of my work under kind supervision of J Garland Zhao who developed 
this vector in house (Zhao and Lever, 2007) 
2.2.11.2. General protocol 
Isolation and identification of insert cDNA 
Bcl-6 pMIG-GFP vector plasmid (parent vector) was kindly gifted by S Crotty (Johnston et al., 
2009). I isolated Bcl-6 cDNA by PCR amplification of the insert by using primers that had Bcl-
6.BAMHI restriction sites at the end (sequences shown in table 2.8). Briefly, acquisition of 
cDNA of Bcl-6 involved the following step. 
 Firstly, transformation of competent E. coli with PCR product was carried out (see 
below) 
 Secondly, only peripheral and discrete colonies were selected and picked for further 
culture (see below). 
 Thirdly, extraction and purification of DNA from the selected colonies was done by 
using Qiagen Mini Prep Kit (see below) and the presence of Bcl-6 band on gel 
electrophoresis was confirmed. In addition, Bcl-6 sequences was further confirmed 
on DNA sequencing (section 2.2.11.2) 
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Introduction of insert DNA into vector 
After acquision of cDNA of Bcl-6, it was ligated with lentiviral expresser plasmids. All 
restriction enzymes were purchased from New England Bio Labs Inc. Both insert and vector 
DNA were treated with BAMHI restriction enzyme to get sticky ends. Thereafter, to prevent 
permanent phosphodiester linkage of any self-annealed vector molecules, 5’ terminal 
phosphate groups were removed using the enzyme calf intestinal phosphatase (CIP). The 
insert was not dephosphorylated and therefore only vector molecule carrying the insert 
could be permanently re-circularised by DNA Ligase. 
Digestion of vector using BAMHI: 
30µl of viral vector 
10µl of BAMHI-HF 
10µl 10xTAS buffer 
20 µl 5xBSA 
30 µl H2O 
This mixture was incubated for 3hrs at 37°C. Then, I precipitated the DNA by incubating 
digestion mixture with 10µl of 3M sodium acetate (pH5.2) and 200µl 0f 100%ethanol at -
80°C for 30 minutes.  The mixture was then centrifuged at 15000rpm for 15minutes at 4°C 
followed by a wash with 70% ethanol and centrifuged again at 15000rpm for 15min at room 
temperature. Pellet was then air dried and dissolved in RNAase free water. This vector was 
dephosphorylated using CIP as manufacturer’s instructions and then digested and 
dephosphorylated vector was purified using QIAquick PCR Purification Kit (Qiagen Inc.) 
However, insert was PCR amplified using BAMHIBcl-6 forward and reverse primers and 
amplified PCR product was then digested with BAMHI-HF according to the manufacturer’s 
instructions. Digested transgene was then isolated using Agarose gel electrophoresis and 
the QIAquick Gel Purification kit (Qiagen Inc.). 
During DNA ligation, the insert was incubated with the plasmid backbone in 1:1, 2:1, 3:1 and 
5:1 molar ratios with 1U T4 DNA Ligase (New England BioLab Inc.). The mixture was 
incubated at room temperature for 1hr.   
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Transformation of competent E. coli with vector 
Recombinant vectors were amplified in the MAX Efficiency DH10B One Shot competent E. 
coli cells (Invitrogen, Life technologies Inc.). A 50µl aliquot of competent cells was thawed 
and incubated on ice with 1-5µl of the ligation reaction, or 5-10ng of purified plasmid for 
30minutes. Cells were subjected to precisely 30seconds of heat treatment in a 42°C water 
bath, and transferred back immediately to ice. Cells were then recovered with 250µl of 
sterile SOC medium (Invitrogen, Life technologies Inc.) at room temperature and incubated 
at 30°C for 90minutes with vigorous shaking. The culture was evenly plated on pre-warmed 
LB Agar plated supplemented with 50µg/ml Ampicillin (LB/Amp plate) to facilitate selection. 
The plates were incubated at 30°C for 16-48hrs. The lower incubation temperature of 30°C 
was used to minimise the incidence of recombination events during bacterial replication of 
the relatively large mammalian expression vectors.  
Selective expansion of recombinant vector 
Single bacterial colonies were cultured for 16-24hrs at 30°C with vigorous shaking, in 3ml 
sterile LB broth supplemented with 50µg/ml of Ampicillin (LB/Amp). For a large scale DNA 
preparation, colonies carrying the plasmid of interest were further sub-cultured by 
inoculation of 1ml of bacterial culture in 500ml LB/ Amp medium for 24-48 hrs at 30°C with 
vigorous shaking. 
Purification of recombinant vector 
Bacterial cultures were centrifuged to obtain transformed cells; these were subjected to 
alkaline lysis and plasmid DNA was purified on a silicon resin according to the 
manufacturer’s instructions with QIAprep MiniPrep or Qiagen Plasmid Maxi prep kits 
(Qiagen Inc.)  DNA was eluted in nuclease free water (Ambio, Life technologies Inc.). The 
purity and approximate plasmid concentration of the preparation was checked using the 
Nanodrop spectrophotometer (Thermo Fisher Scientific Inc.) The presence of insert in LV 
expressor plasmid was confirmed by gel electrophoresis (figure 2.3) as well as by DNA 
sequencing.  
Genetic screening of purified recombinant vectors 
Restriction endonuclease cleavage of the purified plasmids was carried out by incubation of 
1µg of vector DNA for 30minutes at 37°C and the size of resulting fragments was 
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determined using agarose gel electrophoresis. The restriction enzymes used and fragment 
sizes are given in table 2.10.  All restriction enzymes were purchased from New England 
BioLab Inc.  
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Figure 2.3. Gel electrophoresis of Bcl-6 LV vector confirming the Bcl-6 band at 2.1 kbp using 
BamHIBcl-6 forward and reverse primers.  
  
BCL6 band 
Bcl-6 
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Table 2.10. Restriction enzymes fragmentation of DNA backbone  
DNA Restriction enzyme Fragment size 
pCMV-EmGFP-BCL6 BAMHI 2.1kbp; 10kbp 
pCMVΔR8.9 Xho1; EcoR1 10.4kbp; 1.6kbp 
pCMV-VSV-G Xho1 5.3kbp; 1.6kbp 
pRSV-Rev1 Xho1; Bg1II 3.6kbp; .6kbp 
Table 2.9. Restriction enzymes fragmentation of DNA backbone  
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2.2.12. Plasmid constructs 
2.2.12.1. Background 
Lentiviral vectors are a subtype of retroviruses and are highly efficient in infecting dividing 
and non-dividing cells; they have low immunogenicity and achieve long term stable 
expression of transgene in the host.  
Virions are composed of three structural genes-gag, pol, and env-that code for the protein 
necessary for viral integration and replication; two regulatory genes-tat and rev and 
accessory genes- vif, vpr, nef and vpu which are associated with virus infectivity and 
pathogenesis. The viral genome is flanked by long terminal repeats (LTRs) that is essential 
for integration of the viral genome into the host and thereafter also act as a part of the 
promoter for viral gene transcription. A cis-acting Psi-sequence found near the 5’ end of the 
genome is also necessary for packaging replicated viral RNA into virus capsids to sustain 
infection in the host.  
My work used a human immunodeficiency virus-type 1 (HIV-1) derived third generation 
vector as has been used by Zhao et al (Zhao and Lever, 2007; Zhao et al., 2005; Zhao et al., 
2002). This is regarded as a safe vector as most of the accessory genes are deleted and there 
is no tat in the regulatory gene. Third generation lentiviral systems are considered safer 
than second generation systems, however, are more difficult to use because they require 
transfection with four separate plasmids in order to create functional lentivirus vector. 
The plasmids packaging systems in this vector are from two plasmids; one plasmid contains 
gag and pol and second provides rev. To broaden tropism of the vector, heterologous 
envelope from the vesicular stomatitis virus is used and its transgene is provided in a 
vesicular stomatitis virus G glycoprotein (VSV-G) expresser plasmid. These plasmids are 
replication deficient due to complete removal of Psi packaging element and LTRs from the 
plasmids. A transfer plasmid carries the transgene and reporter gene of interest together 
with the cis-acting genetic sequences that allow packaging and integration of the transgene, 
and provides the genetic material for the viral vector; notably promoter enhancer region in 
the 3’ LTR of the transfer plasmid is partially deleted such that the reverse-transcribed pro-
viral 5’LTR is transcriptionally inactive, preventing subsequent replication or mobilisation 
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following transduction. Following co-transfection of these vectors into an appropriate cell 
line, pseudoviral particles carrying the gene of interest are produced. 
2.2.12.2. Lentiviral plasmids in the third generation packaging system 
Plasmids vectors carrying the lentiviral genes were a kind gift from Prof. Andrew Lever and 
Dr. Jing Garland Zhao in the department of Medicine, University of Cambridge. All plasmids 
carried genes for Ampicillin resistance. These plasmids are discussed below. 
Transgene expresser plasmid 
The transgene expresser plasmid carries the transgene that will be integrated into the host 
genome. The transgene and reporter GFP gene are co-expressed from a bi-cistronic 
expression cassette with an internal spleen focus-forming virus promoter and the 
woodchuck hepatitis virus post transcriptional regulatory element. The vector was modified 
to incorporate transgenes for Bcl-6 within the expression cassette.  
The plasmid contains the cis-acting Psi packaging element and the 5’LTR of the original 
provirus for efficient integration of the transgene, but has a 130 base pair deletion in U3 
region of 3’LTR. It lacks most structural, regulatory and accessory genes from the HIV-1 
sequence except 350 base pairs of gag sequence and rev response element (RRE) from the 
env sequence to increase packaging efficiency. A central polypurine tract (cPPT) that has 
been shown to improve transcription and transduction efficiency, has also been introduced 
upstream of the transgene. Bcl-6 transgene expressor plasmid is shown below in figure 2.4. 
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Figure 2.4. Schematic figure for Bcl-6 transgene expressor plasmid, whereSIN=Self-
Inactivating 3' Long Terminal Repeat (LTR 
SFFV=Strong internal promoter of SFFV (Spleen focus forming virus) 
PRE= Post-transcriptional regulatory element 
IRES= EMCV internal ribosome entry site 
RRE= Rev responsive element 
Bcl-6= B cell lymphoma 6 (master regulator of TFH cells) 
Bam HI= Restriction enzyme 
E-GFP= Enhanced green fluorescent protein  
WPRE= Woodchuck Hepatitis Virus Post transcriptional Response element 
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Gag-pol packaging plasmids (pCMV ΔR8.9) 
The plasmid carries the HIV gag and pol structural genes, expressed by human 
cytomegalovirus immediate-early promoter (pCMV) and a Simian virus 40 (SV40) polyA 
tract. Majority of the env sequences has been deleted except for RRE to increase packaging 
efficiency.  
Rev expresser plasmids (pRSV-Rev) 
This plasmid codes for the rev regulatory protein under control of the Rous Sarcoma virus 
(RSV) promoter and a SV40polyA tract. This protein can bind to RRE in the transgene 
expresser plasmid and pCMV ΔR8.9 plasmids, thus regulates virus RNA transport and 
splicing.  
VSV-G expresser (pCMV-VSV-G) 
This plasmid codes for the VSV-G proteins which is expressed by pCMV promoter and 
SV40polyA tract. The VSV-G envelope broadens the tropism and provides stability to the 
vector, thus allows particle concentration by ultracentrifugation.  
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Figure 2.5.  This figure has been adapted from J Garland Zhao’s book (Zhao and Lever, 
2007).  
i. The genomic organisation of the lentivirus. 
ii. The “third generation” of HIV-1 vector constructs with Bcl-6 as a transgene of 
interest. 
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2.2.13. Vector production and transduction 
2.2.13.1. Background and basic principle 
Pseudotyped vectors were generated by transfection of plasmid DNA into 293T cells using a 
modified calcium phosphate method (Chen and Okayama, 1988) and shown below (figure 
2.4). Although the mechanism is not yet clear, it is believed that transfected DNA enters the 
cells by endocytosis and subsequently transfers to the nucleus. Since Graham and Van de Eb 
first established this methods in 1973 (Graham and van der Eb, 1973), many minor 
modifications of the procedure have been described. Among them Chen and Okayama’s 
modified transfection protocol is considered to be highly efficient in achieving stable 
transformation of mammalian cells with supercoiled plasmid DNA (Chen and Okayama, 
1988). In their modified calcium phosphate transfection protocol, DNA-calcium phosphate 
co-precipitate is formed gradually onto the cells in the tissue culture medium during prolong 
incubation (16-18 hours) under controlled conditions of pH 6.95 and 3% CO2 tension.  
2.2.13.2. Protocol 
2.2.13.2.1. Mammalian cell cultures  
HEK293 cells were cultured in full culture medium (DMEM supplemented with 2mM L- 
glutamine, 100IU/ml, penicillin, streptomycin, 10%FCS and Sodium Pyruvate). Cells were 
passaged by incubation with Trypsin-EDTA for 1 min at 370C water bath or till cells visibly 
detached under low power magnification.  
2.2.13.2.2. Production of viruses 
Setting up the plates at day 1 
I split the exponentially growing 293 T cells and seeded them into 10-cm culture dishes at 
the 40-50 % confluence with 9 ml of DMEM supplemented with 10 % FCS and 1ml of split 
cell mix drop wise onto the plates and swirl gently. Make sure the cells are evenly 
dispersed in the culture dishes and then the cells are cultured overnight in the humidified 
37oC incubator in an atmosphere of 5 % CO2. Plates will be harvested in multiples of 3, so 
maximum of 18 plates, one being a transfection control plate. 
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Transfection at day 2  
Early afternoon, (2-3 hours before transfection) I aspirated off old media and added 9ml 
fresh medium and returned the plates to incubator. Late afternoon, I made transfection 
cocktail in 7ml bijous, 1 bijou per plate as follows and shown in figure 2.6. 
737µl H2O 
737µl 2xBBS 
10µl plasmid of interest 
6.5µl pCMV ΔR8.9. 
3.5µl VSVG 
2µl Rev 
72µl CaCl2 
I added H20 and 2xBBS to each bijou, then DNA and finally CaCl2. Each bijou was flicked 
gently as CaCl2 is added, then left undisturbed for 20minutes. Transfection control is 
performed in the same way but with 7µl GFP as the only DNA. After 20 minutes, bijous were 
flicked again and added to the plates drop wise and swirled gently and returned to 
incubator for 12-16 hours.  
Changing the medium and moving the plates to category 2 laboratory at day 3 
Early morning, I aspirated off old medium and replaced with 12ml fresh DMEM medium 
(DMEM, Penicillin, Streptomycin, 10 %FCS, L/ Glutamine and sodium pyruvate) and 
transferred thee plates to category 2 laboratory in department of virology incubator.  
Examination of the plates under UV at day 4 
I examined the control plate for GFP expression under UV. 
Harvesting the virus at day 5 
It should be performed in category 2 laboratory hood. 
Conditioned supernatant carrying the lentiviral particles was collected from three plates 
into a 50ml syringe and filtered through a 0.45µm filter into Beckman Ultra-clear 
centrifugation tubes to concentrate viral particles. It may be necessary to use more than 
one filter, but if more than three filters are required per 30ml of supernatant, then viral 
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production will probably be poor, and it may not be worth continuing. Each tube was 
topped up with few mm from the top with extra DMEM to prevent the tube buckling in the 
centrifuge. I placed the tubes in the swing buckets for SW32 rotor, and balanced to 0.05g 
(bucket 1 balances with bucket 4, 2 with 5 and 3 with 6- this is very important to double 
check these before starting centrifugation). Then buckets were attached with the rotor and 
spun @ 25000 for 2- 2.5 hours. The viral pellet was resuspended in 300µl 1% BSA in PBS; a 
10µl aliquot was removed for testing and the remaining virus preparation was stored -80°C.  
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Figure 2.6. Generation of lentiviral vector by transient co-transfection of 293 T cells, 
adapted from Zhao et al (Zhao and Lever, 2007) 
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2.2.14. Transduction of murine CD4 T cells with Bcl-6 vector  
This was adapted from Johnson et al (Johnston et al., 2009) and McCausland et al 
(McCausland et al., 2007). 
Purification of CD4 T cells  
Single cell suspension of splenocytes were resuspended in 750µl of MACS buffer with 100µl 
of CD4 magnetic beads and left on ice for 20 minutes. After washing and resuspension of 
cells in 500µl of MACS buffer; the cells were passed through the auto MACS machine using 
possels program and positive fraction was collected. Purified CD4 T cells were washed, 
resuspended in full medium (RPMI supplemented with 10% FCS, 100U/ml 
Penicillin/streptomycin, 2mM L-Glutamine (Gibco) and mouse IL-2 (50U/ml) and used for 
activation of CD4 T cells. 
Activation of CD4 T cells 
8x104 purified CD4 T cells in a volume of 100µl per well were placed on 96 well tissue 
culture plate. Then CD23/CD28 mouse T activator dynabeads (life technologies) were 
washed with FACS buffer and resuspended in full medium and added to CD4 T cells plate in 
a way to obtain a bead to cell ratio of 1:1. The plates were incubated in a humidified CO2 
incubator at 37°C for 24 hours. 
Transduction 
Activated CD4 T cells were transferred to 12 well culture plate which was precoated with 
polybrene (10ng/ml) and Bcl-6 vector with multiplicity of infection (MOI) from 1-3 and 
control lentiviral vector without Bcl-6 GFP. These cells were then spun at 1200rpm for 90 
minutes at 4°C with murine IL-2. Cells were washed and medium was replaced with 
minimum medium (RPMI supplemented with 1% FCS, 100U/ml  Penicillin/streptomycin, 
2mM L-Glutamine and 50U/ml of mouse IL-2) and left in humidified CO2 incubator at 37°C 
for 24 hours. After 24 hours, minimum medium was replaced with full medium and left in 
incubator for an additional 72 hours. Cells were then examined under microscope for 
fluorescence indicating the transduction of cells. It is important to note here that not all the 
bm12 CD4 T cells would have been transduced with Bcl-6 vector.   
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Delivery to animals 
After confirmation of GFP under microscope in experimental wells and absence in control LV 
vector wells on bm12 CD4 T cells, cells were washed and beads were removed and cells 
(2x106 CD4 T cells) were injected intravenously into mice. As I mentioned above, in the 
experimental group, mixture of both transduced and non-transduced bm12 CD4 T cells 
would have been transferred.   
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2.2.15. Statistical analysis 
Data were presented as mean ± S.D. where appropriate. Mann Whitney tests were used for 
analysis of non-parametric data. Two-way ANOVA was employed for comparison of 
antinuclear and anti-Kd antibody responses. Graft survival was depicted using Kaplan-Meier 
analysis and groups compared by log-rank (Mantel-Cox) testing. Analysis was conducted 
using Graph Pad 4 (Graph- Pad Software, San Diego, CA, USA). Values of P < 0.05 were 
considered significant. Furthermore, p values were substratified as *P < 0.05, **P < 0.01 and 
***P < 0.001 where applicable. 
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Chapter 3 
Characterisation of germinal centres in a model of chronic rejection (bm12 to 
BL6) 
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3.1. Introduction 
The experimental work in this thesis is an extension of our previous work, examining chronic 
heart allograft rejection in the murine bm12 to C57BL/6 (BL6) strain combination (Win et al., 
2009). The bm12 strain is a naturally occurring mutant of BL6 that differs by only three 
amino acids in the third hypervariable region of the peptide binding groove of the MHC class 
II, I-Ab. This creates the so-called I-Abm12 class II molecule in the bm12 strain.  The amino acid 
changes are at codon 67 (isoleucine in BL6 replaced by phenyalanine in bm12), codon 70 
(arginine in BL6 replaced by glutamine in bm12) and codon 71 (threonine in BL6 replaced by 
lysine in bm12) (Hansen and Tse, 1987; McKenzie et al., 1979; Mengle-Gaw et al., 1984; Tse 
et al., 1985). The BL6 and the bm12 strains only express one MHC class II antigen, because 
the I-E antigen is not expressed due to deletion of the Eα gene. Hence, the two strains are 
mismatched at MHC class II but are otherwise identical at the MHC class I and minor loci. 
3.1.1. Mechanisms of rejection in this model 
Due to minimal mismatch between these two strains, the responder frequency of donor T 
cells that interact with the I-Ab alloantigen was much less than that found in completely 
MHC mismatched groups. Suchin et al (Suchin et al., 2001) found a responder frequency of 
2.5% compared to the 21% in the complete MHC mismatch group. Similar results were 
reported by Busser et al (Busser et al., 2003). Nevertheless there are enough anti-bm12 T 
cells within the BL6 repertoire to elicit acute rejection of bm12 skin allografts by BL6 mice 
(Nagano et al., 1997; Stuart et al., 1984). Many groups have reported chronic rejection of 
bm12 donor heart allografts in BL6 recipients (Gao et al., 2000; Sayegh et al., 2003; Win et 
al., 2009).  
Rejection in this model appears to be dependent upon recipient T cells. The evidence comes 
from Furukwawa et al study (Furukawa et al., 2004) in which development of AV in the 
bm12 donor heart grafts was observed upon transplantation into RAG-1-/- recipients 
following reconstitution with recipient T cells, even in the absence of B cells (Furukawa et 
al., 2004). This AV was dependent upon IFN- γ, as no AV was observed when IFN- γ-/- T cells 
were transferred into RAG-1-/- recipients (Furukawa et al., 2004). Interestingly, AV markedly 
attenuated when bm12 allografts were transplanted into IFN- γ-/- recipients (Nagano et al., 
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1997). Similar results have been reported by other groups as well in which they have shown 
that CD8+ T cells, activated via the CD40-CD40L pathway, mediated the progression of AV via 
their cytotoxic activity and secretion of IFN-γ (Fischbein et al., 2000; Fischbein et al., 2001). 
In keeping with these studies, AV significantly reduced in CD8 T cell knock out recipients 
(Schnickel et al., 2004) suggesting that CD8 T cells playing a role in allograft rejection in this 
model. Recently, Ishii et al investigated the role of CD8 and CD4 T cells in this model by 
transplanting bm12 kidney allografts into CCR5-/- BL6 recipients (Ishii et al., 2014). Although, 
numbers of CD4 T cells infiltrating bm12 allografts were nearly identical in BL6 and CCR5-/- 
BL6 recipients, there was an intense infiltration of CD8 T cells in allografts transplanted into 
CCR5-/- BL6 recipients, that was detectable 1 week after transplantation and gradually 
increased thereafter. The CD8 T cells induced to bm12 allografts in CCR5-deficient recipients 
were reactive to donor I-Abm12 peptide presented by class I MHC molecules (indirect CD8 T 
cell response). Their results demonstrated unique CD8 T cells specificities against disparate 
I-Abm12 peptides which is capable of rejecting the donor kidney allografts in the absence of 
CCR5 expression through indirect pathway (Ishii et al., 2014). However, earlier studies 
(Valujskikh et al., 2006) have contradicted Ishii et al findings.  Valujskikh et al experiments 
suggest that CD8 T cells reactive to self-restricted allopeptide are non-pathogenic 
bystanders within the alloimmune response to fully MHC-disparate heart grafts. By using a 
defined host-restricted, minor transplantation Ag (HY, male antigen), they showed that 
preactivated Ag-specific CD8 T cells did not influence the kinetics of acute cardiac allograft 
rejection, did not influence the development of chronic graft injury, and did not adversely 
affect costimulatory blockade-induced prolongation of graft survival (Valujskikh et al., 2006).  
Further examination of rejection kinetics in this model has shown that both direct and 
indirect pathways of CD4 T cell allorecognition are playing a role in chronic rejection. Thus, 
BL6 CD4 T cells can recognise intact I-Abm12 molecule directly on donor cells or, alternatively, 
as processed allopeptide presented by self MHC class II (I-Ab) on BL6 APCs (indirectly). The 
evidence for the role of direct pathway is derived from the observation of development of 
AV in bm12 donor cardiac allografts upon transplantation into H-2M BL6 (Ardehali et al., 
2002). H-2M BL6 mice express normal levels of MHC class II but possess a defect in peptide 
loading. Hence, recipient CD4 T cells can only recognise I-Abm12 by the direct pathway. 
However, the contribution of the indirect pathway is demonstrated by the prolonged 
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survival and diminished vasculopathy of the bm12 cardiac allografts upon transplantation 
into TCR-transgenic ABM recipients. ABM mice have a monoclonal population of CD4 T cells 
that recognise the bm12 antigen by the direct pathway (Sayegh et al., 2003). Surprisingly, 
ABM recipients reject bm12 skin grafts, perhaps reflecting that skin grafts are generally 
more immunogenic that other vascularized organs. Further evidence about CD4 T cell 
indirect alloreactivity in this model is suggested by the more rapid rejection of bm12 
allografts that occurs when transplanted into BL6 recipients previously primed with 
synthetic I-Abm12 peptide that incorporates the disparate amino acids (Win et al., 2009). It is 
not clear how indirect pathway CD4 T cell will mediate allograft damage because of their 
inability to bind with the graft cells in an antigen specific manner due to lack of their epitope 
on the allograft. It is more likely that these indirect pathway CD4 T cells will be acting as a 
helper to either cytotoxic CD8 T cells or B cells to generate antibodies.  
3.1.2. Development of autoantibody in this model 
Previous work in our department (Win et al., 2009) and by others (McKenzie et al., 1979)  
has shown that alloantibody responses against the I-Abm12 donor antigen are not generated 
in BL6 recipients of bm12 heart allografts. This most likely reflects the absence of 
conformational epitope on the I-Abm12 antigen for recognition by BL6 B cells, rather than an 
absence of the provision of essential CD4 T cell help, because immunisation of BL6 mice 
with F1 (bm12xH-2k) splenocytes results in development of anti-H-2kIgG alloantibody 
(indicating delivery of appropriate T cell help), and yet, anti-I-Abm12 alloantibody is not 
generated (Win et al., 2009). Instead BL6 recipients of bm12 heart allografts developed long 
lasting anti-nuclear IgG autoantibodies with germinal centre secondary follicles evident 
within the recipient spleen on hematoxylin and eosin–stained paraffin sections, indicating T 
cell dependent, humoral immunity (Win et al., 2009). The development of autoantibody was 
determined by hep-2 indirect immunofluorescence, with patterns of staining of the Hep-2 
cells differing markedly between differing recipients. This implies that this humoral  
autoimmune response was directed against multiple different autoantigens (Win et al., 
2009). In this model, we reported development of anti-chromatin, anti-dsDNA and anti-
ssDNA autoantibodies (Win et al., 2009), while Mahesh et al (Mahesh et al., 2007) reported 
development of anti-vimentin autoantibody responses. 
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It is not immediately clear why bm12 allografts trigger humoral autoimmunity in BL6 
recipients. Earlier work by Eisenberg et al. reported that adoptive transfer of bm12 
splenocytes provoked autoantibody development and SLE like immunopathology in BL6 
recipients (Morris et al., 1990a). He further suggested that the autoantibodies that are 
generated during chronic GVH phenomenon are the result of physical T-B cell interactions, 
rather than a consequence of secretion of nonspecific T cell-derived factors. Their 
experiments involved adoptive transfer of bm12 splenocytes into radiation mixed chimeras 
of bm12 and BL6 bone marrow elements which resulted in ANAs secreted only from BL6 B 
cells, despite the potential for bm12 B cells to be activated by bystander mechanisms 
(Morris et al., 1990b). Furthermore, the donor bm12 T cells activated the entire recipient B 
cell population, as demonstrated by the increase in size of the recipient B cells, along with 
uniform expression of higher levels of MHC class II and B7-2 (Sekiguchi et al., 2002). 
However, the development of anti-dsDNA autoantibodies was driven by the self-antigens 
(Sekiguchi et al., 2003). Sekiguchi et al (Sekiguchi et al., 2003) used two different heavy 
chain Ig site directed transgenes; 3H9 knock in (KI) and 3H9/56R KI and adoptively 
transferred bm12 splenocytes to these transgenic mice. Their previous work has shown that 
3H9 KI produces wider repertoire of autoantibodies (Li et al., 2001) and 3H9/56R heavy 
chain KI gives rise to more specific anti-dsDNA antibodies (Chen et al., 1995). On analysis of 
autoantibodies, they found similar levels of anti-ssDNA in the 3H9 and 3H9/56R recipients 
but an increased levels of anti-dsDNA antibodies in 56R KI recipients. In 56RKI mice, the 
difference in increased levels of anti-dsDNA antibodies was due to the presence of the anti-
DNA Ig sd-tg focused allogeneic T cell help on anti-dsDNA B cells. This was confirmed by 
hybridomas showing consistently high percentage of hybridomas that were anti-dsDNA 
positive in 56RKI+ve group. Interestingly, most of the anti-dsDNA clones in the 56RKI+ve set 
were not using the 3H9/56R sd-tg, hence the presence of this high frequency could not be 
directly attributed to the presence of anti-DNA H chain. Rather, the presence of high 
frequency of anti-dsDNAs producing hybridomas was due to the self-antigens which were 
selectively activating these cells in vivo. Genetic analysis of hybridoma panels of the 
rearranged Ig genes correlated this response with the generation of anti-dsDNA B cells 
through secondary rearrangements that replaced the site-directed transgene (sd-tg) with 
endogenous VH genes.  
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There may be two potential mechanisms which may be leading to the development of 
autoantibodies only. Firstly, autoantigens stimulate the toll like receptors, antinuclear 
autoantigens mimic toll-like receptor (TLR) ligands and once internalised, provide additional 
TLR signalling for antibody production (Leadbetter et al., 2002) and secondly, concurrent 
ligation of BCR by autoantigens result in the development of autoantibodies (Harper et al., 
2016). The later possibility was confirmed by adoptive transfer of bm12 CD4 T cells to TCRbd-
/- BL6 mice that are simultaneously immunised with adjuvant alone or with ovalbumin in 
adjuvant. Both groups developed autoantibody, but only those immunised with ovalbumin 
developed IgG anti-ovalbumin antibody. Harper further demonstrated that this 
phenomenon also applied to alloantigenic determinants that were expressed on the donor 
CD4 T cells; that these donor cells could provide help for alloantibody responses against 
their self-antigens. This occurred even though these CD4 T cells were, as expected, tolerant 
to their surface MHC antigens within the donor strain. Thus Harper’s results indicated that 
although donor CD 4 T cells activate all the B cells, differentiation into antibody secreting 
cells requires concurrent ligation of the BCR (see Figure 3.1). This conforms the two signal 
hypothesis of B cell activation (Bretscher and Cohn, 1970).  
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i.  
 
ii.  
 
 
Figure 3.1. Two signal hypothesis of B cell activation in bm12 to BL6 model. 
i. Donor CD4 T cells provide help to recipient B cells by GVH recognition of 
allogeneic MHC II on the B cells surface, irrespective of the peptide bound to 
MHC class II.  
ii. Differentiation to an antibody secreting cell is limited to those B cells that 
simultaneously bind target antigen via their B cell receptor.  
(Adapted from Harper Ines et al et al work) (Harper et al., 2016) 
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An effector role humoral autoimmunity in contributing to slowly evolving AV presumably 
requires long term production of autoantibody. In our previous studies (Motallebzadeh et 
al., 2012; Win et al., 2009), we have shown that autoimmunity triggered by bm12 allografts 
in BL6 recipients was long-lasting, with strong titres maintained up to three months post 
transplantation. It is generally accepted that long lasting humoral responses are the result of 
long-lived plasma cells (Manz et al., 1997; Slifka et al., 1998), which are in turn a product of 
germinal centres. (Good-Jacobson et al., 2010; Han et al., 1995; MacLennan, 1994; 
Takahashi et al., 1998; Vinuesa et al., 2009). Although Shlomchik et al have shown in an 
autoimmune prone mice model that EF antibody responses may result in deposition of 
plasmablasts in the spleen, and further, that these antibody forming plasma cells showed 
evidence of hypermutation, despite not being derived from a germinal centre (William et al., 
2005a; William et al., 2005b). Nevertheless these antibody responses were not long-lived 
(William et al., 2005b). 
The development and maintenance of these GCs is dependent on availability of help from 
TFH cell (Crotty, 2011; Crotty, 2014; Crotty, 2015; Qi, 2012; Vinuesa and Cyster, 2011). The 
TFH cell provides survival signals to follicular B cells for development of GC response that, 
ultimately, provide life time immunity. Conversely, there is emerging evidence that 
dysregulation of these TFH cells may be a trigger in development of autoimmunity. This has 
been shown by Linterman et al in Roquinsan/san mouse model in which aberrant help by TFH 
CD4 T cells resulted in the development of lupus like pathology without any antigenic 
challenge. However, when SAP signalling was inhibited (which is thought to be important for 
the development of GCs) in  Roquinsan/san SAP-ve mice, excessive TFH  cells or spontaneous GCs 
did not form, and lupus like pathology in the animals was ameliorated, thus confirming the 
role of TFH cells for the development of autoimmune GCs. Others have also shown that 
aberrant T cell help can cause spontaneous GC formation and autoimmunity (Luzina et al., 
2001; Vinuesa et al., 2009). Nevertheless, T cell help is critical for the development of long 
lasting germinal centres. Hence, I examined the development of germinal centres in bm12 
to BL6 model, in particular to focus upon the TFH subset of CD4 T cell.  
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3.2. Aims  
Because the previous studies have not investigated the development of germinal centres in 
this model, the aim of this chapter is to characterise the germinal centre humoral responses 
and address the following questions: 
1. Do germinal centres develop in BL6 recipients of a bm12 heart allograft?  
2. If so, is the germinal centre response long lasting? 
3. Are these GC responses mediated by TFH cells? 
4. Does the autoimmune response diversify in this model? 
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3.3. Results  
3.3.1. Development of autoantibody  
Before embarking to investigate development of germinal centres in this model, I decided to 
confirm the previous findings (Win et al., 2009) first by transplanting bm12 heart grafts into 
BL6 recipients and examining autoantibodies in the recipients’ sera, assessing rejection 
kinetics of bm12 allografts and measuring development of allograft vasculopathy in donor 
allografts on explanation.   
Analysis of recipients’ sera by hep-2 indirect immunofluorescence staining demonstrated a 
long lived autoimmune humoral response (figure 3.1). 
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Figure 3.2. Development of antinuclear autoantibodies in BL6 recipients of bm12 donor 
heart grafts 
a. Pictorial presentation of the model in which donor CD4 T cell directly interacts with 
recipient B cells through their MHC class II in a graft versus host fashion and provide 
help for the development of autoantibody. 
b. Relative anti-nuclear autoantibody levels as measured by Hep-2 indirect 
immunofluorescence in BL6 recipients sera demonstrating development of long 
lasting autoantibody responses  in BL6 recipients of bm12 allografts compared to BL6 
recipients who received syngenic heart grafts (p=<0.0001, Two way ANNOVA). Data 
represent mean and SD of n = 4 mice per group.  
c. Representative pictures of hep-2 indirect immunofluorescence slides for bm12 to 
BL6 versus syngenic grafts. 
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3.3.2. Graft survival and histology 
Bm12 allografts were rejected in BL6 recipient slowly with median survival of 56 days 
compared to long term survival of syngeneic BL6 heart grafts (p=0.005, log 
rank)(n=10)(figure 3.3a). Rejection was associated with the development of AV in donor 
bm12 allografts, not observed in BL6 syngeneic grafts (mean luminal stenosis was 76±6 in 
bm12 to BL6 vs 2±2 in BL6 to BL6, p= 0.02) (figure 3.3b). This luminal stenosis was calculated 
as described in methods section (2.2.7.5) in the donor allografts explanted at week 7 post 
transplantation. 
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Figure 3.3. Development of allograft vasculopathy in bm12 donor grafts following 
transplantation into BL6 recipients 
a.  Kaplan-Meier survival curves of bm12 hearts transplanted into BL6 (n=5-10) and 
BL6 hearts transplanted into BL6 (log-rank test, p=0.003).  
b. Development of significant allograft vasculopathy (% luminal stenosis) in donor 
hearts explanted from bm12 to BL6 group compared to syngeneic group at 7 
weeks post transplantation (n= 4-7) (p= 0.02, Mann-Whitney test).   
c. Representative figure for the development of AV, explanted hearts were stained 
with Elastic Van Gieson staining (EVG) in syngenic and bm12 to BL6 group (n= 4). 
  
128 
3.3.3. Histological assessment of recipient spleen sections for the development of germinal centres 
As bm12 allografts were rejected slowly in BL6 (WT) recipients with development of 
allograft vasculopathy and recipient sera demonstrated long lasting autoantibody response, 
the next step was to investigate how these autoantibodies are formed.  
Win’s original work in our department had reported that haematoxylin and eosin (H&E) 
staining of splenic sections from BL6 recipients seven weeks after transplantation with a 
bm12 heart allograft revealed classical light and dark zones, consistent with a germinal 
centre response (Win et al., 2009) but this was not explored further. Therefore, I performed 
immunohistochemistry (IHC) and immunofluorescence (IF) staining on recipients’ spleen 
section to first confirm the development of GC response. As expected, on H and E staining of 
BL6 recipients splenic sections revealed dark and light zones characteristic of secondary 
follicles (Figure 3.4a). To characterise these further, I performed immunofluorescence 
staining on recipient splenic sections with GC-specific markers (PNA (Rose et al., 1980) and / 
or GL7 (Yusuf et al., 2010)).This enabled me firstly to formally quantify the number of GCs 
present within the spleen sections and secondly to identify presence of CD4 T cells within 
the secondary follicles, in the expectation that these cells would represent CD4 T follicular 
helper T (TFH) cells (Garside et al., 1998; Yu and Vinuesa, 2010).  Immunofluorescence 
staining of splenic tissue section from naïve animals was initially performed to optimise the 
staining protocol to be used throughout this thesis. An example of a positive GC and a 
negative GC is shown below in figure 3.4 b and c.  
  
129 
a.  
 
b.         B cell follicle                   positive PNA staining           co-localised  
 
 
 
 
c.                  B cell follicle               negative PNA staining 
                
d.  
                          
e.  
                           
B220 PNA 
130 
Figure 3.4. Immunofluorescence staining of spleen sections showing presence or absence 
of germinal centres. All the pictures were taken at 20x magnification 
a. A representative image of dark zone and light zone in recipient B cell follicle on 
haematoxylin and eosin staining in splenic sections of BL6 recipients who received 
bm12 heart grafts. Staining was performed at 7 weeks post transplantation. Light 
zone characteristic of germinal centre is highlighted by black line. 
b.  A representative image of a positive germinal centre (GC) immunofluorescence 
staining as seen in BL6 recipient spleen sections of bm12 allografts. Staining was 
performed with anti-B220 antibody (Ab) and anti PNA Ab and co-localization of B220 
and PNA highlighting the presence of GC. 
c. A representative image of a negative GC where B cells did not develop into GC as 
seen in splenic sections of BL6 recipients who received syngeneic BL6 heart grafts 
Staining was performed at 7 weeks post transplantation with anti-B220 Ab and anti 
PNA Ab.  
d. Isotype control for IgG, stained with Rat IgG2b kappa. This is an isotype control for 
B220 IgG. 
e.  Isotype control for IgM stained with Rat IgM. This is an isotype control for GL7 IgM 
antibody. 
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The germinal centres were quantified in spleen sections of BL6 recipients of bm12 and BL6 
hearts by calculating the percentage of GC positive B cell follicles to total number of follicles 
(section 2.2.8.5). On quantification of GCs, a significantly high percentage of GCs was found 
in BL6 recipients of bm12 allografts compared to syngeneic controls at week 7 post 
transplantation (p= 0.02) (figure 3.5). 
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Figure 3.5. Quantification of germinal centres in BL6 recipients of bm12 allografts 
a.  Immunofluorescence staining of spleen sections showing presence of germinal 
centres in naïve BL6 and BL6 recipient of bm12 heart graft at week 7 post 
transplantation. Staining was performed with anti-B220 Ab (i panels) and anti PNA (ii 
panel) and anti-GL 7 Ab (ii panel). Co-localization of B220 and PNA (iii panel, merged) 
and B220 and GL 7 (iii panels, merged) highlighting the presence of GCs. All the 
pictures were taken at 20x magnification. 
b.  Quantification of germinal centres in BL6 recipients of bm12 allografts or syngenic 
BL6 heart grafts at week 7 post transplantation. This showed that more than 50% of 
the primary follicles differentiated into secondary follicles or germinal centres as 
demonstrated by PNA+ and / GL 7+ B220 follicles in the WT BL6 recipients of bm12 
hearts compared to BL6 hearts (syngenic) at week 7. Data represent mean and SD of 
n = 4-5 mice per group, *P < 0.05, (Mann-Whitney test).  
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These GCs were further characterised by identifying follicular dendritic network within GC 
by staining with FDC marker FDC-M1 and localisation of CD4 T cells in GCs. CD4 T cells were 
found to be seen within secondary follicles as well as within germinal centres B cells (figure 
3.6). 
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Figure 3.6. Presence of CD4 T cells and FDC network within GC B cells in spleen sections of 
BL6 recipients of bm12 heart grafts at week 7 post transplantation 
a. Staining was performed with anti-PNA Ab (upper left) and anti CD4 Ab (upper right) 
and anti-B220 Ab (lower left). Co-localization of B220, PNA and CD4 (lower right) 
highlighting the presence of CD4 T cells in GCs highlighted with a white box in lower 
right panel (x20). The area of co-localisation of CD4 T cells with B cells and GC was 
zoomed in to show the close proximity of CD4 T cells (red) with GC (green) B cells 
(Blue) as shown in figure on the right with a white circle. 
b. Presence of FDC network within GCs at 20x magnification. Staining was performed 
with anti-PNA Ab (upper left) and anti FDC-M1 (upper right) and anti-B220 Ab (lower 
left). Co-localization of B220, PNA and FDC (lower right) highlighting the presence of 
FDC network in GCs.  
c. This FDC network was further examined at 63x magnification where the network was 
better appreciated. Staining was performed with anti-PNA Ab (upper left) and anti 
FDC (upper right) and anti-B220 Ab (lower left). Co-localization of B220, PNA and FDC 
(lower right) highlighting the presence of FDC network in GCs. 
d. Merged figure of PNA, FDC and B200 showing close proximity of FDCs with GC B cells 
(x63), scale bar is 20µm. 
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Having confirmed GC response in this model at week 7 post transplantation, the next 
question was when they start and how long they last. GC responses were quantified in 
recipient spleen at days 7, 15, 50 and 100 after transplantation, by staining with germinal 
centre markers (PNA and or GL 7) and B cell markers. There were no germinal centres 
evident at day 7. However, GCs were first observed at day 15, with more than 30% of the B 
cell follicles exhibiting a GC phenotype. By day 50, more than 50% of the B cell follicle 
stained positively for GC markers, with a GC response still present 100 days after transplant 
(figure 3.7).  
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Figure 3.7. Quantification of GCs at various time points in BL6 recipients of bm12 allografts 
Recipient splenic sections showing the appearance of GCs at day 15, and their presence till 
day 100 post transplantation.  
Data represent mean and SD of n = 4 mice per group, *P < 0.05, (Mann-Whitney test).  
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3.3.4. Identification of TFH signature markers of CD4 T cells 
Although other subsets of follicular helper cells have been described, the CD4 TFH cell is still 
considered fundamental for GC responses against conventional T-dependent protein 
antigen (Crotty, 2011; Crotty, 2014; Crotty, 2015; Qi, 2012; Vinuesa and Cyster, 2011). I 
characterised this subset in my model by staining recipient splenocytes with anti CXCR5 and 
anti PD1 antibodies as has been described in the literature (Crotty, 2011; Yu and Vinuesa, 
2010; Yusuf et al., 2010). Staining was carried out as described in methods (section 2.2.3)  
On flow cytometric analysis, 3.1±0.9 % of the live activated CD4 T cells acquired the TFH cell 
phenotype as characterised by CXCR5hi and PD1hi, when compared to naïve BL6 CD4 T cells 
(0.4±.1%) (figure 3.8). It is important to mention here that flow pattern did not reveal a 
distinct population of TFH CD4 T cell, but rather a shoulder and so it is difficult to describe 
exactly. 
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Figure 3.8. Identification of follicular T helper cells using flow cytometry at day 15 in 
splenocytes of BL6 recipients of bm12 heart grafts 
The live CD44hi CD4 T cell population was selected and TFH cells were identified on the basis 
of dual staining with CXCR5hi and PD1hi. Naive unchallenged BL6 CD4 T cells are shown as a 
control TFH cell population (n=3). 
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3.3.5. Confirmation of the longevity of humoral response by ELISPOT 
Because circulating autoantibodies are detected to three months following transplantation 
in this model, I next addressed whether antibody secreting cells (ASCs) could be detected in 
recipients’ spleen and or bone marrow. ELISPOT assays was performed in BL6 recipients’ 
splenocytes and bone marrow cells at week 7 post transplantation in order to detect pan 
IgG ASCs and dsDNA specific ASCs, by coating ELISPOT plates with pan IgG and dsDNA 
autoantigens (see section 2.2.6). 
ELISPOT assay showed the presence of significantly higher number of positive spots for ASCs 
cells for pan IgG and dsDNA antibodies in BL6 recipients of bm12 allografts, both in bone 
marrow and spleens when compared with the syngeneic controls (figure 3.9). Within the 
BL6 recipients of bm12 allografts group, there was no difference in the APCs between 
spleen and bone marrow at week 7 post transplantation. 
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Figure 3.9. Longevity of autoantibody responses demonstrated by ELISPOT assay 
a. Statistically significant number of antibody secreting  cell (ASC) spots were 
demonstrated in the autoantibody producing group (bm12 to BL6) for pan-IgG and anti-
dsDNA antibody both in spleen and bone marrow compared to syngenic grafts (n=4). 
This assay was performed in recipients’ splenocytes and bone marrow cells at 7 weeks 
post transplantation. 
b. Representative figure of spots for IgG and dsDNA-antibody secreting cell in naïve BL6 
and BL6 recipient of bm12 allograft in spleen and bone marrow at 7 weeks post-
transplantation. 
Data represent mean and SD of n = 4 mice per group, (Mann-Whitney test).  
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3.3.6. Is there a diversification of humoral response? 
3.3.6.1. Indirect immunofluorescence images from the same animal showing different patterns 
Germinal centres underpin clinical humoral autoimmunity and during GC response, different 
proteins are typically targeted. This raises the potential that the GC response and specifically 
SHM may lead to epitope diversification and development of response against new target 
autoantigens. 
The images of the  hep-2 indirect immunofluorescence slides from the BL6 recipients of 
bm12 allografts revealed different patterns of staining within the same animal over time 
following transplantation (see figure 3.10), suggesting that a variety of nuclear and 
cytoplasmic autoantigens can act as targets for the humoral autoimmune response. 
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Figure 3.10.Identification of various patterns of autoantibodies in BL6 recipient of bm12 
heart graft on hep-2 indirect immunofluorescence 
Various patterns from week (wk) 1 to wk 15, seen on hep-2 indirect immunofluorescence 
demonstrating the presence of various types of anti-nuclear and cytoplasmic 
autoantibodies. All pictures are taken at x20 magnification. 
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3.3.6.2. Development of late anti-vimentin on ELISA  
Diversification of the humoral response was assessed by examining the development of 
anti-vimentin autoantibody in the recipients at early and late time points. Vimentin 
autoantibody was selected as a surrogate marker for diversification of humoral response as 
it has been shown contributing to chronic rejection in experimental rodent models and in 
clinical transplantation (Mahesh et al., 2007; Rose, 2013; Rose and Smith, 2009).  
Anti-vimentin autoantibody was detected by performing ELISA assay on recipient sera at 
week 7 and week 15. ELISA assay was performed as described in section 2.2.5.3.  
Anti-vimentin autoantibody ELISA of recipient sera demonstrated an increase in anti-
vimentin at a late time point compared to early time point as shown below in figure 3.11. 
Notably, this autoantibody was detectable by week 15 in approximately half of WT 
recipients of bm12 heat allografts.  
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Figure 3.11. Diversification of humoral responses as demonstrated by development of 
anti-vimentin autoantibody at week 15 post transplantation  
Anti-vimentin ELISA demonstrating the levels of anti-vimentin IgG antibody at early (week 7) 
and late time points (week 15) (p=0.007), following transplantation of bm12 heart grafts 
into WT BL6. 
Data represent mean and SD of n = 5-8 mice per group, **P < 0.01, Mann-Whitney test was 
used. 
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3.4. Summary 
In summary, we conclude from this chapter that, 
1. Long-lasting germinal centre responses are observed in recipients of chronically-
rejecting heart allografts.  
2. Germinal centre humoral immunity was associated with deposition of antibody 
producing cells in recipient spleen and bone-marrow.  
3. TFH CD4 T cells were identified on the basis of their homing to the secondary follicle 
and by expression of characteristic phenotypic markers CXCR5 and PD1. 
4. The humoral autoimmune response may diversify at late time point to incorporate 
reactivity against vimentin.  
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3.5. Discussion 
Germinal centre responses against conventional protein antigens have been extensively 
studied in the last few years, but have not so far been described in transplantation. In this 
chapter, GC responses were characterised by immunofluorescence staining and flow 
cytometry staining in a model of chronic rejection, in which the humoral autoimmune 
response is dependent upon graft versus host recognition by passenger donor CD4 T cells 
(Win et al., 2009). On immunofluorescence staining, GCs were identified by GL7 and / or 
PNA positive B cell follicles in recipient spleen sections following allograft transplantation 
and homing of CD4 T cells within these germinal centres (figure 3.4, 3.5 and 3.6). On flow 
cytometry staining, a subset of CD4 T cells was identified possessing dual positivity for 
CXCR5hi and PD1hi surface markers (figure 3.8), presumably representing the follicular 
helper CD4 T cell subset. Furthermore, deposition of LLPC within the bone marrow as shown 
by ELISPOT assay (figure 3.9) may be representing the long lived nature of humoral 
autoimmunity in this model.  
T-dependent humoral responses are composed classically of two components. The initial 
extrafollicular component provides early immunity, whereas the germinal centre 
component provides long lasting durable immunity. In bm12 to BL6 heart allograft model, 
weak autoantibody responses are detectable early (in the first 2 weeks), which presumably 
represent an extrafollicular response. After 2 weeks, autoantibody titres rise quickly and 
plateau at between week 5 and 7, and remain detectable thereafter. These later responses 
are likely the result of a germinal centre response. The presence of this long lasting antibody 
in the recipients is similar to transplant recipients who are sensitised or who have 
experienced antibody mediated rejection several years post transplantation. Despite the 
fact that in this model, humoral response is directed against self-antigens, there are some 
similarities with clinical transplantation, in that donor specific alloantibody that develops 
after transplantation, is associated with poorer transplant outcomes, is also long-lasting, 
and presumably an output of a germinal centre response. Due to these similarities, a deeper 
understanding of transplant associated autoimmunity (TAA) may be helpful in elucidating 
the underlying mechanisms responsible for the development of allograft vasculopathy, and 
may inform the development of approaches that prolong allograft survival. 
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GCs were characterised on immunofluorescence staining by PNA positivity and or GL 7 
positivity of the B cells (Butcher et al., 1982; Coico et al., 1983; Rose et al., 1980). The critical 
step in the development of these long lasting and class switched (CS) GC autoantibodies is 
the help provided to B cells by TFH cells. TFH cells are defined by their homing into the B cell 
follicle, coupled with surface markers such as CXCR5, PD1 and ICOS (Vinuesa et al., 2005; Yu 
and Vinuesa, 2010). Consistent with this, I could identify CD4 T cells co-localising within the 
GC areas on microscopy (figure 3.6), and flow cytometric analysis revealed a subset of CD4 T 
cells with the signature CXCR5hi, PD1hi markers (figure 3.8).  
Timing of development of the GCs may be different for different immunogenic challenges. 
For a conventional immunogenic challenge, the GCs have been described to appear as early 
as day 7 post immunisation (Blink et al., 2005; Garside et al., 1998), and then regress 
between week 3 to week 14 (Bachmann et al., 1996; Jacob et al., 1991; Kelsoe, 1996; Liu et 
al., 1991). However, in this model of chronic rejection, the development of GCs took almost 
2 weeks to appear as seen with IF (figure 3.7). But, it may be possible that the IF may not be 
robust enough to detect the development of GCs during week one.  
Germinal centres are long lasting in this model and can be seen up to three months post 
transplantation (figure 3.7).  The long lasting presence of GCs may be due to the continuous 
presence of antigens in the form of heart graft (Bachmann et al., 1996) or due to the SHM 
which may lead to epitope diversification and development of response against new target 
autoantigens (MacLennan, 1994). In support, development of anti-vimentin autoantibody at 
a late time point has been seen in this model (figure 3.11). Furthermore, it may be possible 
that long lived GCs are due to re-utilisation of autoreactive GCs by heterologous antigens as 
the activated B cells will prefer to enter into an existing GC where the existing structure 
already persist (Bergqvist et al., 2013; Schwickert et al., 2009). However, it is not possible to 
tease out the re-utilisation hypothesis in this model as polyclonal B cells are responding to 
polyclonal CD4 T cells. 
Each individual GC is thought to be seeded by a very small number of oligoclonal B cells that 
then undergo massive expansion (Faro and Or-Guil, 2013). B cells acquire antigen from FDCs 
and then process and present that antigen to T helper cells at the T-B cell border. Prolonged 
interaction with those CD4 T cells results in differentiation into the TFH cell subset and in 
return the B cells receive survival signal from TFH cells to form GCs (Garside et al., 1998; 
151 
Linterman et al., 2012; MacLennan, 1994). Different GCs will have different antibodies 
outputs and memory B cells depending upon the type of antigens they were challenged and 
at different time points different antibodies can be seen. Like in SLE, a wider spectrum of 
autoantibodies is seen and their titres vary with time which may correspond to the disease 
activity as well. In my work, as the GCs are autoreactive, hence each of the GC might be 
producing different autoantibody. Some of them may be specific to ssDNA autoantigen, 
some may be to dsDNA and others may be against chromatin or vimentin. Different types of 
autoantibodies are observed as shown by different patterns of autoantibodies on indirect 
immunofluorescence hep-2 analysis (figure 3.10) and development of late anti vimentin on 
ELISA (figure 3.11). On indirect immunofluorescence, the different patterns of 
autoantibodies were observed even within the same animal at different time points (figure 
3.10). These included various types of anti-nuclear autoantibodies and cytoplasmic 
autoantibodies. However, the fluorescence intensity of the cytoplasmic autoantibodies was 
very high and it was difficult to identify a definite pattern of cytoplasmic autoantibodies on 
analysis.  It will be interesting to examine it further by diluting the recipient sera to 
characterise definite patterns of autoantibodies which may be helpful in determining the 
contribution of various types of autoantibodies to chronic rejection. The development of 
this diversified humoral response raised two questions: whether the GCs contribute to 
diversification of humoral responses and whether this diversification contributes to graft 
failure. Both these questions are addressed in later chapters. 
One of the outcomes of GCs is deposition of LLPC in the bone marrow niche, which can 
produce antibody for the life time of the individual. The rate limiting factor for survival of 
plasma cells is their bone marrow niche. If a niche is destroyed or plasma cells leave its 
niche, it will soon die (Manz et al., 2002). Spleen can also be a source of antibody production 
(Slifka et al., 1995), but whether it can retain LLPCs (Sze et al., 2000), as happens in the bone 
marrow, is contentious. Hoyer at al (Hoyer et al., 2004) has shown in a murine model of SLE 
(NZB/W) that 40% of the ASCs from the spleen were non-dividing and long lived plasma 
cells. In my work, comparable number of ASCs specific for IgG and dsDNA were seen both in 
bone marrow and spleen on ELISPOT assay (figure 3.9). However, these ASCs needs to be 
further characterised to establish whether there is a difference in the terminally 
differentiated non-dividing plasma cells between spleen and bone marrow.  
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The present results suggest that long-lasting germinal centre responses are observed in 
recipients of chronically-rejecting heart allografts which needs further exploration to 
address the following questions; 
 What is the contribution of donor and recipient CD4 T cells to the development of 
these GCs? 
 Are GCs central to diversification of humoral responses? 
 Do GC autoantibody responses contribute to progression of allograft vasculopathy? 
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Chapter 4 
Host TFH cell is required for the development of long term germinal centre 
autoantibody responses 
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4.1. Introduction 
In the previous chapter, I have shown that humoral autoimmunity triggered by heart 
transplantation is long lasting, with strong titres maintained three months after 
transplantation. Recipient splenic sections demonstrated the presence of GCs on confocal 
immunofluorescence microscopy. Within these GCs, CD4 T cells were also identified, in 
keeping with a population of TFH cells that are providing essential help for maintenance of 
the GC (Crotty, 2015; Linterman et al., 2009; Qi, 2012). Abnormalities in antigen 
availability, T cell help or the threshold at which B cells respond to these stimuli in 
germinal centres can result in the development of long lasting autoimmunity in the 
recipients (Linterman et al., 2009; Vinuesa et al., 2009). In Linterman et al work, this 
autoimmunity was triggered due to Roquin-mediated dysregulation of T cells which resulted 
in aberrant expansion of TFH subset and development of spontaneous autoreactive GCs 
(Linterman et al., 2009). These findings raised important and yet unanswered questions with 
respect to my work. Firstly, whether passenger donor CD4 T cells within a heart graft trigger 
a GC autoantibody response and if so, whether the autoreactive TFH cells are of donor origin 
or recipient origin or both? If the TFH cells are donor derived, this indicates their survival in 
an allogenic host. In contrast, if TFH cells are recipient-derived, this suggests that GVH 
responses trigger secondary activation of an autoreactive recipient CD4 T cell population, 
possibly through the ability of activated autoreactive B cells to act as professional APCs and 
present peptide autoantigens for self-restricted recognition by naïve autoreactive recipient 
CD4 T cells. The latter concept – that one ‘dysfunctional’ population of helper CD4 T cells 
may trigger humoral autoimmunity that is then sustained by TFH differentiation of a second 
population of CD4 T cells, has not been previously described and would have important 
implications for how autoimmune disease manifests. Investigation of the relative roles of 
donor and recipient CD4 T cells in providing TFH cell function in our transplant model may 
therefore have wider relevance for autoimmune disease in general. 
Aside from durable production of autoantibody, long-lasting autoreactive GCs may also 
contribute to autoimmune disease progression by promoting diversification of the B cell 
response to incorporate different target autoantigens, some of which may be particularly 
pathogenic. This process is termed as T and B cell epitope diversification (Mitchison, 1971; 
Rajewsky et al., 1969). Epitope diversification has been described differently by investigators 
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based on their work (Fatenejad et al., 1993; Mamula, 1998; Mamula and Janeway, 1993; 
Mamula et al., 1992; Shlomchik et al., 2001; Singh and Hahn, 1998). Mamula and Janeway 
suggested the role of B cells as an efficient antigen presenting cell for various components 
of antigen and thus recruiting naïve CD4 T cell to provide help to B cells for development of 
antibodies (Mamula and Janeway, 1993; Mamula et al., 1992). Their experimental work 
demonstrated that immune responses are initiated by priming of CD4 T cells by immune-
dominant epitopes presented by APCs like DCs. The primed CD4 T cells then activate the 
antigen specific B cells which internalise the antigen more efficiently and in high 
concentrations and become competent in activating more naïve CD4 T cells for progression 
of this autoimmune phenomena. They have shown this by eliciting autoimmune responses 
to mouse autoantigen cytochrome c and ribonucleoproteins. Priming with one 
immunogenic peptide of one autoantigen was able to generate CD4 T cells responses to 
other peptides within the same protein like cytochrome c (Mamula et al., 1992). 
On the other hand, Singh et al (Singh and Hahn, 1998) has described this as a reciprocal T-B 
determinant spreading where the induction of first T cell by peptides from an autoantibody 
molecule could lead to help provided to a variety of B cells displaying a cross-reactive 
version of the original determinant of the autoantibody. This response spreads in this way 
by reciprocal T-B stimulation until large cohorts of T and B cells have been expanded. This 
whole concept is shown below by copying figure form Singh et al paper (Singh and Hahn, 
1998).  
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However, Shlomchik et al suggested (Shlomchik et al., 2001) a positive feedback mechanism 
between T-B cell interaction and new autoantigen release following any organ damage in 
autoimmune prone conditions. Once T cells are primed by DCs, they can activate the 
genetically prone autoimmune B cells. These autoantigen-stimulated B cells undergo 
hypermutations and affinity maturation resulting in the development of pathological autoan 
tibodies. These pathological autoantibodies damage the organs and result in the release of 
further self-antigens which are again taken up by specific antigen presenting B cells in a 
second round of T cell activation. Autoreactive humoral autoimmune responses are typically 
long-lasting and thus potentially a facet of a GC reaction, but whether this diversification is 
exclusively a consequence of the GC has not been clarified. 
We have shown the development of dsDNA autoantibodies in this model previously (Win et 
al., 2009) and the late development of anti-vimentin autoantibody in the previous chapter 
(Figure 3.10). The model therefore provides the opportunity to investigate GC-mediated 
epitope diversification, by using the development of anti-vimentin autoantibody as a marker 
of that diversification. 
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4.2. Aims 
The aims of this chapter are: 
1. To determine the role of donor and recipient CD4 T cells in the development of GC 
autoantibody responses. 
2. To investigate the contribution of germinal centres to diversification of humoral 
responses. 
3. To examine whether a monoclonal population of CD4 T cells is sufficient to drive 
diversification of humoral response, or whether additional T cell subsets are 
required. 
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4.3. Results 
4.3.1. Replication of the same results with adoptive transfer of cells as those observed with murine 
allografts 
Adoptive transfer of column purified bm12 CD4 T cells was carried out into BL6 recipients. 
CD4 T cells were purified as described in section 2.2.1.5. Recipient’s splenic sections were 
stained with anti-B220 and anti-GL 7 and or anti-B220 and anti-PNA to identify and quantify 
GCs at 7 weeks after adoptive transfer. Recipients’ sera were examined for autoantibodies 
by hep-2 indirect immunofluorescence. Of note, in all adoptive transfer experiments, 2x106 
purified CD4 T cells were adoptively transferred into recipients unless stated otherwise.  
On staining of recipient splenic sections with GC markers, more than 60% of the follicles 
differentiated into GCs (figure 4.1). This demonstrated that adoptive transfer of bm12 CD4 T 
cells replicated the results as those observed with the bm12 allografts. 
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Figure 4.1. Development of germinal centres in BL6 recipients of bm12 CD4 T cells at week 
7 after adoptive transfer. 
a. A representative image of dark zone and light zone in secondary splenic B cell follicle 
on haematoxylin and eosin staining of splenic sections at week 7 after adoptive 
transfer of bm12 CD4 T cells into BL6.  
b. Immunofluorescence staining of spleen sections showing presence of germinal 
centres in BL6 recipient of bm12 CD4 T cells. Staining was performed with anti-B220 
Ab (left) and anti PNA (middle) and co-localised B220 and PNA staining (right). All the 
pictures were taken at 20x magnification 
c. Immunofluorescence staining of spleen sections showing presence of germinal 
centres in BL6 recipient of bm12 CD4 T cells. Staining was performed with anti-B220 
Ab (left) and anti GL 7 (middle) and co-localised B220 and GL 7 staining (right). All the 
pictures were taken at 20x magnification.  
d. Quantification of germinal centres in BL6 recipients of bm12 CD4 T cells or naïve BL6 
at week 7 post adoptive transfer. This showed that more than 60% of the primary 
follicles differentiated into secondary follicles or germinal centres as demonstrated 
by PNA+ and / GL 7+ B220 follicles in the WT BL6 recipients of bm12 CD4 T cells 
compared to naïve BL6 (n=4) (p=0.01). 
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Consistent with this, there was development of long lasting autoimmunity in the recipients, 
as demonstrated by presence of long lasting IgG autoantibodies in recipient’s sera (figure 
4.2). 
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Figure 4.2. Development of long lasting autoantibodies in BL6 recipients of bm12 CD4 T 
cells 
Relative anti-nuclear autoantibody levels as measured by Hep-2 indirect 
immunofluorescence in BL6 recipients sera demonstrating development of long lasting 
autoantibodies in BL6 recipients of bm12 CD4 T cells compared to BL6 recipients who 
received syngenic BL6 CD4 T cells (p=<0.0001, Two way ANNOVA). Data represent mean and 
SD of n = 4 mice per group.   
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Having established that adoptive transfer of bm12 CD4 T cells generated long lasting GC 
humoral autoimmunity in wild-type BL6 recipients, I next sought to investigate the 
contribution of recipient CD4 T cells to the response. Thus, T cell deficient BL6 recipients 
(TCRbd-/-) received either column purified donor bm12 CD4 T cells alone (2x106 cells), or 
donor bm12 (2x106 cells) and WT BL6 recipient (4x106 cells) CD4 T cells simultaneously 
(figure 4.3).   
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Figure 4.3.  CD4 T cells were manipulated in the BL6 recipients, showing two groups, group 
1-without recipient CD4 by using TCRbd-/- transgenic animals and group 2- T cell deficient 
recipient with both donor and recipient CD4 T cells. 
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Before proceeding to use TCRbd-/- mice as a recipient for these adoptive transfer 
experiments, I examined the follicular architecture of B cells in unmanipulated mice from 
this strain. Follicular architecture was compared between naive TCRbd-/-, and TCRbd-/- mice 
reconstituted with bm12 or BL6 CD4 T cells. Spleens were harvested from naïve TCRbd-/- mice 
and challenged animals at week 7 after adoptive transfer of purified bm12 or BL6 CD4 T cells 
or bm12 plus BL6 CD4 T cells simultaneously. On haematoxylin staining of cryo-sections, 
naïve TCRbd-/- mice and TCRbd-/- mice reconstituted with either bm12 or BL6 CD4 T cells did 
not demonstrate any secondary follicular pattern. However, simultaneous reconstitution of 
TCRbd-/- with both bm12 and BL6 CD4 T cells restored secondary follicular architecture as we 
observe in WT BL6 (figure 4.4). 
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Figure 4.4. Low-power photomicrographs of H&E stained cryostat splenic sections of: non-
reconstituted or reconstituted T cell deficient TCRbd-/- mouse 
 (a); naïve Tcrbd-/- mouse, (b); week 7 after reconstitution with purified BL6 CD4 T cells 
(2x106 cells) (c), Seven weeks after reconstitution with purified bm12 CD4 T cells (2x106 
cells) (d), seven weeks after reconstitution with purified BL6 CD4 T cells (2x106 cells) and 
simultaneous challenge with purified bm12 CD4 T cells (2x106 cells). Classical B cell 
architecture is readily evident in reconstituted mice, with characteristic light and dark zone 
secondary germinal centre follicles observed in mice simultaneously challenged with 
purified bm12 CD4 T cells (d). Scale bars 200µm. 
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4.3.2. Both donor and recipient CD4 T cells are essential for the development of germinal centres 
In order to determine the role of recipient CD4 T cells, bm12 CD4 T cells were adoptively 
transferred into TCRbd-/- (group 1). Recipients’ sera and spleen sections were assessed for 
the development of autoantibody response and GC response respectively.  
Hep-2 indirect immunofluorescence demonstrated that the autoantibodies were short-
lasting compared to WT responses. Examination of recipient splenic sections with 
haematoxylin and eosin staining showed only primary follicles that lacked characteristic dark 
and light zone GC differentiation. Consistent with this, immunofluorescence staining 
confirmed the absence of a GC response, in that splenic sections did not stain with PNA and 
/ or GL7 staining (figure 4.5). 
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Figure 4.5. Adoptive transfer of bm12 CD4 
T cells into TCRbd-/- recipients resulted in 
the development of short lasting 
autoantibody and recipient splenic 
section revealed no germinal centres at 7 
weeks post adoptive transfer. All pictures 
are taken at x20m magnification. 
a. Autoantibody levels showing short 
lasting autoantibodies in TCRbd-/- 
recipients.  
b. H and E staining showing the 
primary follicles only. 
c. Immunofluorescence staining of 
splenic sections 7 weeks after 
adoptive transfer of bm12 CD4 T 
cells into TCRbd-/- .Staining was 
performed with anti-B220 Ab (red, i 
panels),  anti PNA (green, upper ii 
panel) and anti-GL 7 Ab (green, 
lower ii panel). Co-localization of 
B220 & PNA (upper iii panel) and 
B220 & GL 7 (lower iii panel) 
highlighting absence of GCs in the 
TCRbd-/- recipients. 
d. On quantification of GCs, germinal 
centres were significantly lower 
than the WT response.  
*p=<0.05, Two way ANOVA for a and Mann 
Whitney test for d was used. 
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Because circulating autoantibody response was short lasting and without GC response in 
TCRbd-/- recipients, I next addressed whether antibody secreting cells (ASC) could be 
detected in recipients’ spleen or bone marrow. ELISPOT assays was performed in BL6 
recipients’ splenocytes and bone marrow cells at week 7 after adoptive transfer in order to 
detect pan IgG antibody secreting cells (ASCs) and dsDNA specific ASCs, by coating ELISPOT 
plates with pan IgG and dsDNA autoantigens (see section 2.2.7.). 
Consistent with the short lasting autoantibody response, there were significantly fewer 
spots in TCRbd-/- recipients for pan IgG and anti-dsDNA, both in bone marrow and spleens 
compared to WT responses (figure 4.6). 
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Figure 4.6. ELISPOT assay showing the short lasting humoral response in the absence of 
GCs in TCRbd-/- recipients following adoptive transfer of bm12 CD4 T cells 
Statistically significant lower number of antibody secreting  cell spots were demonstrated in 
TCRbd-/- recipients of bm12 CD4 T cells compared to WT response for pan-IgG and anti-
dsDNA antibody both in spleen and bone marrow (n=4), (*p=<0.05, Mann Whitney test was 
used).  
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T cell deficient mice challenged with bm12 CD4 T cells showed short lasting humoral 
response, next I sought whether reconstitution of these mice with donor (bm12 CD4 T cells, 
2x106 cells) and host (WT BL6 CD4 T cells, 4x106 cells) simultaneously, will restore GC 
humoral response at week 7 after the adoptive transfer. 
Interestingly, reconstitution of TCRbd-/- recipients with both donor and WT host CD4 T cells 
restored long lasting autoantibody response and a GC response comparable to that 
observed in similarly challenged WT recipients (figure 4.7). 
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Figure 4.7: Restoration of long lasting GCs on 
reconstitution of TCRbd-/ - with donor and host 
CD4 T cells. 
a. Autoantibody levels in TCRbd-/- 
recipients reconstituted with donor and 
recipient CD4 T cells demonstrating long 
lasting levels of autoantibodies, 
comparable to WT responses. 
b. H and E staining showing the dark zone 
as demarcated with red dotted line 
from light zone. 
c. Immunofluorescence staining of splenic 
sections 7 weeks after reconstitution of 
TCRbd-/ -    with donor (bm12) and host 
(BL6) CD4 T cells. Staining was 
performed with anti-B220 Ab (red, i 
panels), anti PNA (green, upper ii panel) 
and anti-GL 7 Ab (green, lower ii panel). 
Co-localization of B220 & PNA (upper iii 
panel) and B220 & GL 7 (lower iii panel) 
highlighting restoration of GCs in the 
TCRbd-/- recipients reconstituted with 
WT BL6 CD4 T cells.  
d.  Quantification of GCs in splenic 
sections of the recipients 7 weeks after 
adoptive transfer of bm12 CD4 T cells 
into BL6, TCRbd-/- or TCRbd-/- with BL6 
CD4 T cells at week 7. (n=4)  
 
*P < 0.05, **P < 0.01 and ***P < 0.001), Two 
way ANOVA for a and Mann-Whitney test for d. 
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These experiments thus demonstrate that both donor and recipient CD4 T cells are essential 
for the development of GCs, raising the question which of these populations was 
responsible for provision of TFH cell function. In order to investigate this, TCRbd-/- recipients 
were reconstituted with SAP-ve CD4 T cells from SAP-/- transgenic mice. SAP signaling is 
essential for the development of the CD4 TFH cell subset (Crotty et al., 2003; Kamperschroer 
et al., 2006). Thus if TFH cell function is provided by the recipient CD4 T cell population, GC 
activity would not be observed upon transfer of bm12 CD4 T cells into a TCRbd-/- BL6 
recipient reconstituted with SAP-ve BL6 CD4 T cells.  
On reconstitution of T cell deficient recipient with bm12 (2x106) and SAP-ve BL6 (4x106) CD4 
T cells simultaneously, splenic GC reactions were not detectable. Interestingly, however, 
high strong autoantibody responses were generated initially after transfer, but declined 
rapidly from week 3 onwards (figure 4.8), in keeping with a self-limiting extrafollicular 
response. The early autoantibody response in this group was greater than that observed in T 
cell deficient recipients challenged with purified bm12 CD4 T cells (figure 4.5), possibly 
suggesting that the recipient SAP-/- CD4 T cells are contributing to the development of the 
extrafollicular response.  
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Figure 4.8: Failure of the B cell follicles to 
differentiate into GCs on restoration of T 
cell deficient recipients with bm12 and 
SAP-ve.BL6 CD4 T cells with short lasting 
autoantibodies. 
a. Relative anti-nuclear 
autoantibody levels as measured 
by Hep-2 indirect 
immunofluorescence in TCRbd-/- 
recipients reconstituted with 
donor and SAP-/- BL6 CD4 T cells 
demonstrating short lasting 
autoantibodies which was initially 
very high and then it starts 
declining after week 5. 
Autoantibodies were statistically 
significantly higher in T cell 
deficient recipients reconstituted 
with SAP-ve CD4 T cells compared 
to WT response. 
b. Quantification of GCs in splenic 
sections of the recipients 7 weeks 
after adoptive transfer of bm12 
CD4 T cells into TCRbd-/-
reconstituted with SAPve- BL6 CD4 
T cells demonstrating that GCs 
were significantly less than WT 
responses.                      
*P < 0.05 and **P < 0.01, Two way 
ANOVA for a and Mann Whitney 
for b was used. 
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Hence, donor CD4 T cells are important for initiating recipient humoral autoimmunity, but 
thereafter, recipient CD4 T cells provide help for the development and maintenance of long-
lasting GC reactions. Then I sought to investigate which of the population of CD4 T cells 
localises to GCs.   
Because bm12 is a natural mutant of BL6 WT animal and all of the cells are CD45.2 positive 
in both of them, CD45.1 BL6 transgenic mice were used as a recipient in order to 
differentiate between donor and recipient CD4 T cells.  
Column purified bm12 (CD45.2) CD4 T cells were adoptively transferred into CD45.1.BL6 
recipients as per methods (section 2.2.1.5). Recipient splenic sections were examined for 
the presence of GCs and CD4 T cells at various time points (figure 4.9). Confocal staining was 
carried out in order to examine the anatomical localisation of donor and or recipient CD4 T 
cells within GCs. Firstly presence of CD4 T cells within the GCs was confirmed by staining 
recipients’ splenic sections with anti-CD4, anti-B220 and anti-GL7 antibodies and secondly 
donor CD4 T cells were identified within GCs by staining recipients’ splenic sections with 
anti-CD45.2 (donor), anti-CD4 and anti GL7 antibodies. Because all the recipient cells were 
CD45.1 positive including B cells, T cells and DCs, it was not possible to see the recipient 
CD45.1 CD4 T cells in GCs. Hence, recipient splenic sections were stained with anti-GL7, anti-
CD4 and anti-CD45.2 antibodies, and the fraction of CD4 T cells which was not positive for 
CD45.2, was considered as recipient (CD45.1) in origin. 
Of note, I was unable to combine more than three fluorochromes on one tissue section 
during staining due to availability of only three fluorochrome filters on our confocal 
microscope.  
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Figure 4.9. Experimental model showing adoptive transfer of donor bm12 (CD45.2) CD4 T 
cells into CD45.1 BL6 recipients 
Splenic sections of recipients were stained with anti-CD4, anti-B220 and anti-GL7 antibodies 
to identify CD4 T cells in GCs or with anti-CD45.1/anti-CD45.2, anti-CD4 and anti-GL7 
antibodies to see the presence of donor or recipient CD4 T in the GCs. 
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Adoptive transfer of purified donor CD4 T cell (2x106) was carried out into CD45.1 BL6 
recipient. Recipient spleens were harvested at day 16 (week 2), (the time when GCs were 
first observed in BL6 WT recipients (figure 3.7)), and splenic sections examined for the 
presence of donor (CD45.2) and recipient (CD45.1) CD4 T cells within the GCs. On staining, 
CD4 T cells were identified in periarteriolar lymphoid sheaths (PALS), B cells follicles and GC 
(figure 4.10 i). Staining with anti-CD45.2 (donor) and anti-CD45.1 (recipient) antibodies 
revealed the presence of both donor and recipient CD4 T cells within the GC areas (figure 
4.10 ii). Detailed analysis of stained sections demonstrated that most of the CD4 T cells 
localising to GC areas were of donor origin. There was, however, also a population of CD45.2 
negative CD4 T cells within the GC. Furthermore, the presence of recipient CD45.1 positive 
CD4 T cells was seen in PALS area, B cell follicles and in GCs areas on staining splenic 
sections with anti-CD45.1, anti-CD4 and anti-GL7 antibody. Of note, as all the recipient cells 
carry CD45.1 marker on their surface, CD45.1 staining demonstrated a good architecture of 
follicles and PALS area as shown in right hand panel of figure 4.10 ii. 
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Figure 4.10. Confocal immunofluorescence to identify donor and recipient CD4 T cells in 
GC B cells after adoptive transfer of bm12 CD4 T cells into CD45.1 recipients at day 16 
confirming the presence of both donor and recipient CD4 T cells in GC B cell area. (Figure is 
representative of 4 animals). GL7 is green, CD4/CD45.2/CD45.1 is red and B220 is blue 
coloured staining. i). Presence of CD4 T cells (red)  in PALS area (right lower end corner-in 
red, highlighted with white line ) and in GC B cells (green) as identified by staining with anti 
CD4 antibody (red), anti GL7 antibody (green) and anti B220 antibody (blue).  
ii). Presence of donor (CD45.2) CD4 T cells (red) in GC B cells (green) as identified by staining 
with anti-CD45.2 antibody (red), anti-GL7 antibody (green) and anti-CD4 antibody (blue) in 
the left sided figure (ii).However, on the right side, presence of recipient CD4 T cells is 
shown as stained with anti-CD45.1 antibody (red), anti-CD4 antibody (blue) and anti-GL7 
antibody (green). Scale bar is 100µm for figure i) left handed panel and 50µm for the rest of 
the figures. 
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At day 30 (week 4) after adoptive transfer of bm12 CD4 T cells into CD45.1 recipients, fewer 
donor cells were seen in GC areas as demonstrated by fewer of the CD4 T cells were found 
to be positive for CD45.2 as shown below in figure 4.11 ii.  
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Figure 4.11. Confocal immunofluorescence to identify donor and recipient CD4 T cells in 
GC B cells after adoptive transfer of bm12 CD4 T cells into CD45.1 recipients at day 30 
confirming the presence of both donor and recipient CD4 T cells in GC B cell area, fewer 
donor CD45.2 CD4 T cells than recipient non CD45.2 positive CD4 T cells in GC B cells. DAPI is 
black, GL7 is green, CD45.2 is red and B220 is blue coloured staining. i). Presence of CD45.2  
positive cells (red) in GC B cells (green) as identified by staining with anti-CD45.2 antibody 
(red), anti-GL7 antibody (green) and anti-B220 antibody (blue). Germinal centre (green) area 
in the left panel is zoomed in to identify the presence of donor CD45.2 (red) cells in GC B 
cells area to 5 times as shown in the right panel. 
ii). Presence of donor (CD45.2) CD4 T cells (red) in GC B cells (green) as identified by staining 
with anti-CD45.2 antibody (red), anti-GL7 antibody (green) and anti-CD4 antibody (blue) in 
the left sided figure. Germinal centre (green) area in the left panel is zoomed to identify the 
presence of donor CD45.2 positive (red) CD4 T cells (blue) in GC B cells area to 5 times as 
shown in the right panel.   
Scale bar is 50µm for left handed panel and 10µm for right handed panel figures. 
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As shown above in figure 4.5 that B cells in T cell deficient mice did not differentiate into 
GCs after being challenged with bm12 CD4 T cells, this raised a question of where these 
donor bm12 CD4 T cells were homing in these recipients. To investigate this, TCRbd-/- 
recipient splenic sections were stained with anti-CD4 and anti-B220 antibody and looked for 
their localisation on confocal at 7 weeks post adoptive transfer of cells. On staining, CD4 T 
cells which are essentially of donor origin, localised in PALS area and margins of B cell 
follicles as shown below in figure 4.13. 
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Figure 4.13. Confocal immunofluorescence of recipient TCRbd-/- recipient splenic to identify 
CD4 T cells in B cell follicles at week 7 post adoptive transfer of bm12 CD4 T cells, 
demonstrating presence of CD4 T cells in PALS area and primary B cells follicles 
demonstrated by staining with anti-CD4 and anti-B220 antibody. Scale bar is 20µm. 
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This set of experiments demonstrate that at an early time point, both donor and recipient 
CD4 T cells were present in GC areas, suggesting that either of them or both populations 
would be acting as a TFH cells. Localisation of donor and recipient CD4 T cells at a late time 
point was carried out in transplantation experiments which will be discussed in the next 
chapter (section 5.4.2. and figure 5.4b).  
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4.3.3. Blocking SAP signalling in donor and recipient CD4 T cells  
To definitively find out that whether donor or recipient CD4 T cells are functioning as TFH 
cells in maintaining GC autoimmunity in this model, adoptive transfer of column purified 
bm12 (2x106) or SAP-ve.bm12 CD4 T cells (2x106) into SAP-ve BL6 or WT BL6 recipients was 
carried out respectively. Autoreactive humoral responses were assessed by hep-2 indirect 
immunofluorescence assay of circulating autoantibody, and by quantitation of splenic GC 
activity.  
4.3.3.1. Blocking SAP signalling on recipient CD4 T cells abrogates long term GCs 
Adoptive transfer of bm12 CD4 T into SAP-ve B6 (SAP-ve.B6) recipients provoked a short 
lasting autoantibody response which was significantly low compared to WT response (figure 
4.14a). However, recipient splenic sections showed the development of germinal centres at 
early time point (week 3) but at late time point (week 7) GC response was not above the 
base line (figure 4.14b). 
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Figure 4.14: Failure of B cell follicles to sustain long term germinal centres after adoptive 
transfer of bm12 CD4 T cells into SAP-ve.BL6 (SAP-ve.BL6) recipients 
a. Relative anti-nuclear autoantibody levels as measured by Hep-2 indirect 
immunofluorescence in SAP-ve.BL6 recipients following adoptive transfer of bm12 CD4 T 
cells demonstrating significantly low levels of autoantibodies compared to WT response 
(two way ANOVA, p= 0.008). 
b. Quantification of GCs in splenic sections of the SAP-ve.BL6 recipients at early (week 3) 
and late time points (week 7) after adoptive transfer of bm12 CD4 T cells, demonstrating 
that GCs were less than WT response but did not reach statistical significance at week 3 
(p=0.142), but at week 7 this difference achieved significance due to amelioration of GCs 
(Mann Whitney test, p= 0.015). 
Data represent mean and SD of n = 4 mice per group. 
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This confirmed that inhibition of SAP signalling in the recipients abrogated long term GC 
autoantibody response. Furthermore, it highlighted that donor CD4 T cells may be providing 
a limited and transient TFH function for GC autoimmunity. 
4.3.3.2. Blocking SAP signalling on donor CD4 T cells failed to inhibit long term GCs 
Having established that inhibition of SAP signalling in the recipient CD4 T cells resulted in 
abrogation of long term GCs in the recipients, I next sought to investigate the role of 
inhibition of SAP signalling in donor CD4 T cells. This was carried out by using donors in 
which SAP signalling was knocked out by crossing bm12 males with SAP-/+ females as 
discussed in methods section 2.1.1 and 2.2.10. After the confirmation of SAP-ve.bm12 status 
of donors on gel electrophoresis as described in methods section 2.2,1 and 2.2.10, they 
were used for experiments.  
Hep-2 indirect immunofluorescence of recipient sera from SAP-ve.bm12 groups 
demonstrated long lasting autoantibody which was in consistent with the presence of GCs in 
recipient splenic sections at 7 weeks post adoptive transfer. This humoral autoimmune 
response was comparable with the WT response (figure 4.15). 
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Figure 4.15. Development of autoantibodies and long term GCs in BL6 recipients following 
adoptive transfer of SAP-ve.bm12 purified CD4 cells (2x106).  
a. Relative anti-nuclear autoantibody levels as measured by Hep-2 indirect immunofluorescence 
in BL6 recipients following adoptive transfer of donor SAP-ve.bm12 CD4 T cells demonstrating 
comparable autoantibodies titres compared to WT response (two way ANOVA, p= 0.148). 
b. Quantification of GCs in splenic sections of the BL6 recipients at week 7 after adoptive 
transfer of SAP-ve.bm12 CD4 T cells demonstrating that GCs were comparable with that of WT 
(Mann Whitney test, p= 0.190). 
Data represent mean and SD of n = 4 mice per group. 
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To further examine this critical role of the recipient CD4 T cell population in maintaining 
humoral GC autoimmunity, WT BL6 mice were challenged intravenously with 2x106 column 
purified CD4 T cells from ‘bm12.Kd’ mice (that express additional transgenic H-2Kd 
alloantigen). Four weeks later, CD4 T cells were purified from these challenged mice and 
transferred into secondary naïve BL6 recipients. We have recently reported that, as a 
consequence of the mismatched I-Abm12 antigen, purified bm12.Kd CD4 T cells generate graft 
versus host responses in BL6 recipients, resulting in long-lived anti-Kd-alloantibody and 
autoantibody production, despite the transferred bm12.Kd CD4 T cells being killed within the 
first week after transfer by host adaptive immune recognition of the H-2Kd alloantigen 
(Harper et al., 2016). Thus, BL6 mice were culled 4 weeks after challenge with bm12.Kd CD4 
T cells (by which time only recipient-strain CD4 T cells will have survived) and column 
purified CD4 T cells from these mice was adoptively transferred into secondary naive BL6 
recipients. Serum was sampled weekly from the secondary recipients, and their spleens 
assessed at 7 weeks for GC activity. As shown in Figure 4.16, adoptive transfer of purified 
CD4 T cells from bm12.Kd-challenged mice provoked GC humoral autoimmune responses in 
the secondary recipients (Figure 4.16). This confirms that recipient CD4 T cells are not only 
maintaining the GC response, but can trigger humoral autoimmunity upon transfer into 
naïve mice.  
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Figure 4.16. BL6 WT CD4 T cells potential for initiating and maintaining autoimmunity in 
secondary naïve WT BL6 host. 
a. Column purified bm12.Kd CD4 T cells (2x106) were transferred into naïve BL6 
recipients, and four weeks later, CD4 T cells were purified from these challenged 
mice and (2x106 CD4 T cells) transferred into secondary naïve BL6 recipients 
(Bm12.Kd BL6BL6).  
b. Hep-2 indirect immunofluorescence demonstrating the development of long 
lasting autoantibodies in BL6 recipients of BL6 CD4 T cells from BL6 recipients of 
bm12.Kd CD4 T cells (Bm12.Kd BL6BL6) which is significantly higher than 
syngeneic BL6 CD4 T cells (BL6BL6) but less than Bm12.KdBL6 responses 
(p=.003). 
c. Quantification of GCs in splenic sections of the BL6 recipients of BL6 CD4 T cells 
from BL6 recipients of bm12.Kd CD4 T cells (Bm12.Kd BL6BL6) at week 7 on 
immunofluorescence staining by staining with anti-GL7 for germinal centres and 
anti-B220 for B cell follicles. On quantification, it showed that GCs were 
significantly higher than syngeneic group but less than Bm12.KdBL6. 
Data represent mean and SD of n = 4 mice per group, *P < 0.05, **P < 0.01 and ***P < 
0.001; 2-way ANOVA in ii and Mann-Whitney test in iii. 
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4.3.4. Germinal centres are central to diversification of humoral responses 
Having established that donor CD4 T cells initiated recipient autoantibody responses that 
were then maintained as a GC reaction by TFH cells of recipient origin, I sought to address 
the following: 
1. Do the autoreactive humoral responses in BL6 recipients of bm12 CD4 T cells 
diversify with time, as occurs in BL6 recipients of bm12 heart grafts? 
2. If so, is this epitope diversification mediated by a germinal centre response? 
In order to address the first question, anti-vimentin autoantibody was measured and 
compared by anti-vimentin antibody ELISA at an early and late time point in BL6 recipients 
of bm12 CD4 T cells as described in method section (2.2.5.3). On analysis, it was found that 
there was a surge in anti-vimentin autoantibody at a late time point compared to early time 
point (figure 4.17). These findings were in accordance which were seen by bm12 allografts 
into BL6 as described in the last chapter in section 3.3.6.2. 
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Figure 4.17. Anti-vimentin autoantibody responses as measured by ELISA at early and late 
time point 
Anti-vimentin ELISA demonstrating that relative levels of anti-vimentin IgG antibody were 
significantly higher at week 15 compared to week 7 following transfer of purified bm12 CD4 
T cells into naïve BL6 recipients.  
Data represent mean and SD of n = 4 mice, (p= Mann-Whitney test). 
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To address the second question, sera from the challenged groups were tested for the 
presence of vimentin autoantibody.  
On analysis, anti-vimentin autoantibody levels were not above base line in TCRbd-/- mice 
challenged with bm12 CD4 T cells, nor in challenged SAP-ve  BL6 mice. In contrast, late anti-
vimentin (week 15) responses were detected in challenged TCRbd-/- mice that had also been 
reconstituted with naïve BL6 CD4 T cells – the only group in which long-lasting GC responses 
were observed (figure 4.18).  
  
195 
 
 
Figure 4.18. Diversification of humoral responses as demonstrated by development of 
anti-vimentin autoantibody at early and late time points after adoptive transfer of bm12 
CD4 T cells into BL6 / TCRbd-/- / TCRbd-/-+ BL6 CD4 T cells / SAP-ve BL6 recipients 
Anti-vimentin ELISA demonstrating the relative levels of anti-vimentin IgG antibody at early 
(week 7) and late time points (week 15). It showed that significantly higher anti-vimentin 
levels in BL6 (WT) and TCRbd-/- +BL6 recipients at week 15 compared to week 7 but not in 
TCRbd-/- and SAP-/- BL6 recipients.  
Data represent mean and SD of n = 4 mice per group, n= not significant,*P < 0.05, (Mann-
Whitney test).  
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This experiment demonstrated that GCs may be playing a major role in diversification of 
humoral response.  
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4.3.5. Monoclonal population of CD4 T cells is capable of driving diversification of humoral response 
in donor induced autoimmunity 
The findings raise the interesting question of precise antigen-specificity of the recipient CD4 
T cells that provide secondary TFH cell help in our model.  
Essentially, host TFH cells are recognising the processed autoantigens presented in the 
context of MHC class II by the activated autoreactive B cells and result in the development 
of autoreactive GCs. These autoreactive GCs then lead to inter-molecular epitope 
diversification, to encompass, along with other targets, responses against vimentin 
autoantigen. However, if we replace WT host CD4 T cells with TCR75 CD4 T cells (that 
recognise the dominant peptide epitope of the H2.Kd MHC class I antigen in the context of I-
Ab) then Kd specific B cells would present the Kd antigen to TCR75 CD4 T cells and result in 
the development of only Kd specific GCs and there should be no anti-vimentin autoantibody 
response. 
In order to investigate this, TCRbd-/- or WT B6 mice were reconstituted with TCR75 T cells/ 
SAP-ve. TCR75 CD4 T cells and simultaneously adoptively transferred column purified CD4 T 
cells from bm12 donor mice that express additional H-2Kd class I alloantigen as a transgene 
(bm12.Kd). The experimental model is shown below in figure 4.19. 
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Figure 4.19. Experimental model in which TCRbd-/- or WT BL6 recipients were reconstituted 
with purified TCR75 or TCR75 SAP-/- CD4 T cells (1x103 TCR75 CD4 T cells) and 
simultaneously with purified bm12.Kd CD4 T cells (2x106). 
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Sera from BL6 recipients of bm12.Kd CD4 T cells demonstrated development of anti-
vimentin autoantibody response at a late time point (figure 4.20) similar to that observed in 
bm12 to BL6 cell adoptive transfer experiment. In this groups, I have already shown that 
recipients developed LL autoantibody and alloantibody, which were consistent with the 
development of GCs (figure 4.16 a, b and c). 
These results demonstrate that Kd specific and autoantigen specific TFH cells were helping 
the respective populations of activated B cells to produce Kd alloantibody and 
autoantibodies respectively. 
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Figure 4.20. Development of late anti-vimentin autoantibody response in BL6 recipients of 
bm12.Kd CD4 T cells.  
Anti-vimentin ELISA demonstrating development of significantly high levels of anti-vimentin 
autoantibody at week 15 compared to week 7 (p=.02) 
Data represent mean and SD of n = 4 mice per group,*P < 0.05, Mann-Whitney test. 
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After having established that BL6 recipients of bm12.Kd CD4 T cells reproduced 
diversification of autoantibody in the same manner as that observed in bm12 to BL6 model, 
the next step was to adoptively transfer bm12.Kd CD4 T cells into TCRbd-/- recipients and to 
examine humoral response in the recipients and diversification. 
On adoptive transfer of bm12.Kd CD4 T cells into TCRbd-/-, recipient sera showed 
development of autoantibody and alloantibody which was in consistent with our previous 
work (Harper et al., 2016). But B cells did not differentiate into GCs as demonstrated by GL7 
negative B cell follicles. Despite the presence of autoantibody, anti-vimentin autoantibody 
was not above the base line (figure 4.21). These findings were in consistent with bm12 to 
TCRbd-/- experiment results that in the absence of secondary host TFH cells, recipients did not 
develop GCs and there was no late anti-vimentin autoantibody response (figure 4.18). 
The next step was to investigate that whether monoclonal population of CD4 T cells is 
sufficient enough to drive this diversification. In order to investigate this, TCRbd-/- were 
reconstituted with CD4 T cells from TCR75 as shown above in figure 4.19. On reconstitution 
of these TCRbd-/- recipient with TCR75 CD4 T cells, GCs were restored with LL autoantibody 
and anti-Kd antibody in the recipients. Interestingly, the anti-vimentin autoantibody formed 
earlier compared to WT scenario (bm12.Kd  to BL6), demonstrating stronger help provided 
by monoclonal population of CD4 T cells for the development of anti-vimentin autoantibody 
compared to WT (figure 4.21).  
Furthermore, this ability of monoclonal population of CD4 T cells to drive humoral response 
diversification in GVH, was confirmed by reconstituting TCRbd-/- recipients with SAP-ve 
TCR75.CD4 T cells and challenged with bm12Kd cell simultaneously (figure 4.19). These SAP-ve 
TCR75.CD4 T cells were monoclonal population of CD4 that recognise the dominant peptide 
epitope of the H2.Kd MHC class I antigen in the context of I-Ab but were not able to provide 
TFH cell function for the development of GCs due to inhibition of SAP signalling. Following 
adoptive transfer, recipient sera showed the presence of autoantibody and anti-Kd antibody 
but B cells did not differentiate into GCs and there were no anti-vimentin autoantibody 
(figure 4.21). 
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Figure 4.21. Restoration of autoantibody response, Kd antibody and GCs on reconstitution 
of TCRbd-/ - with bm12.Kd CD4 T cells and TCR75 CD4 T cells but not with SAP-ve TCR75.CD4 T 
cells 
i. Relative anti-nuclear autoantibody levels as measured by Hep-2 indirect 
immunofluorescence in TCRbd-/- recipients of bm12.Kd CD4 T cells with or without 
TCR75 CD4 T cells or SAP-ve TCR75.CD4 T cells, demonstrating development of 
long lasting autoantibodies in all the groups which are comparable in all the 
groups.  
ii. Kd ELISA demonstrating development of relative anti-Kd antibodies in TCRbd-/- 
recipients reconstituted with SAP-/- TCR75.CD4 T cells demonstrating 
development LL anti-Kd antibody which was significantly less than TCRbd-/- 
recipients reconstituted with TCR75 but more than WT and TCRbd-/- recipients. 
iii. On quantification of GCs, germinal centres were significantly lower in TCRbd-/- 
recipients reconstituted with SAP-ve TCR75.CD4 T cells compared to WT and 
TCRbd-/- recipients reconstituted with TCR75 CD4 T cells. 
iv. Anti-vimentin ELISA demonstrating that anti-vimentin autoantibody was not 
above the base line in TCRbd-/- recipients reconstituted with SAP-ve TCR75.CD4 T 
cells while in TCRbd-/- reconstituted with TCR75 CD4 T cells demonstrated high 
levels of anti-vimentin even at week 7.  
Data represent mean and SD of n = 4 mice per group, ns=not significant, *P < 0.05, **P < 
0.01 and ***P < 0.001, Two way ANOVA for figure i, ii and Mann-Whitney test for iii, iv. 
This experimental work revealed that monoclonal population of CD4 T cells was sufficient to 
drive diversification of autoimmune humoral response in recipients once triggered by donor 
CD4 T cells. The possible explanation may be that initial transient autoreactive GC triggered 
by bm12Kd cells may be sustained by TCR75 CD4 T cells.  
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4.3.6. Factors which may be preventing donor bm12 CD4 T cells to acquire TFH function  
Because donor bm12 CD4 T cells do not undergo TFH cell differentiation (figures 4.14 and 
4.15), this raised the intriguing question as to why not; bm12 mice readily mount 
conventional T cell-dependent antibody responses (Huygen et al., 1993; McIntyre and 
Seidman, 1984). We think there are two likely explanations.  
1. Firstly, for any particular donor alloreactive bm12 CD4 T cell clone, its target epitope 
is likely to be expressed at much higher frequency on the surface of the host (BL6) B 
cells and DCs, than would normally be the case for conventional recognition of a self-
restricted peptide epitope. Because in GVH, donor CD4 T cells interact with all the 
MHC class II complexes in the recipient irrespective of the bound peptide, hence the 
donor precursor frequency that responds to a particular MHC class II alloantigen is 
100 to 1,000 fold greater than for the response against conventional, self-restricted 
peptide (Ali et al., 2016; Macdonald et al., 2009). During this process, donor CD4 T 
cells may have non-productive interactions with non-B cell APCs, most probably with 
dendritic cells (DCs). These non-productive interactions may result in their inability 
to function as a TFH cell. Contrary to this hypothesis, Deenick et al has suggested that 
prolonged DC interaction can drive TFH differentiation (Deenick et al., 2010).  
In this respect there is one potential possibility that successive interaction of donor 
CD4 T cells with dendritic cells (DCs) may result in progressive reduction in Bcl-6 
expressed by donor CD4 T cells. Hence donor CD4 T cells do not acquire TFH cell 
signature markers which prevent their entry and retention into B cell follicles for 
development of long term germinal centres. Hence, we hypothesised that 
overexpression of Bcl-6 on donor bm12 CD4 T cells will make them to function as TFH 
cells for development of GC response.  
2. Secondly, although a remarkably diverse set of bm12 CD4 T cell clones are activated 
by GVH recognition of recipient MHC class II, no individual clone binds with 
sufficiently-strong affinity to enable differentiation into follicular helper CD4 T cells. 
It has been suggested that T cell receptor antigen binding strength determines the 
fate of CD4 T cells to acquire a durable TFH cell function (Fazilleau et al., 2009). In 
order to investigate this concept of antigen binding strength in direct allorecognition, 
we used TCR75 CD4 T cells’ ability to recognise I-Ab-restricted Kd peptide epitope in a 
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direct allorecognition fashion.TCR75 CD4 T cells are a monoclonal population of CD4 
T cells and we have shown recently that they acquire TFH cell function when 
recognising dominant Kd- peptide in the context of I-Ab in an indirect fashion (Conlon 
et al., 2012).  
4.3.6.1. Lentiviral transduction of bm12 CD4 T cells with Bcl-6 transgene 
As I have shown above that adoptive transfer of bm12 CD4 T cells into TCR bd-/- did not result 
in formation of germinal centres; I selected this model to investigate whether upregulation 
of Bcl-6 on donor CD4 T cells will result in development of germinal centres in TCRbd-/- 
recipients. For upregulation, I used viral transduction of donor CD4 T cells with Bcl-6 as has 
been described by Johnston et al (Johnston et al., 2009). The plasmid construct, vector 
production and bm12 CD4 T cells transduction with Bcl-6 vector are described in 2.2.11 to 
2.2.14. 
Bcl-6 GFP was confirmed on transduced bm12 T cells (bm12.Bcl6 CD4 T cells) under 
microscope while LV vector which was without Bcl-6 GFP, was used as a control vector 
during transduction of bm12 CD4 cells. After confirmation of Bcl-6 GFP, cells were washed 
and beads were removed and 2x106 donor bm12 CD4 T cells with Bcl-6 GFP (bm12.Bcl6) or 
bm12 CD4 T cells with control vector (control bm12 CD4 T cells) were injected intravenously 
into TCRbd-/- mice. 
Autoantibody responses were examined by hep-2 indirect immunofluorescence and GCs 
were assessed by staining recipient splenic section with anti-B220, anti-CD4 and anti-GL7 
antibodies. The germinal centres were significantly higher in bm12.Bcl-6 group compared to 
the control group. Similarly, the autoantibodies were comparable between the two groups 
up to week 5 but thereafter higher in Bcl-6hi group compared to the control group (figure 
4.22).  
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Figure 4.22. Development of long-lasting autoantibodies and GCs in TCRbd-/- recipients of 
bm12 CD4 T cells which artificially overexpressed Bcl-6 by lentiviral transduction 
i. Representative imaging depicting GFP-Bcl-6 expression in transduced bm12 CD4 
T-cells and control bm12 CD4 T-cells without Bcl-6-GFP expression. Cells were 
cultured with Bcl-6 LV vector and control vector with stimuli and checked for 
fluorescence at day 4. Scale bar 100µm. Confirmation of presence of green 
fluorescence on donor bm12 CD4 T cells as seen under microscope showing 
presence of green fluorescence in bm12.Bcl-6 high group but not in the control 
group. 
ii. Experimental model used for this experiment in which 2x106 either donor bm12 
CD4 T cells with high Bcl-6 or control bm12 CD4 T cells were adoptively 
transferred into TCRbd-/- recipients. 
iii. Development of long lasting autoantibody in TCRbd-/- recipients of bm12.Bcl-6 
donor CD4 T cells compared to control bm12 CD4 T cells.  
iv. On quantification of germinal centres in recipient splenic sections at week 7, 
recipients of bm12.Bcl-6 donor CD4 T cells produced significantly higher 
percentages of GCs compared to control group. 
v. Representative immunofluorescence images for GL7 positive staining on 
recipients’ splenic sections; showing presence of GL7 positive B cells in follicles in 
bm12.Bcl-6 group but not in control group. Scale bar is 250µm. 
a. Immunofluorescence staining of recipients’ splenic sections following 
adoptive transfer of control donor CD4 T cells demonstrating B cells did not 
differentiate into GCs.  
b. Immunofluorescence staining of recipients’ splenic sections following 
adoptive transfer of donor CD4 T cells with high Bcl-6 demonstrating 
presence of GL7 positive B cells in follicles confirming the presence of GCs.  
Data represent mean and SD of n = 4-5 mice per group, ns=not significant, *P < 0.05, **P < 
0.01 and ***P < 0.001, t-test for figure iii and Mann-Whitney test for iv. 
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4.3.6.2. Affinity of GVH recognition by bm12 CD4 T cells is insufficiently strong to 
enable TFH cell differentiation  
The second point which we wanted to assess in regards to bm12 CD4 T cells inability to 
become TFH cell subset was to investigate whether it is the direct allo-recognition of MHC 
class II on recipient B cells by donor CD4 T cells which is not strong enough for them to 
differentiate into TFH cell subset. Transfer of TCR75 CD4 T cells into the B6.Kd T cell deficient 
(BL6.Kd.TCRbd-/-) mice was carried out.  BL6.Kd mice express H2.Kd MHC class I antigen as a 
transgene (Honjo et al., 2004) and TCR75 mice recognise the dominant peptide epitope of 
the H2.Kd MHC class I antigen in the context of I-Ab. Because BL6.Kd mice constitutively 
express target I-Ab-restricted Kd peptide epitope, transfer of TCR75 T cells was expected to 
provoke GVH recognition and humoral autoimmunity in similar fashion to bm12 CD4 T cells 
(figure 4.25 i). However, we have also shown that TCR75 T cells have the ability to 
differentiate into TFH cells in the B6 host (for example, following transplantation of BL6 
recipients with a BALB/c heart graft), indicating that they recognise target Kd epitope with 
strong affinity (Conlon et al., 2012) (figure 4.23 ii). Thus failure of B cells to differentiate into 
GCs in the adoptively transferred BL6.Kd.TCR bd-/- recipients would support our hypothesis.  
There was no detectable anti-H2-Kd IgG alloantibody, most likely because, as the H-2d MHC 
antigens are membrane proteins, they provoke robust, central deletional B cell tolerance 
(figure 4.23 iii), however there was long lasting autoantibodies and interestingly, B cells did 
not differentiate into germinal centres (figure 4.23 iii, iv and v). There was late 
augmentation of autoantibody response probably reflecting that every TCR75 CD4 T cell, 
being monoclonal population of CD4 T cells, is providing help to B cells compared to 
polyclonal bm12 CD4 T cells. 
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Figure 4.23. Failure of B cells to differentiate into germinal centres in BL6.Kd.TCRbd-/- 
recipients following adoptive transfer of 103 TCR75 CD4 T cells. 
i. Mice model showing adoptive transfer of TCR75 CD4 T cells from TCR75 mice 
into BL6.Kd.TCRbd-/- recipients with haplotypes for donor and recipient for MHC 
class I and class II and schematic pictures showing the interaction between donor 
TCR75 CD4 T cells with recipient B cells through direct allorecognition of Kd on 
MHC class I. 
ii. Indirect TCR75 CD4 T cells acquiring TFH cell phenotype as shown by dual 
positivity for CXCR5hi and PD1hi live CD T cells(Conlon et al., 2012).  
iii. Serum levels of anti–H-2Kd IgG alloantibody following adoptive transfer of TCR75 
CD4 T cells upto week 7. 
iv. Development of autoantibodies in BL6.Kd.TCRbd-/- recipients following adoptive 
transfer of TCR75 CD4 T cells compared with bm12 to BL6 and bm12 to TCRbd-/- 
group. The autoantibodies were significantly less than TCRbd-/- group (bm12 to 
TCRbd-/-) but comparable to WT response (bm12 to BL6). 
v. Quantification of germinal centres in BL6.Kd.TCRbd-/- recipients of TCR75 CD4 T 
cells at week 7 compared with WT response and TCRbd-/- response. This showed 
that B cells did differentiate into BL6.Kd.TCRbd-/- and TCR bd-/- recipients.  
Data represent mean and SD of n = 3-4 mice per group, ns=not significant, *P < 0.05, two 
way ANNOVA for figure iii and Mann-Whitney for iv.  
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4.4. Summary 
In this model of graft versus host allorecognition, we have shown that 
1. Adoptive transfer of cells replicated the results as those observed with heart grafts. 
2. Donor CD4 T cells trigger donor induced autoimmunity in the recipients and they 
were found to provide TFH cell function at an early stage which is transient. 
3. Donor induced autoimmunity in recipients is maintained and propagated once 
triggered by donor CD4 T cells by a second subset of CD4 T cells which act as a TFH 
cell for development of long term GCs. This TFH cell function is provided by 
recruitment of recipient CD4 T cells, which act as a TFH cell for development of GCs. 
4.  Germinal centres may be driving diversification of these humoral responses as 
measured by the appearance of late anti-vimentin autoantibody as a surrogate 
marker for humoral response diversification. 
5. Monoclonal population of CD4 T cells is capable of maintaining and propagating 
diversification of humoral responses once initiated by donor CD4 T cells.  
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4.5. Discussion 
Although long lasting germinal centres (figure 3.5 in Win et al paper )(Win et al., 2009) 
develop in our model of chronic rejection, the role of donor and recipient CD4 T cell in the 
development of this long lasting humoral autoimmunity was unclear. In this chapter, I have 
shown that donor CD4 T cells initiate and trigger the donor induced autoimmunity in the 
recipients but thereafter recipient CD4 T cells act as TFH cells and help primary B cell follicles 
to differentiate into GCs for maintenance and propagation of humoral response. I further 
extended my findings by showing that activated recipient CD4 T cells from WT BL6 recipients 
are not only capable of maintaining germinal centres but they can trigger autoimmunity in 
naïve WT recipients as well (figure 4.16). This demonstration that one population of helper 
CD4 T cells initiates humoral autoimmunity in recipients, but that a second population of TFH 
cells is required for its maintenance as a GC reaction, has important implications for how 
autoimmune-related phenomena manifest. 
The most salient feature of this work is the presence of robust GC responses in BL6 
recipients’ splenic sections of bm12 CD4 T cells at week 7 (figure 4.1) and the absence of this 
GC autoimmune response in T cell deficient BL6 (TCRbd-/-) recipients (figures 4.5) . Germinal 
centre response was restored when the T cell deficient recipients were reconstituted with 
host BL6 CD4 T cells simultaneously (figure 4.7). The criticism regarding TCRbd-/- recipients 
was that B cells in these animals might not be developing normally in the absence of host T 
cells, hence B cells in the TCRbd-/-recipients did not had the ability to differentiate into 
secondary follicles i.e. germinal centres. In this respect although haematoxylin and eosin 
staining of naive TCRbd-/-animals splenic sections did not show any specific follicular 
architecture, reconstitution with WT BL6 CD4 T cells restored their follicular architecture 
and simultaneous administration of bm12 CD4 T cells and WT BL6 CD4 T cells resulted in 
development of GCs (figure 4.4), thus suggesting critical role of recipient CD4 T cells. 
However, absence of late GCs when SAP signalling was inhibited in recipient CD4 T cells 
(Sh2d1a−/−) and restoration of late GCs when SAP signalling was inhibited on donor bm12 
CD4 T cells (Sh2d1a−/− ) by using SAP-ve BL6 recipients and SAP-ve.bm12 donor CD4 T cells 
respectively confirmed this critical role of recipient CD4 T cells (figure 4.14 and 4.15). 
Sh2d1a−/− mice are thought to have essentially normal CD4 T and B cells with relatively 
narrow defects in NK T cells (Czar et al., 2001). Furthermore, the ability of activated 
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recipient CD4 T cells in triggering autoantibodies in naïve WT BL6 confirms this role that 
they are not capable only in initiating humoral autoimmunity in recipients but they can 
propagate this through providing help to B cells for development of GCs (figure 4.16). 
Although there was early GCs in SAP-ve recipients of bm12 CD4 T cells, it did not sustain for 
long term (figure 4.14), this is in consistent with presence of donor bm12 CD4 T cells in 
CD45.1.BL6 recipients at day 16 and day 30 (figure 4.11 and 4.12). Furthermore, our initial 
experiments with adoptive transfer also confirmed the presence of a population of donor 
bm12 CD4 T cells acquiring TFH cell phenotype at day 23 (Qureshi et al., 2019). From this it is 
possible that donor CD4 T cells are providing initial transient TFH cell function at an early 
time point but at late time point it is the recipients CD4 T cells which are providing the 
critical TFH cell function for long term humoral autoimmunity. This raised many unanswered 
questions like why donor bm12 CD4 T cells do not acquire TFH cell function and what is the 
nature of antigen recognition by the recipient TFH cell population. 
The potential reasons for failure of bm12 CD4 T cells to act as TFH cells could be due to their 
short life span in the host / exhaustion / down regulation of Bcl-6 (master regulator) on 
donor CD4 T cells because of their interaction on MHC class II on recipient DCs or weaker 
interaction with MHC II-peptide complex which is not strong enough to sustain the TFH cell 
function.  
In this respect, inability of TCR75 CD4 T cells to acquire TFH cell function when interacting 
with peptide-MHC class II complex in BL6.Kd.TCRbd-/- in a direct allorecognition fashion, 
(figure 4.24) especially with our previous work in which we have shown that these TCR75 
CD4 T cells acquire TFH cell function when recognising dominant peptide in the context of I-
Ab through indirect allorecognition (Conlon et al., 2012), support the concept  that CD4 T 
cells acquiring TFH cell function depends on their pathway of allorecognition (Macdonald et 
al., 2009). Recipient CD4 T cells might be acquiring TFH cell function because of the unusual 
nature of allorecognition in this model. Interaction of donor CD4 T cells with recipient MHC-
peptide complex activates multiple clones of CD4 T cells (precursor frequency of ~5 – 10%) 
(Busser et al., 2003), but this interaction may be of low affinity and we know that only those 
CD4 T cells which interact with MHC-peptide complex with highest affinity will differentiate 
into TFH cells (Fazilleau et al., 2009). Furthermore, due to this unusual form of direct 
allorecognition, TCR75 CD4 T cells may not maintain their TFH function and GC maintenance 
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requires renewal of the TFH cell by continual differentiation of secondary subset of CD4 T 
cells during the course of a GC response. In support, recent work by Shulman has 
demonstrated that unlike GC B cells, which are clonally restricted, TFH cells emigrate from 
the follicles and invade the neighbouring follicles. These newly emigrated TFH cells then 
contribute to B cell selection and augment ongoing GC responses (Shulman et al., 2013).  
The other possibility of down regulation of Bcl-6 in donor bm12 CD4 T cells due to 
successive interaction with DCs may be the limiting factor for them to acquire TFH cell 
function. In support, artificial overexpression of Bcl-6 directs them to acquire TFH cell 
function and they help B cells to differentiate into GCs (figure 4.23) which is in consistent 
with the previous work where it has been shown that artificial overexpression of Bcl-6 on 
CD4 T cells help them to differentiate into TFH cells (Johnston et al., 2009).  
Demonstration of a monoclonal population of CD4 T cells which are capable of driving and 
maintaining humoral response diversification in TCRbd-/- recipients of bm12Kd and TCR75 
CD4 T cells (figure 4.22), supports that TCR75 TFH CD4 T cells might be providing help to 
autoreactive GC B cells for development of long term donor induced autoimmunity. As we 
know that bm12.Kd cells get killed within one week of their adoptive transfer and thereafter 
it is the TCR75 CD4 T cells which would be providing help for development of GCs (Harper et 
al., 2016). However we also know that TCR75 CD4 T cells  differentiate into TFH cell while 
recognising dominant peptide Kd on I-Ab and result in development of only anti-Kd 
alloantibody (Conlon et al., 2012), and potentially these GC are exclusively Kd specific. But 
apart from long term alloantibody, there is a long lasting autoantibody response as well in 
recipient sera with development of late autoimmune response to vimentin in this group 
compared to TCRbd-/- recipients challenged with bm12.Kd cells alone. This may propose that 
TCR75 TFH cells would be providing help to autoreactive GC B cells by providing help to the 
already existing autoreactive GC B cells. This seems true especially in the light of early GCs in 
SAP-ve.BL6 recipients of bm12 CD4 T cells. Furthermore, this set of experiment also 
demonstrates that B cells are capable of driving the epitope diversification of humoral 
response which is in consistent with Mamula et al work (Mamula, 1998; Mamula and 
Janeway, 1993). However, it contradicts to Mamula’s work in suggesting that B cell epitope 
diversification is possible in the absence of T cell epitope diversification as there was only 
monoclonal population of CD4 T cells which was capable of driving the diversification of 
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humoral repose in case of GVH allorecognition. However, it is important to examine that 
whether TCR75 CD4 T cells would be capable of triggering autoimmune humoral response 
and diversification of that humoral response in the absence of GVH allorecognition by 
assessing humoral responses in B6.TCRbd-/- recipients of B6.Kd cells which have 
simultaneously received TCR75 CD4 T cells. 
This raised multiple interesting questions that how TCR75 CD4 T cells (Kd specific) are 
providing help to the development of long lasting autoantibody response and whether 
autoimmunity is the result of GC response or EF response. It seems likely that diversification 
of humoral response is the result of GC response as there were no GCs and late anti-
vimentin autoantibody when SAP-veTCR75 CD4 T cells were transferred into TCRbd-/- 
recipients (figure 4.22). The possible explanation may be that during affinity maturation, Kd 
specific B cells may pick up autoantigens and receive unlinked help from TCR75 CD4 T cells 
to develop ASC for autoantibodies which remains unchecked due to unavailability of T 
follicular regulatory cell (TFR) control. However, this needs further work to confirm that GCs 
are purely Kd specific and to identify the mutations at BCR which leads to the development 
of autoimmune response. Furthermore, more work is required to identify that whether the 
adoptively transferred subset of TCR75 CD4 T cells may develop into TFH cell only or TFR cell 
as well.   
The differentiation of recipient TFH cells following adoptive transfer of bm12 CD4 T cells is 
presumably driven by antigen presentation by B cells that have been activated following 
interaction with donor CD4 T cells. B cells are then capable of ‘soliciting’ their own help 
(Stockinger et al., 1996), and hence, it is likely that recipient CD4 T cells are responding to 
self-restricted peptide autoantigen that is presented by the activated B cell. 
In this model, the demonstration of a late anti-vimentin response in recipients’ groups who 
developed germinal centres in their splenic sections may suggest that diversification of 
humoral autoimmune response is potentially the result of germinal centres. In the process 
of somatic hypermutation and affinity maturation it is possible for GC B cells to encompass 
additional autoantigens, including pathogenic ones, and thus lead to the development of 
pathologic disease in the recipients like SLE or RA. The autoantigen availability during GC 
response may be the result of apoptosis during affinity maturation. Although I chose to 
study the anti-vimentin response as a surrogate marker for diversification of humoral 
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response due to previously-reported association with rheumatoid arthritis, SLE (Davidson, 
2014) and in allograft vasculopathy (Mahesh et al., 2007; Rose, 2013), despite the 
development of late anti-vimentin in recipients, it is surprising that autoimmune disease 
manifestations were not observed routinely in our recipients’ native organs (Harper et al., 
2016; Motallebzadeh et al., 2012; Win et al., 2009), particularly when one considers that 
administration of bm12 splenocytes into BL6 model is used as a model for SLE (Eisenberg 
and Via, 2012). We do see occasional skin and gut manifestations, consistent with 
autoimmune disease, in long-term surviving recipients of bm12 CD4 T cells (> 6 months), 
however comparing this work with the previous work, the difference of appearance of 
disease may be related to number and type of cells transferred into recipients.  
In conclusion, I have shown that donor CD4 T cells initiate donor induced autoimmunity in 
the recipients and thereafter recipient CD4 T cells act as TFH cell and provide help to 
autoreactive B cells to differentiate into GC which in turn diversify humoral autoimmune 
response. It also provides an insight into the underlying pathogenesis of autoimmune 
disease that at the time of disease manifestations, the trigger for the autoimmunity like viral 
challenge may not be present but there may be a different factor which may be maintaining 
the disease process. Like in this scenario, it is the recipient TFH cells which are maintaining 
and propagating the donor induced auto-immunity in the recipient and developing selective 
strategies to target the pathogenic population of TFH cells may be a future avenue to deal 
with different autoimmune diseases.  
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Chapter 5 
Germinal centre autoantibody responses contribute to progression of allograft 
vasculopathy 
  
218 
5.1. Introduction 
Although allograft rejection is generally considered to be mediated by adaptive immune 
recognition of graft alloantigens, an association of host autoimmunity with chronic rejection 
of organs has been increasingly reported (Dave and Bayless, 2014; Dragun et al., 2013; 
Dragun et al., 2016; Fedoseyeva et al., 2002; Fedoseyeva et al., 1996; Fedoseyeva et al., 
1999; Haque et al., 2002; Mahesh et al., 2007; Zhang and Reed, 2016), particularly following 
heart and lung transplantation. These autoimmune responses were directed against several 
tissue specific self-proteins and appear to be the direct result of transplant, however the 
mechanisms that lead to their development and contribution to graft rejection remain 
poorly understood. I have discussed in detail the role of autoimmunity in chronic rejection in 
section 1.5. Briefly, the strongest clinical evidence for an effector role of autoimmunity 
contributing to chronic rejection of organs is from lung transplant recipients where T cell de 
novo autoimmunity directed against  collagen type V protein has been shown contributing 
to progression of bronchiolitis obliterans syndrome in recipients (Burlingham et al., 2007). 
Similarly in heart transplant recipients’ antibodies against cardiac myosin (CM) or detection 
of CM peptide-reactive T cells was highly and independently indicative of allograft 
vasculopathy (Kalache et al., 2011). Furthermore, in kidney transplant recipients, antibodies 
to collagen-IV and fibronectin have been shown contributing to transplant glomerulopathy 
(TG) (Angaswamy et al., 2014). Nevertheless, several key questions relating to transplant 
associated autoimmunity (TAA) remain unanswered. It is not known whether autoimmunity 
contributes to chronic rejection independently or whether it is augmenting conventional 
alloimmune response directed against the allograft.  In Angaswamy et al study, 
development of antibodies to self-antigens (Ags) like fibronectin and collagen IV was 
thought to augment the deleterious effects of DSA in TG recipients (Angaswamy et al., 
2014). In another study in lung transplant patients, recipients with pre-existing 
autoantibodies to self-antigens were found to be at an increased risk for development of 
primary graft dysfunction and chronic rejection (Tiriveedhi et al., 2013).  
There are only few rodent studies which suggest an effector role for autoimmune responses 
in chronic graft rejection. Fedoseyeva et al (Fedoseyeva et al., 2002; Fedoseyeva et al., 
1999) showed that modulation of T cell response to cardiac myosin (CM) can result either in 
accelerated rejection (Fedoseyeva et al., 1999), or indefinite heart graft survival in the 
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absence of immunosuppression (Fedoseyeva et al., 2002). Their experimental work 
suggested that immunity to CM detected in heart-grafted mice is consistently mediated by 
CD4 T cells releasing Th-1 cytokines (IL-2, IFN-Ɣ), but not type 2 cytokines. Sensitization of 
recipient mice to CM before transplantation induces a potent proinflammatory Th1 anti-CM 
response which results in accelerated rejection of donor graft.  
Similarly, in another rodent study, collagen V specific CD4 T cell lines were isolated from 
lung allograft recipients which proliferated in response to collagen V but did not induce any 
pathology in lungs of normal rats. These cell lines were CD4+ve and CD25-ve but produced 
IFN-gamma in response to collagen V. Adoptive transfer of one of these cell line abrogated 
the established transplant tolerance in lung allografts and produced severe inflammatory 
changes in iso-grafts (Haque et al., 2002). Thus, their work demonstrated that lung allograft 
rejection involves both allo- and autoimmune responses, and graft destruction that occurs 
during the rejection response may expose allograft-infiltrating T cells to potentially antigenic 
epitopes in collagen (V). However, these studies have focused only on T lymphocyte 
autoimmune responses; but not how they develop in post-transplant recipients and 
contribute to graft rejection. 
Most of the work on how these autoimmune responses develop comes from conventional 
immunology looking at various autoimmune diseases like SLE and RA. In this regard, 
although humoral autoimmune disease was traditionally thought to be germinal centre (GC) 
mediated (Brink, 2014; Vinuesa et al., 2009), extrafollicular (EF) responses can also result in 
affinity matured autoantibody production (William et al., 2002). However, it is not clear how 
autoantibodies form in transplant recipients whether they originate from GCs or EF or both. 
Nevertheless, recent work in conventional immunology has shown that GC autoimmune 
responses require help from TFH cells (Linterman et al., 2009; Vinuesa et al., 2016) and it 
raises the possibility of developing selective strategies that target this subset, in anticipation 
of prolonging allograft survival in recipients.  
In the previous chapter, I have shown that in bm12 to BL6 heart transplant model, long 
lasting autoantibodies are the result of germinal centres (figure 3.5) and TFH cells were 
identified based on their homing to GC B cells (figure 3.6) and phenotypic markers (figure 
3.8 ) (chapter 3). Furthermore, adoptive transfer experiments (chapter 4) demonstrated that 
donor CD4 T cells initiate and trigger donor induced autoimmunity in recipients but 
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thereafter, host TFH cells maintain and propagate this autoimmunity through germinal 
centre formation. In this chapter we will extend our findings of adoptive transfer 
experiments into murine heart allograft model of chronic rejection to identify the role of 
donor and recipient CD4 T cells in TAA and its contribution to the development of allograft 
vasculopathy. This will also help us to identify which of them is acting as a TFH cell. 
Identification of TFH cell will help us to develop future strategies to selectively block TFH cells 
to inhibit GC autoimmune response in order to prolong allograft survival. Of note, the 
experimental details, results, discussion and future implications written in this chapter has 
already been published in my papers (Qureshi et al., 2019; Qureshi et al., 2018).   
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5.2. Aims 
The aims of this chapter are: 
1. To identify the relative contribution of donor and recipient CD4 T cells in the 
development of transplant associated auto-immunity. 
2. To investigate whether GC autoimmunity contributes to progression of allograft 
vasculopathy independent of alloimmune responses. 
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5.3. Experimental model 
In order to examine the role of donor and recipient CD4 T cells in the development of TAA, I 
used wild- type (WT) mice and T cell deficient mice (that lack all TCR-αβ and TCR-γδ CD4 and 
CD8 T cells) (TCRbd-/) as recipients of either CD4 T cell-replete or CD4 T cell-depleted bm12 
heart allografts. Furthermore, in order to assess whether the observed difference in 
outcomes between WT and TCRbd-/- recipient was related to deficiency in specific T cells 
population, in certain experiments, TCRbd-/- recipients were reconstituted with purified 
syngeneic WT BL6 CD4 T cells on the day of transplant (figure 5.1). 
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 bm12 Donor BL6BL Recipient CD4 T cell transfer 
WT WT WT  –   
RcCD4 
CD4  T cell  
depleted  
WT  – 
DnCD4 WT  TCR bd
-/-
 – 
Dn.RcCD4 WT TCR bd
-/-
 +BL6 CD4 
Figure 5.1.  Experimental model showing WT, RcCD4, DnCD4, Dn.RcCD4 groups used to 
identify the role of donor and recipient CD4 T cells.  
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Antinuclear autoantibodies were assessed by indirect immunofluorescence in recipient sera 
(section 2.2.4), germinal centre activity was examined by staining recipients splenic cryo 
sections for germinal centre makers (section 2.2.7.3), graft survival was assessed by manual 
palpation of donor hearts in the recipients (section 2.1.2.1) and allograft vasculopathy was 
calculated morphometrically by measuring the mean luminal stenosis of intra myocardial 
vessels of the explanted hearts (section 2.2.7.5) as described in methods. GCs were 
quantified at day 50 or week 7 unless stated otherwise. Allograft vasculopathy was 
calculated at day 50 or week 7 unless stated otherwise. For autoimmune responses to 
vimentin, anti-vimentin ELISA was performed on recipient sera at week 7 and week 15 for 
development of late anti-vimentin autoantibody as described in section 2.2.5.3. 
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5.4. Results 
5.4.1. Both donor and recipient CD4 T cells contribute to progression of allograft vasculopathy 
As expected from my previous chapter work, class-switched anti-nuclear autoantibodies 
form when CD4 T cell help was provided exclusively by the donor CD4 T cell (bm12 to TCRbd-
/-), these autoantibody titres were comparable with WT response (bm12 to BL6) (figure 5.2 
a). However, there was no autoantibody when B cell help was only provided by the recipient 
CD4 T-cells (CD4 depleted bm12 to WT.BL6) (figure 5.2 a). Interestingly, CD4 T-cell replete 
recipients of CD4 T-cell replete donors developed autoantibodies which were comparable to 
WT response.  Despite the development of autoantibodies in TCRbd-/- recipients of CD4 T 
cell-replete bm12 heart allografts; the donor grafts did not develop AV. However, AV only 
developed when both donor and recipient were CD4 T cell replete (figure 5.2b), resulting in 
allograft rejection (figure 5.2 c). This demonstrated two things; firstly that both donor and 
recipient CD4 T cells are required for allograft rejection and secondly autoantibodies seem 
to be playing a role in rejection as there was no AV in CD4 T cell depleted bm12 donor 
allografts when transplanted into WT BL6 recipients (figure 5.2a) (Qureshi et al., 2018).  
Although our previous studies have suggested a role of autoantibody in graft rejection 
(Motallebzadeh et al., 2012; Win et al., 2009); in order to find out a definite contribution of 
autoantibody in chronic rejection of allograft in this model, I hypothesised that augmented 
autoantibody response in the recipients will result in accelerated rejection of donor bm12 
allografts compared to WT rejection kinetics. In order to do this, I primed bm12 hearts by 
transplanting WT BL6 skin grafts to bm12 recipients to get bm12 heart grafts that contained 
memory CD4 T cells with specificity for the WT BL6 recipients. Weekly tail bleeds were 
carried out from the bm12 recipients and flow cytometry was performed on peripheral 
blood lymphocytes (PBLs) to check for memory CD4 T cells phenotype by staining with anti-
CD44 and anti-CD62L antibodies as described in methods (methods section 2.2.1.3 and 
2.2.3.2). Flow cytometry of PBLs demonstrated memory phenotype of CD4 T cells after week 
4.  At week 7, bm12 recipients of BL6 skin grafts were sacrificed; spleens and hearts were 
harvested from the recipients.  Bm12 primed hearts were transplanted into WT BL6 
recipients and spleens were examined to confirm the presence of memory CD4 T cells 
(figure 5.3a).  Humoral response was examined by autoantibody responses in recipients’ 
sera and germinal centres by quantification of GL7 positive B cells. Augmented autoantibody 
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response were observed in the primed group compared to WT (figure 5.3b), in keeping with 
the presence of germinal centres in recipient splenic section (figure 5.3c) and rapid rejection 
of the donor heart allograft was observed with AV (figure 5.3d and e) (Qureshi et al., 2019; 
Qureshi et al., 2018).  
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Figure 5.2. Donor and recipient CD4 T cell populations are required for autoantibody-
mediated allograft vasculopathy 
a). Autoantibody development was dependent upon transfer of donor bm12 CD4 T cells, but 
independent of recipient CD4 T cells. Autoantibody responses in BL6 recipients of syngeneic 
BL6 heart allografts are also shown.  
b). At explant, the severity of allograft vasculopathy was determined morphometrically and 
expressed as percentage luminal stenosis (histogram), with representative 
photomicrographs of elastin van Gieson stained paraffin sections, depicting typical fibro-
proliferative arterial intimal thickening observed in rejecting heart allografts (scale bars 
50μm). Severe vasculopathy was only observed in groups in which donor and recipient CD4 
T cell subsets were present.  
c) Kaplan-Meier curves depicting allograft survival. 
Data represent mean and SD of n = 4-10 mice per group, with discrete data-points in (b) 
depicting individual animals. ns – not significant: *P < 0.05, **P < 0.01 and ***P < 0.001: 2-
way ANOVA in (b), Mann-Whitney test in (b), log rank test in (c).  
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Figure 5.3: Augmented anti-nuclear autoantibody response and accelerated heart allograft 
rejection following transplantation from donors primed against recipient 
(a) WT (BL6) mice were transplanted with hearts from bm12 donors sensitised to 
recipients by challenge with WT (BL6) skin grafts 7 weeks previously (primed bm12). 
Control recipient BL6 mice received heart allografts from unmodified bm12 donors 
(WT). Memory CD4 T cells were identified with live, CD4 T cells, having D62lo and 
CD44hi markers on flow cytometry.  
(b) Anti-nuclear autoantibody titres following transplantation.  
(c)  Recipient’s splenic germinal centre activity at week 4 post transplantation. 
(percentage of secondary follicles to total number of follicles). 
(d) Kaplan-Meier curves depicting allograft survival. 
(e) Donor allograft vasculopathy in primed bm12 hearts at their explants compared to 
WT donors AV.  
Data represent mean and SD of n = 4-10 mice per group. ns – not significant: *P < 0.05, **P 
< 0.01 and ***P < 0.001: 2-way ANOVA in (b), Mann-Whitney test in (c, e) and log rank test 
in (d).  
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5.4.2. Host TFH cells are required for maintenance of germinal centre autoantibody response 
Because the bm12 allografts did not demonstrate allograft vasculopathy on explantation 
from TCRbd-/- recipients despite the presence of autoantibody response in the recipients’ 
sera, we hypothesised that the host CD4 T cells may be providing critical role of TFH cell 
function for the development of germinal centre response in the WT BL6 recipients and 
those GC mediated humoral responses may be contributing to the rejection of donor 
allografts. In order to investigate this, germinal centre activity was assessed in recipients’ 
splenic cryo sections at week 7 post transplantation. Splenic sections were stained as 
described in methods (2.2.7.3) and quantified as described in methods (2.2.7.5). 
On staining, splenic GC activity was not detectable in TCRbd-/- recipients of WT bm12 heart 
allografts or in WT BL6 recipients of CD4 T cell depleted donors, but was readily evident in 
WT BL6 recipients of WT bm12 heart grafts or in TCRbd-/- recipient mice that had been 
reconstituted with recipient WT BL6 CD4 T cells, with the majority of B cell follicles 
exhibiting GL7 positive GCs (figure 5.4a). This demonstrated that both donor and host CD4 T 
cells are required for the development of GCs. The next question was whether it is donor or 
recipient or both CD4 T cell populations which are providing the critical TFH cell function.  
In order to investigate this, I used confocal immunofluorescence microscopy to locate the 
presence of CD4 T cells within the GC follicles which would be consistent with the TFH cell 
subset (Yu and Vinuesa, 2010). On staining, a population of CD4 T cells was identified in BL6 
recipients of bm12 heart allografts within splenic GCs (figure 5.4b). However both donor 
and recipient cells were CD45.2 positive, hence I was unable to tease out whether the CD4 T 
cells were of donor or recipient origin. In order to investigate this, I challenged CD45.1 BL6 
mice with congenic CD45.2 bm12 allografts and confocal imaging was performed on 
recipient splenic sections seven weeks post transplantation. Although CD4 T cells were 
identified within the GCs, donor CD4 T cells (CD45.2 positive) were not detectable (figure 
5.4b, 3rd row). This suggested that potentially the follicular helper CD4 T cells were 
predominantly of recipient origin. However, it was not possible to confirm this with CD45.1 
staining because of simultaneous binding of anti-CD45.1 antibody to surrounding 
endogenous (recipient) CD45.1 positive B cells (figure 5.4b, 4th row).  
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In order to overcome this caveat, GC splenic responses were assessed seven weeks after 
transplantation of CD45.2 bm12 heart grafts into CD45.2.TCRbd-/- BL6 recipients that had 
been simultaneously reconstituted with CD45.1.BL6 CD4 T cells at the time of 
transplantation. Using this approach, a population of the transferred congenically labelled 
(CD45.1+ve) BL6 CD4 T cells were readily evident within the GC B cells (figure 5.4c)(Qureshi et 
al., 2018). 
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Figure 5.4: Recipient T follicular helper CD4 T cells are required for maintaining recipient 
germinal centre autoantibody responses 
a. Frequency of splenic GCs, expressed as a proportion of total B cell follicles 
(histogram), in the various recipient groups as depicted in figure 5.2. Images depict 
representative confocal images of GL7pos GCs within recipient splenic B cell follicles 
for the wild-type donor / recipient combination (top row) and for wild-type bm12 
hearts transplanted into Tcrbd-/- BL6 recipients (bottom row). *P < 0.05 Mann-
Whitney test (n=5).  
b. Confocal immunohistochemistry of splenic sections seven weeks after 
transplantation of wild-type (WT) BL6 mice with WT bm12 heart allografts (top row) 
confirmed the presence of T cells (red) within GC foci (GL7pos:green) in B cell follicle 
(blue). Following transplantation of CD45.2 bm12 heart allografts into congenic 
CD45.1 BL6 recipients, CD4 T cells within secondary GC follicles were again readily 
evident (2nd row). However, congenically labelled (CD45.2) donor cells were not 
detectable in the B cell follicle (3rd row). Due to the simultaneous presence of CD45.1 
on B cells in CD45.1 BL6 recipients, the staining for CD45.1+ve CD4 T cells is not 
conclusive (4th row). 
c. Seven weeks after transplantation of CD45.2 bm12 hearts into CD45.2 Trcbd-/- BL6 
mice CD4 T cells, a population of congenic (CD45.1) recipient BL6 CD4 T cells 
(transferred at transplantation) was readily evident within the GC (far right – 
expanded image with CD45.1 CD4 T cell population circled.  
Data are representative of 4 mice per group (a) and of two independent experiments (b 
& c). Image scale bars; 40µm for figure a, b and c. 
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5.4.3. Inhibition of SAP signalling on recipient CD4 T cells prolongs graft survival 
In the previous chapter, I have shown that inhibition of SAP signalling in recipient CD4 T cells 
prevents development of long term GCs in SAP-ve.BL6 recipients of bm12 CD4 T. I extended 
these findings to transplant settings to answer two questions: 
 Firstly, to address the role of recipient CD4 T cells as TFH cells in maintaining GC 
humoral autoimmunity following transplantation,  
 And secondly, to assess that whether blocking TFH cells in donors or recipients 
prolongs allograft survival? 
In order to investigate this, WT bm12 or Sh2d1a-/-.bm12 (SAP-ve. bm12) donor heart 
allografts were transplanted into Sh2d1a-/-.BL6 (SAP-ve.BL6) or WT BL6 recipients. Recipient 
sera were assessed for autoantibody response, splenic sections were looked for germinal 
centres and donor grafts were assessed for development of AV.  
As expected from my adoptive transfer work (previous chapter); transplantation into SAP-
ve.BL6 recipients resulted in antinuclear autoantibody responses, however autoantibodies 
were either equal or more than those observed in WT BL6 recipients (figure 5.5a). 
Interestingly, splenic germinal centre activity was not above the base line when assessed 
seven weeks after transplantation (figure 5.5b). Importantly, in the absence of late germinal 
centre activity, heart grafts survival was prolonged (figure 5.5c) and allograft vasculopathy 
was minimal (figure 5.5d).  
Although we have shown previously that there was no autoantibody in B cell deficient 
recipients (µMT) of bm12 heart allografts and AV was attenuated in donor allografts, AV was 
measured by allograft severity score (Win et al., 2009) which is different from the degree of 
luminal stenosis as measured by morphometric analysis (method section 2.2.7.5) in my 
work. Hence, bm12 donors were transplanted into B cell deficient recipients (µMT) and AV 
was measured again in this work to rule out any contribution from cellular arm of adaptive 
alloimmunity. On calculation of percentage luminal stenosis in donor allografts, allograft 
vasculopathy of bm12 donor allografts in SAP-ve.BL6 recipients was similar in severity as that 
observed in µMT recipients (figure 5.5d).  
This demonstrated that blocking SAP signalling in recipient CD4 T cells resulted in failure of B 
cells to differentiate into GCs and prolonged allograft survival with minimal AV; hence 
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suggesting that recipient CD4 T cell are acting as TFH cell. Then I sought to investigate 
whether donor CD4 T cells are acting as TFH cell as well by transplanting SAP-ve.bm12 heart 
grafts into WT BL6 recipients.  
On analysis, WT BL6 recipients of SAP-ve.bm12 heart grafts developed GC autoantibody 
responses (figure 5.5 a and b) that were comparable to the responses observed in WT. SAP-
ve.bm12 allografts were rejected at the same tempo as that observed in WT bm12 heart 
grafts (figure 5.5c). The severity of AV was also similar between SAP-ve bm12 and WT groups 
(figure 5.5d). This demonstrated that donor CD T cells can interact with recipient B cells 
even in the absence of SAP signalling in donor CD4 T cells and long lived GCs still form in 
splenic follicles in the WT BL6 recipients, which explains that TFH cell function is being 
provided by the recipient CD4 T cells which were SAP competent in the recipients (Qureshi 
et al., 2018).  
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Figure 5.5: Germinal centre autoantibody responses mediate progression of allograft 
vasculopathy 
Wild-type (WT) or SAP-deficient (Sh2d1a-/-) bm12 heart allografts were transplanted into 
wild-type (WT) or SAP-deficient (Sh2d1a-/-) C57BL/6 (BL6) recipients (WT bm12 donor to WT 
BL6 recipient (WT); WT bm12 donor to Sh2d1a-/-BL6 recipient (SAP-ve BL6); Sh2d1a-/-bm12 
donor to WT BL6 recipient (SAP-ve bm12).  
a. Following transplantation, recipient anti-nuclear IgG autoantibody responses were 
measured weekly and expressed relative to positive hyperimmune control serum 
(1000 units) in three groups. 
b. Frequency of splenic GCs, expressed as a proportion of total B cell follicles 
(histogram), in the various recipient groups. Primary follicles failed to differentiate 
into GCs when SAP signalling was inhibited in recipients (SAP-ve BL6) but not when 
SAP signalling was inhibited in donors (SAP-ve.bm12 group).  
c. Kaplan-Meier curves depicting allograft survival. 
d. At explant, the severity of allograft vasculopathy was determined morphometrically 
and expressed as percentage luminal stenosis (histogram), with representative 
photomicrographs of elastin van Gieson stained paraffin sections, depicting typical 
fibroproliferative arterial intimal thickening observed in rejecting heart allografts. 
Severe vasculopathy was only observed in groups in which germinal centre 
autoimmune responses were observed. Also the severity of AV in bm12 allografts 
was not different between SAP-ve BL6 recipients and B cell deficient (µMT) 
recipients.  
Data represent mean and SD of n = 4-10 mice per group, with discrete data-points in c 
depicting individual animals. *P < 0.05, **P < 0.01 and ***P < 0.001 (2-way ANOVA in a 
Mann-Whitney test in b and d, and Kaplan-Meier log rank analysis in c).  
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5.4.4. Germinal centre autoantibody responses contribute to intermolecular epitope diversification 
In order to investigate whether autoantibody is causing damage to the allograft, the 
allografts were examined for endothelial complement deposition by staining the frozen 
allograft sections with C4d staining. As reported previously (Win et al., 2009), the 
autoantibody responses generated in WT BL6 recipients of WT bm12 allografts were 
associated with C4d deposition in allografts (figure 5.6a). After confirmation of complement 
deposition in bm12 allografts following transplantation in WT BL6 recipients; complement 
deposition was investigated in all the other groups. Despite the development of antinuclear 
autoantibody and absence of a late GC response, complement deposition was not detected 
in bm12 allografts transplanted into SAP-ve BL6 or TCRbd-/- recipients. However, this 
complement deposition was observed in allografts where GC autoantibody responses were 
seen; i.e. bm12 allografts transplanted into WT.BL6 CD4 T cell reconstituted TCRbd-/- 
recipients, and SAP-ve.bm12 allografts into WT BL6 recipients (figure 5.6a).  
This raised a question of whether germinal centres are contributing to maturation and 
diversification of autoimmune humoral response which in turn leads to progression of 
allograft vasculopathy. In order to examine this, in vitro assay was performed to test the 
ability of sera obtained from recipients from different groups at week 7 to induce 
migration/proliferation of cultured bm12 endothelial cells across a scratch wound in an 
attempt to evaluate the functional revelation of autoantibodies to induce EC migration 
and/proliferation because it may mimic migration of endothelial cells in response to 
antibody-mediated damage in vivo (Jin et al., 2014). 
In order to perform in vitro endothelial migration assay, bm12 endothelial cells were 
cultured as described in methods (2.2.8) and a linear scratch was created in the centre then 
sera from different recipients were added and looked for migration/proliferation under low 
microscopy. Number of cells moved across the scratch was calculated. On analysis, sera 
from WT recipients of CD4 T cell-replete bm12 heart allografts triggered vigorous 
endothelial cell (EC) migration /proliferation, but in vitro EC responses were not observed 
with sera from either SAP-ve.BL6 or TCRbd-/- recipients. However, sera from TCRbd-/- recipients 
reconstituted with WT.BL6 CD4 T cells restored the vigorous EC migration/proliferation; this 
was similar to that observed in WT recipients (figure 5.6b)(Qureshi et al., 2018). 
Furthermore, in order to remove any confounding factors to this assay because of the 
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presence of complement factors and other proteins in serum, autoantibody was column-
purified (section 2.2.8.5) from recipients’ sera from different groups and then used to assess 
the migration/proliferation of EC across a scratch wound. Not surprisingly, similar patterns 
of EC migration were observed when column-purified immunoglobulins from the 
transplanted recipients were added, with negative fraction from column purification not 
eliciting EC responses (figure 5.6c)(Qureshi et al., 2018). Thus GC autoantibody responses 
were able to trigger donor bm12 endothelial cells migration and/ or proliferation in vitro 
which may be mimicking in vivo graft damage by GC autoantibodies. From this we 
postulated that the requirement of GC autoimmunity in progression of allograft 
vasculopathy may be reflecting the diversification of humoral autoimmune responses that 
encompass and target additional and potentially pathogenic autoantigens over time after 
transplantation which may be detrimental to allografts.   
To test diversification of humoral response, development of anti-vimentin autoantibody was 
checked in sera obtained from recipients from various groups at week7 and week 15.  
As shown in chapter 3 (figure 3.10), there was a surge in anti-vimentin autoantibody at 
week 15 compared to week 7 in WT BL6 recipients of bm12 heart allografts. Interestingly, 
there was no detectable anti-vimentin autoantibody at week 7 in all the groups. However, 
there was a surge in anti-vimentin autoantibody response at week 15 in either WT 
recipients of SAP-ve.bm12 heart grafts or TCRbd-/- recipients reconstituted with WT BL6 CD4 T 
cells. But this rise in anti-vimentin autoantibody at late time point was not observed in SAP-
ve.BL6 or TCRbd-/- recipients of bm12 heart grafts (figure 5.6d) (Qureshi et al., 2018).  
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Figure 5.6: Germinal centre autoantibody responses trigger endothelial cell responses and 
are associated with intermolecular epitope diversification  
a. Immunohistochemical staining of explanted allografts reveals endothelial 
complement C4d deposition in donor recipient strain combinations in which late GC 
activity was observed (WT, Dn.RCCD4, SAP-ve bm12: group designations as in Figure 
5.2 and 5.5), but not in strain combinations in which late GC activity was not present 
(DnCD4 and SAP-ve BL6).  
b. Endothelial C4d complement deposition correlated with the ability of week 7 sera 
from transplanted recipients to induce in vitro proliferation / migration of bm12 
cultured endothelial cells in ‘scratch-wound’ assay (y-axis - number of cells 
encroaching into scratch). Representative photomicrographs of migration into the 
scratch wound are included. As positive control, commercial anti-H-2Db mAb was 
added to endothelial cells.  
c. In vitro proliferation / migration of bm12 cultured endothelial cells in ‘scratch-
wound’ assay following addition of serum immunoglobulin (column-purified from 
sera of week 7 transplanted recipients). Migration was not observed with the 
negative fraction following column purification of sera from WT group (histogram). 
Representative photomicrographs of migration into the scratch wound are included. 
As positive control, commercial anti-H-2Db mAb was added to endothelial cells. 
d. Anti-vimentin IgG autoantibody responses in recipient groups were determined at 
weeks 7 and 15 after transplantation by indirect ELISA. Late anti-vimentin responses 
developed in those recipient groups in which GC activity was observed at week 7.  
Data represent mean and SD of n = 4-8 mice per group, with discrete data-points in b & c 
depicting samples from individual animals. *P < 0.05, **P < 0.01 (Mann-Whitney test). 
Image scale bars are 50µm.   
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5.4.5. B cells are essential for diversification of humoral responses 
In this model of chronic rejection, we have reported that donor CD4 T cells interact with 
MHC class II complexes on recipient B cells in a peptide degenerate fashion through direct 
allorecognition (Harper et al., 2016); however, it seemed logical that B cells would have to 
interact with recipient derived TFH cells in a peptide-specific fashion in order to sustain 
autoreactive GCs as observed in WT recipients. To test this hypothesis, bone marrow 
chimeric mice were created with H2-DMa mice in Rag2-/- after sub-lethal irradiation as 
described in methods (2.1.9) (figure 5.7a). Rag2-/- does not have any B or T cells and H2-DMa 
mice have selective defect in B cells which were unable to exchange CLIP (class II-associated 
invariant chain peptide) and were impaired in their capacity to present endogenously 
processed peptides (Alfonso et al., 2001; Miyazaki et al., 1996). In the chimeric Rag2-/- mice, 
T and B cells would be from H-2DMa mice and DCs would be from H-2DMa and Rag2-/- mice, 
thus DCs would be providing an opportunity for initial priming of CD4 T cells and absence of 
DMa molecule on B cells would limit their ability to present a wider repertoire of 
endogenously processed peptides to CD4 T cells. After confirmation of chimerism in Rag2-/- 
showing presence of B cells, T cells and DCs (figure 5.7); H2-DMa chimeric mice were 
challenged with bm12 allografts. Recipients were checked for development of autoantibody 
response, GCs and anti-vimentin autoantibody(Qureshi et al., 2018). 
On analysis of recipient sera; early autoantibody formed , which was above background 
levels in recipients of syngeneic BL6 grafts (figure 5.7b), confirming the peptide degenerate 
nature of the help provided by donor bm12 CD4 T cells to recipient B cells. In contrast to WT 
recipients, there was no augmentation of this autoantibody at late time point which was in 
consistent with failure of B cells to differentiate into GCs as shown by quantification of GCs 
at week 7 in recipients’ splenic sections (figure 5.7c). This was in line with the fact that B 
cells were unable to present endogenous peptides; and peptide-specific help was unable to 
recruit TFH cells for development of GC response. In the absence of GC response, 
diversification of B cells response to target anti-vimentin reactivity was not observed (5.7d) 
and allograft survival was prolonged (figure 5.7e) (Qureshi et al., 2018). 
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Figure 5.7: B cell antigen presentation is required for germinal centre autoimmunity 
a. H-2b mice with an isolated defect in B cell antigen presentation (B.DM-/-) were 
created by adoptive transfer of bone marrow from H-2DM genetically-deficient mice 
into sub-lethally irradiated Rag2-/- mice. Flow cytometry plots, gating on live 
lymphocyte fraction (left and middle) and macrophage / dendritic cell fraction 
(right), demonstrating that the resultant B-DM-/- mice have restored expression of 
CD19+ve B cells and CD4+veCD4 T cells (gated numbers represent percentage of live 
lymphocytes). Whereas all B cells will be defective for H-2DM expression, other 
antigen presenting cell subsets will partially originate from the H-2DM+/+ Rag2-/- bone 
marrow fraction and hence are capable of relatively normal antigen presentation. 
b. Following transplantation of B-DM-/- mice with bm12 heart allografts, antinuclear 
autoantibody responses 
c.  germinal centre activity  
d. anti-vimentin autoantibody responses  
e. and allograft survival  
All the above were assessed as described for Figures 5.4 and 5.5 and compared to 
responses observed in wild-type (WT) BL6 and recipients of syngeneic (BL6) transplants.   
Data represent mean and SD of n = 4-10 mice per group, with discrete data-points in d 
depicting samples from individual animals.  *P < 0.05, **P < 0.01 (2-tailed t-test for individual 
time-points in b, Mann-Whitney test in c and d, and Kaplan-Meier log rank analysis in e). 
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5.4.6. Late B cell depletion prevents epitope diversification and prolongs allograft survival 
To further address the role of GC in diversification; we hypothesised that once GCs have 
developed, inhibition of GC B cells to mature and mutate to form diversified humoral 
response would curtail the diversification phenomenon. To test this, WT BL6 recipients of 
bm12 allografts were treated with depleting anti-CD20 monoclonal antibody, on days 25, 35 
and 45 after transplant, with depletion confirmed by flow cytometric analysis of peripheral 
blood (Ali et al., 2016). Anti CD-20 monoclonal antibody would deplete immature, mature 
established GC B cells but would be ineffective against autoreactive plasma cells, such as 
those that are resident in bone marrow as a result of initiation of germinal centre response 
(Hoyer et al., 2005). B cell depletion was initiated at week three due to the fact that in this 
model GC develop around day 15 (chapter 3, figure 3.7) and we wanted to block GC B cells 
once they have developed, thus preventing diversification of humoral response, but we can 
still see GC output in the form of bone marrow plasma cells. In support of this, late 
treatment with anti-CD20 did not affect deposition of long lived plasma cells specific for 
double-stranded DNA (dsDNA) into the bone marrow which is consistent with the 
comparable autoantibody titres between treated and untreated recipients (Figure 5.8a). 
Splenic GC activity was however less than the WT (figure 5.8c) and it was consistent with 
abrogation of late anti-vimentin response (figure 5.8d). All donor allografts survived till day 
100 with minimal vasculopathy (figure 5.8e). However, donor hearts were beating 
appreciably less strongly prior to explant. Histologic assessment revealed marked cellular 
infiltrate within allografts and was associated with fibrotic scarring (figure 5.8f) (Qureshi et 
al., 2018).  
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Figure 5.8: Late B cell depletion prevents epitope diversification and improves allograft 
survival 
C57BL/6 (BL6) recipients were treated with depleting anti-CD20 on days 25, 35 and 45 after 
transplantation with bm12 heart allografts.  
a. Seven weeks after transplantation, IgG-secreting (top row) and anti-double-stranded 
DNA (dsDNA, bottom row) antibody secreting cells were enumerated in spleen (left) 
and bone marrow (right) by standard ELISPOT assay and expressed as antibody 
secreting cells (ASCs)/ million cells plated. Shown for comparison are responses in 
wild-type BL6 recipients of wild-type bm12 heart allografts (wild-type) and those 
observed in naïve, untreated wild-type and Tcrbd-/- BL6 mice (a).  
b. Anti-nuclear IgG autoantibody responses in anti-CD20 treated recipients were similar 
to those observed in untreated recipients  
c. Frequency of splenic GCs seven weeks after transplant was reduced in anti-CD20 
treated groups compared to WT.  
d. (c). The reduction in GC was associated with amelioration of the late anti-vimentin 
autoantibody response in treated group (anti-CD20) vs untreated group (WT)  
e. Donor grafts were assessed at explant at week 7 for AV which revealed significant 
reduction in AV in treated group. 
f. Elastin van Gieson stained paraffin sections of allografts at explant revealed 
widespread foci of cellular infiltration (f, scale bars 50µm).   
Data represent mean and SD of n = 4-8 mice per group, with discrete data-points in d & e 
depicting samples from individual animals.  *P < 0.05 (2-way ANOVA in b, and Mann-
Whitney test in a, c, d & e).  
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5.4.7. Germinal centre autoantibody responses independently mediate progression of allograft 
vasculopathy  
So far, I have shown the definite role of recipient CD4 T cells, acting as a TFH cells for 
maintaining and propagating donor induced autoimmunity through germinal centre 
formation. This GC autoimmunity in turn is contributing to progression of allograft 
vasculopathy especially in the light of our previous work in which we have shown that BL6 
recipients of bm12 heart allografts do not develop alloantibody responses against 
mismatched I-Abm12 MHC class II antigen (Win et al., 2009). However, we want to exclude 
any possible contribution to allograft rejection from conventional recipient CD4 T cell 
allorecognition of the mismatched I-Abm12 alloantigen either through direct or indirect 
pathway (Ali et al., 2013). In order to examine this, we created ‘mixed chimeric mice’ 
modified from Sykes’ work (Nikolic et al., 2010). This mixed chimeric mice was created by 
adoptive transfer of bone marrow from CD45.2.bm12 mice into CD45.1.BL6 with CD4 and 
CD8 depleting antibodies and anti-CD154 antibodies at various time points (method section 
2.1.8.1). The recipient mice were tail bled at week 7 to perform flow cytometry to check the 
chimeric state which confirmed that CD45.1.BL6 mice stably embraced a congenic 
population of CD45.2.bm12 bone marrow (Chm.bm12/BL6 mice) (figure 5.9a). We 
hypothesised that in these mice the persistence of stable chimeric state would signify 
ongoing adaptive tolerance towards the mismatched MHC-class II alloantigens, however a 
subsequent challenge with bm12 allograft to the recipients will break this tolerance and by 
breaking the tolerance donor CD4 T cells in  the allografts will provide help to recipient B 
cells and result in autoimmunity. 
Mixed chimeric mice were challenged with bm12 allograft and recipients’ sera were checked 
for antinuclear autoantibody and late anti-vimentin autoantibody levels, recipient splenic 
sections were looked for germinal centres and donor allograft vasculopathy were calculated 
at explant. 
Antinuclear autoantibody response was robust (figure 5.9b) and long-lasting comparable to 
WT responses; this was in keeping with germinal centre response (figure 5.9c). Allografts 
developed severe vasculopathy (figure 5.9e) and rejected at the same tempo as that of WT 
(figure 5.9f). Allografts also demonstrated wide spread complement deposition (figure 5.9g). 
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Analysis of vimentin revealed that late anti-vimentin autoantibody was above background 
level (figure 5.9d). 
The above results suggested that donor CD 4 T cells were capable of breaking B cell 
tolerance despite stable tolerant state to the mismatched I-Abm12 alloantigen that was 
present at the transplant. Passenger CD4 T cells within the allograft stimulated GC mediated 
humoral autoimmune response which resulted in progressive allograft vasculopathy and 
eventual allograft failure. However, it did not exclude the possible role of autoimmunity in 
breaking the allotolerance in the chimeric mice or possible contribution of recipient 
adaptive alloimmune responses generated against the MHC class II I-Abm12 alloantigens 
towards chronic allograft failure.  
Furthermore, as we have reported previously (Harper et al., 2016) that despite the 
development of a robust GC autoimmunity response in the recipients in this model of 
chronic rejection (bm12 to BL6); the recipients did not develop any obvious signs of chronic 
graft versus host disease within the time frame of our experiments. This raised a question 
why the autoantibody formed in recipients is damaging the donor arterial system and thus 
causing allograft vasculopathy but apparently preserving the native arterial system. 
Interestingly, when syngeneic BL6 heart grafts were transplanted into BL6 recipients in 
which humoral autoimmunity was simultaneously provoked by adoptive transfer of purified 
bm12 CD4 T cells at the day of transplant, the heart grafts survived indefinitely without 
developing any vasculopathy (figure 5.9e). These experiments suggested that ischaemic-
reperfusion injury was not itself sufficient to induce susceptibility in the syngeneic 
transplant to autoantibody mediated damage (Qureshi et al., 2018).   
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Figure 5.9. Donor: recipient bone-marrow chimeric mice reject donor strain heart 
allografts  
a. Creation of mixed haematopoietic chimeric mice, stable bm12→C57Bl/6 mixed 
haematopoietic bone marrow chimeric mice were created by conditioning sub-
lethally irradiated (4 Gy total body irradiation) congenic CD45.1 BL6 mice with anti-
CD8, anti-CD4, and anti-CD154 mAbs, followed by intravenous injection with CD45.2 
bm12 bone marrow cells (diagram). The presence of mixed haematopoietic 
chimerism was assessed 7 weeks later by flow cytometric analysis of peripheral 
blood mononuclear cells (representative histogram plots depicted), and identifying 
bm12 donor (CD45.2) and BL6 recipient (CD45.1) fractions within gated T cell (top 
row) and B cell (bottom row) populations. Mixed stable chimeric recipients were 
challenged with bm12 donor allo-grafts and the results were compared to those 
achieved in wild-type C57BL/6 recipients of a bm12 heart allograft (WT.BL6) and to 
C57BL/6 recipients transplanted with a syngeneic C57BL/6 heart allografts and 
challenged intravenously with purified bm12 CD4 T cells and (syngeneic+bm12).  
b. Antinuclear autoantibody levels, which were comparable to WT and 
syngeneic+bm12 
c. Frequency of splenic germinal centre activity at week 7, comparable to WT. 
d. Late anti-vimentin IgG autoantibody response was present in chimeric recipients. 
e. Allograft vasculopathy of week 7 explants, the severity of AV of allografts 
transplanted in chimeric recipients was the same as that of WT but no donor AV in 
syngeneic+bm12 group. 
f. Allografts were rejected at the same tempo as that of WT. 
b, c, d, e and f were assessed as described in Figures (5.2, 5.4 and 5.5) and  
g. At explant at 7 weeks, cryostat immunohistochemistry of donor grafts confirmed 
widespread endothelial C4d complement deposition in chimeric recipients; scale bar 
20μm.  
Data represent mean and SD of n = 4-10 mice per group, with discrete data-points in c & d 
depicting samples from individual animals. *P < 0.05 (2-way ANOVA in a, Mann-Whitney 
test in b, c and d, and Kaplan-Meier log rank analysis in e).  
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To definitely examine the role of humoral autoimmunity independent of alloimmune 
response in development of allograft vasculopathy, we selected to investigate the rejection 
of parental strain heart allograft by F1 hybrid offspring (Uehara et al., 2005). Previously 
(Uehara et al., 2005), it has been suggested that NK cells contribute to rejection of parental 
allografts when transplanted into F1 hybrid offspring by generation of IFN-γ from recipients. 
In this transplant model, anti-donor T cell reactivity lacks but it retains anti-donor NK cell 
responses. They further suggested that amelioration of AV in donor heart grafts by 
inhibition of recipient NK cells by treatment of recipients by anti-NK 1.1 monoclonal 
antibody argues that NK cells activated by the absence of self MHC class I molecules on 
donor endothelium participate in the pathogenesis of AV. However, autoimmune responses 
were not studied in that study. Hence, we hypothesised that in this model graft versus host 
allorecognition by passenger donor cells would trigger recipient GC autoimmunity, but that 
adaptive alloimmune recognition of donor parental antigens would not be possible in the F1 
recipients. 
In order to do that, transplantation of BALB/c heart grafts with or without CD4 T cells into F1 
BALB/c x C57BL/6 (CB6F1) recipients were carried out. Recipients’ sera was checked for 
development of antinuclear autoantibody responses, recipient splenic sections were 
examined for development of GCs, donor heart allografts were calculated for development 
of allograft vasculopathy at explant and also examined for complement deposition. 
Transplantation of BALB/c grafts into CB6F1 resulted in development of long lasting 
autoantibodies in the recipients (figure 5.10a), which was in keeping with the presence of 
germinal centres in recipient splenic sections (figure 5.10c). These GC autoimmune 
responses were associated with development of allograft vasculopathy (figure 5.10d) and 
intra-allograft endothelial complement deposition (figure 5.10e). However, alloantibody 
responses against MHC class I H-2Kd antigen were not generated, suggesting that self-
tolerance to the BALB/c H-2d antigens was maintained in the F1 recipients (figure 5.10b). As 
expected, these GC autoimmune responses were absent when CD4 T cells depleted BALB/c 
donors were transplanted into CB6F1 recipients (figure 5.10a and c) and explanted donor 
allografts showed minimal allograft vasculopathy (figure 5.10d) without complement 
deposition (figure 5.10e). These findings were consistent with the requirement of donor CD4 
T cells to stimulate GC mediated autoimmunity in recipients. In order to further evaluate the 
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interplay between donor and recipient CD4 T cells for development of this donor induced 
autoimmunity in the recipients, Sh2d1a-/-.F1 (SAP-ve F1) recipients were created as 
mentioned in methods (2.1.1) with the expectation that inhibition of SAP signalling in the 
recipients will block the recipient CD4 T cells to provide help to the activated B cells to form 
germinal centres and thus will ameliorate the AV in donor heart grafts as was seen in bm12 
to BL6 model.  
Interestingly, transplantation of BALB/c donor allograft into Sh2d1a-/-.F1 (SAP-ve F1) 
recipients abrogated the GC response (figure 5.10a and c) and heart grafts developed 
minimal vasculopathy (figure 5.10d) with no complement deposition in intra-allograft 
endothelial cells (figure 5.10e).  
Then we investigated the effect of NK cells on rejection kinetics in this model by depleting 
NK cell in the recipients. We presumed that depleting NK cells in the recipients would 
augment humoral autoimmune response.  Depletion of recipient NK cells was carried out as 
described previously (Ali et al., 2016) and in methods (2.1.6). Transplantation of BALB/c 
allografts to NK-cell depleted recipients although resulted in GC autoantibody responses but 
the allografts remained disease free without any complement deposition. This suggested a 
critical role for NK cells in either mediating alloantibody or autoantibody mediated graft 
damage or in triggering innate immune ‘missing self’ recognition of the parental BALB/c 
strain.  
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Figure 5.10: Germinal centres autoantibody responses independently mediate progression 
of allograft vasculopathy.  
Wild-type BALB/c heart allografts were transplanted into either unmodified BALB/c x 
C57BL/6 F1 (CB6F1) mice or CB6F1 mice genetically deficient in expression of SAP (SLAM 
associate protein (SAP-ve CB6F1)) or CB6F1 mice depleted of NK T cells (NK1.1-ve CB6F1). 
Heart grafts from CD4 T cell-depleted BALB/c donors were transplanted into unmodified 
CB6F1 recipients (CD4-ve BALB/c).  
a. Following transplantation, anti-nuclear IgG autoantibody by hep-2 indirect 
immunofluorescence on recipient sera. 
b. Following transplantation, anti-Kd alloantibody in recipient splenic sera by H-2 Kd 
ELISA.  
c. Recipient splenic GC activity till week 7.  
d. Donor allograft vasculopathy at week 7.  
a), c), d) were assessed as described in Figures 1 & 2.  
e. Cryostat immunohistochemistry of heart allografts at week 7 revealed widespread 
endothelial C4d complement deposition in CB6F1 recipients, but not in CD4-ve BALB/c 
allografts nor in NK1.1-ve CB6F1 recipients. Scale bar 20μm.  
Data represent mean and SD of n = 4-9 mice per group, with discrete data-points in d 
depicting samples from individual animals. *P < 0.05 (2-way ANOVA in a, and Mann-Whitney 
test in c & d). 
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5.5. Summary 
In summary, this work makes several important and novel observations (figure 5.11) 
• Recipient humoral autoimmunity is triggered by graft-versus-host recognition by donor 
CD4 T cells, but its maintenance as a germinal centre response requires help from CD4 T 
cells in the recipient that have undergone follicular helper T cell differentiation. 
• Humoral autoimmunity can contribute to allograft rejection, but only as a germinal 
centre response. Germinal centre response is associated with epitope diversification to 
target additional autoantigens. 
• Germinal centre autoantibody responses can effect allograft rejection independently of 
host alloimmunity. 
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Figure 5.11: Proposed model for interaction between donor CD4 T cells and recipient B 
and T cells for initiation and maintenance of germinal center autoimmunity 
Passenger donor CD4 T cells within the heart allograft provide ‘peptide-degenerate’ help to 
host B cells for production of anti-nuclear IgG autoantibody (1). Subsequent ‘cognate’ 
interaction between activated B cells and recipient T follicular helper (TFH) cells results in 
long-lasting germinal center responses (2), which lead to inter-molecular epitope 
diversification, to encompass, along with other targets, responses against vimentin 
autoantigen (3). This diversification is associated with development of antibody-mediated 
allograft vasculopathy and eventual graft failure (4).  
  
260 
 
5.6. Discussion 
Although the development of autoimmunity has been increasingly associated with chronic 
rejection of organs especially following heart and lung transplantation; how this 
autoimmunity contributes to allograft rejection remains poorly understood. Previous studies 
from us and other groups have shown that graft specific autoimmunity affects allografts in 
close concert with adaptive alloimmune responses which are directed against mismatched 
MHC alloantigens. This contribution from autoimmune response is described as either 
precipitating or augmenting alloimmune response towards graft damage (Cardinal et al., 
2013; Harper et al., 2016; Lovegrove et al., 2001; Yoshida et al., 2006) or this autoimmune 
response itself may be the result of ongoing vigorous alloimmune mediated graft damage 
(Fukami et al., 2009; Valujskikh et al., 2002 ). In this chapter I have extended our previous 
investigations into bm12 to BL6 model of heart allograft vasculopathy, and have shown that 
although host autoantibody responses were stimulated by donor CD 4 T cells, this donor 
CD4 T cells induced autoimmunity in the recipient was maintained by provision of help to 
recipient B cells from recipient derived TFH cells which helped recipient B cells to 
differentiate into germinal centres. Maintenance and propagation of this donor induced 
autoimmunity by recipients’ TFH cells through GC autoantibody response is, in turn, a major 
determinant of graft outcome (figure 5.5c and d). Furthermore, by replicating these findings 
with another model in which the host adaptive alloimmune response against the donor was 
not possible (figure 5.10), I have provided a strong evidence for an independent causative 
role for graft specific autoimmunity in chronic organ rejection. 
Bm12 to BL6 model has been one of the most studied models of chronic rejection due to 
minimal mismatch between donor and recipients. However, surprisingly, role of 
autoantibody has not been described. Nevertheless, our previous studies (Harper et al., 
2016; Motallebzadeh et al., 2012; Win et al., 2009) and the current data continue to 
emphasize the contribution of autoimmune humoral response to graft damage. The most 
salient feature of this work is the presence of robust GC responses in BL6 recipients splenic 
sections of bm2 allografts at week 7 and the absence of this GC autoimmune response in 
SAP-ve BL6 recipients of bm12 allografts. This failure of recipient B cells to differentiate into 
GC autoimmune responses in SAP-ve recipients resulted in reduction in AV and prolongation 
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of bm12 allograft survival. SAP-ve mice have normal B and T cell function apart from some 
defect in NK T cells and TFH cells (Czar et al., 2001). Hence in this model, in which there is no 
demonstrable alloantibody against donor I-Abm12 (Win et al., 2009) and short lived direct 
pathway response against the disparate I-Abm12 MHC class II (Ali et al., 2016), it seems likely 
that robust and long lasting GC autoantibody response which is dependent on recipient TFH 
cells is contributing to allograft chronic rejection. However, autoimmunity does not seems 
to be the only mediator of AV as AV does develop in B cell deficient recipients (figure 5.5d ) 
(Win et al., 2009) but with less severity. Furthermore, from this work, an additional role of 
cellular alloimmunity in graft rejection has been suggested from late B cell depleted 
recipients work in which bm12 allografts demonstrated minimal AV but presence of cellular 
infiltrates in parenchyma with fibrosis and a decrease in heart beating noticed at the time of 
explant. This piece of work suggests that humoral autoimmunity mediates progression of 
graft damage by affecting graft endothelium and cellular alloimmunity effect graft 
parenchyma (Fischbein et al., 2001). 
The demonstration that donor CD4 T cells stimulate GC autoimmunity in the recipients and 
recipient CD4 T cells are acting as a TFH cell for durable GCs which is the major determinant 
for progression of allograft vasculopathy, raised several questions which are unanswered; 
why is the donor population of CD4 T cells unable to provide TFH cell function to support 
long term GCs; what is the nature of antigen recognition by recipient CD4 T cells and how 
does the GC autoimmune response contribute to allograft rejection.  
With regards factor which may be preventing donor bm12 CD4 T cells to acquire TFH cell 
function we have had a detailed discussion in previous chapter with adoptive transfer of 
CD4 T cells. Importantly two of the hypotheses in this regard have been tested as well 
(figure 4.23 and 4.24). Firstly, my work has suggested that donor bm12 CD4 T cells were 
unable to provide long term TFH cell function due to their direct interaction with recipient B 
cells through their MHC class II in a peptide degenerate fashion which is non-specific and 
low affinity interaction (Sewell, 2012) (figure 4.23).  Secondly, again this direct 
allorecognition of MHC II on DCs by donor bm12 CD4 T cells may result in downregulation of 
Bcl-6 which may limit their ability to provide long term TFH cell function (figure 4.24). 
Furthermore, we discussed that it may be possible that long term GC maintenance may 
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require renewal of the existing TFH cells by continual differential of CD4 T cells into new TFH 
cells to the already existing GC (figure 4.22)  (Shulman et al., 2013). 
The differentiation of recipient CD4 T cells into TFH cell is probably driven by antigen 
presentation from recipient activated B cells following their first interaction with donor 
bm12 CD4 T cells. As B cells are capable of soliciting their own help (Stockinger et al., 1996) 
and it is quite possible that once B cells are activated by donor CD4 T cells then they would 
be presenting self-restricted peptide autoantigens on MHC class II to recipient CD4 T cells 
and by doing so would be recruiting naïve autoreactive recipient CD4 T cells for 
differentiation into TFH cells and ultimately for graft rejection. This provides an explanation 
why in the bm12 to BL6 model, a monoclonal population of host direct pathway CD4 T cells 
was found to be unable to mediate allograft rejection (Sayegh et al., 2003). 
The observed complement deposition in allograft and in vitro migration of donor 
endothelial cells to autoantibody reflects that the damage caused by GCs is primarily 
dependent on the quality of autoantibody produced as there was no migration in groups 
where B cells failed to differentiate into GCs. This reflects GC B cells ability to produce 
mutated plasma cells through somatic hypermutation which in turn secret high affinity 
autoantibodies coupled with deposition of mutated plasma cells into bone marrow as a 
continual supply of high affinity autoantibody for life time. In support, dsDNA specific bone 
marrow plasma cells were associated with GC response in WT recipients of bm12 donors 
(figure 5.8a). Presence of autoimmune responses to vimentin autoantibody at a late point 
suggests the possibility of epitope diversification to encompass additional pathogenic 
autoantigens, may also be an important function of GC in mediating graft rejection. 
However, my work does not conclusively prove this diversification phenomenon from other 
attributes of GCs. Furthermore, in our experiments it does not quite show that it is 
specifically involved in graft damage as it developed after graft rejection and half of the 
recipients did not develop this autoantibody. However, we selected this as a surrogate 
marker of diversification due to previous studies which have shown its contribution to 
allograft vasculopathy (Mahesh et al., 2007; Piotti et al., 2014; Xu-Dubois et al., 2016). 
Nevertheless, it is a type III intermediate filament protein, expressed ubiquitously in 
mesenchymal cells and involved endothelial cell adhesion (Dave and Bayless, 2014). Hence 
its targeting by humoral autoimmunity in accelerating allograft vasculopathy is credible. 
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Furthermore, a number of other auto-antigens have been suggested to be associated with 
AV like autoantibodies to cardiac myosin (Kalache et al., 2011), collagen V (Tiriveedhi et al., 
2013) and perlecan (Cardinal et al., 2013); however more extensive work is required to 
validate which, if any, of the autoantibody or autoantibodies are pertinent for vasculopathy 
progression. 
The demonstration of development of allograft vasculopathy in parental allograft which 
were transplanted into F1 hybrid recipients provides the strongest evident for humoral 
autoimmunity contributing to progression of AV independent of adaptive alloimmune 
response. As in bm12 to BL6 model, in this parental to F1 model, development of GC 
autoimmunity was dependent on passenger donor CD4 T cells in donor heart graft. 
Interestingly, the donor grafts remained disease free when transplanted into SAP-ve.F1 
hybrid recipients (figure 5.10d). Although our recent work has shown that passenger CD4 T 
cells can provide help to host alloreactive B cells for generating alloantibody against MHC 
alloantigen expressed on donor cells (Harper et al., 2016), however alloantibody was not 
generated in the F1 recipients in this model, most likely because, as the H-2b and H-2d MHC 
antigens are membrane proteins, hence they provoke robust, central deletional B cell 
tolerance (Hartley et al., 1991) (figure 5.10b) 
Despite the fact that robust GC autoimmunity is generated in the recipients in bm12 to BL6 
and parental to F1 hybrid model, the autoimmune disease manifestations were not 
observed in our recipients’ native organs (Harper et al., 2016; Motallebzadeh et al., 2012). 
This is interesting in the light of Eisenberg work, who have used this as a model of systemic 
lupus erythematosus (SLE) (Eisenberg and Via, 2012). However, our group has noticed 
occasional skin and gut manifestations consistent with autoimmune disease in long term 
surviving recipients (more than 6 months). Interestingly, in my work, of the group which 
developed early and augmented autoantibodies and accelerated rejection following 
challenge with primed bm12 allografts, 2 of 5 recipients had to be culled early due to the 
development of similar features. Thus it appears that the level of autoantibody was not high 
enough in our WT recipients of bm12 heart grafts to provoke systemic autoimmune disease 
and it is likely that in other studies where it was used as a model of SLE, the number of cells 
and type of cells transferred were different than in our studies. Hence it is likely that the 
development of SLE like disease depends on the number and type of donor cells which were 
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transferred into recipients. Further experiments are needed to check firstly how many CD4 T 
cells were present in donor hearts when harvested from bm12 donor grafts and secondly to 
examine the development of autoantibodies in the recipients after adoptive transfer of 
different number of CD4 T cells to identify number of CD4 T cells required to trigger 
autoimmunity in the recipients and systemic manifestation of autoimmune diseases.  
Although one of the recent studies has shown the development of native arterial disease in 
BL6 recipients of bm12 heart grafts, this was shown only in atherosclerosis-prone mice 
(apoE-ve) (Zhou et al., 2015) and autoantibodies were not examined in this study. But our 
findings suggest that they would have developed autoantibodies and it is likely that those 
autoantibodies may be contributing to native arteriopathy. This would be consistent with a 
two-hit hypothesis, whereby the potential for autoantibody to affect arterial disease is 
greatly enhanced by concurrent damage that possibly exposes previously sequestered 
target autoantigen (Win and Pettigrew, 2010). The insult to the sequestered self-antigens 
for their exposure or release may not be the antigen non-specific ischaemic reperfusion 
injury as in our experiment which showed that the syngeneic donor heart grafts remained 
disease free that had been simultaneously primed for humoral autoimmunity (figure 5.8e). 
A possible alternative is that allograft damage is initiated by innate immune recognition of 
non-self allo-antigen either by monocytes/macrophages (Chow et al., 2016; 
Oberbarnscheidt et al., 2014; Zecher et al., 2009) or NK cells (Kroemer et al., 2008). 
Recipient’s monocytes can respond to allogenic non-self-determinants like polymorphism in 
alpha signal regulatory protein (α SIRP) (Dai et al., 2017) on donors. In contrast, MHC 
incompatibility can result in alloreactive NK cells, which may be cytolytic to allogeneic cells 
(Kroemer et al., 2008). Uehara et al (Uehara et al., 2005) have also reported that parental 
allografts did not reject when transplanted into NK-cell depleted F1 recipients. This is in 
consistent with our findings as well. However, with the evidence of development of GC 
autoimmunity in F1 recipients of parental allografts (figure 5.10), the requirement for NK 
cells in rejection of parental heart allografts most likely reflects Fc-receptor mediated 
recognition of bound autoantibody on graft endothelium. Although the underlying 
mechanism remain unclear, these autoantibodies responses may synergise or partially 
dependent upon simultaneous complement activation (Yin et al., 2004). This is consistent 
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with our findings that complement deposition was not observed within allografts explanted 
from NK-cell depleted recipients (figure 5.10) who remained disease free as well. 
 
  
266 
Implications of this work 
The implications for this work is that bm12 to BL6 model remains the most widely studied 
experimental model which has minimal mismatch in MHC alloantigens between donor and 
recipients which is related with clinical transplantation as every effort is made in clinical 
transplantation to minimise the mismatch. However, doing so, there is a possibility that 
donor CD4 T cells survive long enough to trigger autoimmunity in recipients through GVH 
recognition. This is consistent with the ‘passenger lymphocyte syndrome’ seen in recipients 
of solid organ allografts and is increasingly emphasized (Nadarajah et al., 2013; Turner et al., 
2014). To what extent this donor induced autoimmunity in recipients contribute to allograft 
rejection remains unknown. However, our study demonstrated that donor induced 
autoimmunity in the recipients mediates progression of allograft vasculopathy independent 
of adaptive alloimmune responses. We have shown that irrespective of the mechanisms and 
factors which initiate this autoimmunity in recipients, recipient’s TFH CD4 T cells help B cells 
to differentiate into GCs resulting in long term autoimmunity and has deleterious impacts 
on allograft vasculopathy. Development of this TAA in human transplant recipients would 
likely have detrimental impact on transplant outcomes. This is particularly relevant to the 
emerging evidence to develop strategies that aim to promote transplant tolerance in an 
attempt to prolong graft survival by achieving mixed haematopoietic chimerism (Li and 
Sykes, 2012), as in our experiments with mixed bone marrow chimeric recipients in which 
donor passenger CD4 T cells in allografts were capable of  breaking the established 
tolerance to alloantigens in recipients and resulted in development of long lasting 
autoantibodies. Development of this long lasting autoimmunity effects allografts 
deleteriously. These findings are consistent with the previous murine study by Shinoda et al 
(Shinoda et al., 2014) in which depletion of both donor and recipient Foxp3+ve.T-regs cells 
resulted in allograft rejection despite persistence of chimerism. Hence, one should be 
cautious of the development of autoimmunity while achieving tolerance through mixed 
haematopoietic chimerism. Hence, modulation of donor related factors should be 
considered in developing therapeutic approaches to achieve tolerance in recipients like 
modulating the donor lymphocyte fraction prior to implantation during ex-vivo 
normothermic donor organ perfusion.  
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As the development of these autoantibodies was initiated by donor CD4 T cells in this model 
but maintained by recipient CD4 T cells through germinal centres, manipulation of various 
pathways on this subset of CD4 T cells may prolong graft survival. In line with this, inhibition 
of SAP signaling in recipients prolonged allograft survival significantly (figure 5.5). Similarly, 
antibiotic treatment of both donor and recipients prolonged skin grafts in minimal mismatch 
model by modulating composition of microbiota (Lei et al., 2016). Kim et al have shown 
amelioration of antibody mediated rejection by blocking germinal centres through co-
stimulation blockade in nonhuman primate kidney transplant model (Kim et al., 2014). 
Vincenti et al have shown improved kidney graft and patient survival in human kidney 
transplant recipients by selectively blocking the activated CD4 T cells via CTLA4 pathway 
(Vincenti, 2016). 
Finally my findings have wider implications in understanding the underlying mechanisms 
responsible for development of autoimmune phenomena. The experiments in which SAP 
signalling was inhibited in donor bm12 CD4 T cells which were incapable of differentiation 
into long term TFH cells are nevertheless the key trigger for generating long lasting humoral 
autoimmunity. Furthermore bm12Kd transfer experiments confirming that late help to 
follicular B cells is being provided by the naïve host CD4 T cells which differentiate into long 
term TFH cell for development of long lasting autoimmunity; suggest that at the time of 
autoimmune disease manifestations the trigger for the autoimmunity like any viral 
challenge or environmental factors may not be present but there may be a different factor 
which may be maintaining the disease process. This is very pertinent in idiopathic 
immunological disorders as the triggering factor for these diseases may not be identifiable 
at the time of symptoms hence understanding of the underlying mechanism for these 
autoimmune diseases would be helpful in devising therapeutic strategies.  Likewise in my 
work, although donor CD4 T cells triggered autoimmunity in recipients, they could not 
maintain it for long term and it was the recipients TFH cell which maintained and propagated 
the donor induced auto-immunity in the recipient through long term GCs; developing 
selective strategies to target the pathogenic population of TFH cells may be a future avenue 
to deal with different autoimmune diseases. 
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Limitations of this work 
It is important to highlight the limitations of this work that in some of the experiments the 
experimental number of mice was small and there was lack of appropriate control for each 
set of experiment. However, results from each set of experiment was cross examined by 
multiple modalities and in different group of animals to overcome this deficit and to confirm 
the findings. Furthermore I agree that this deficiency can be avoided in future work by 
designing experiment which should be more focused with appropriate numbers, good 
planning and possibly using little may control for each set of experiments. With respect to 
bm12 to BL6 model, potential mutations in using the inbred bm12 mice was clearly a point 
of concern and should have used the commercially available bm12 mice to avoid this 
problem. However, this strain was genotyped regularly and compared to the commercially 
available bm12 strain for any potential mutations.   
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